PhIRDA
中国药促会

INNOVATION

中国医药创新促进会

China Pharmaceutical Innovation and Research Development Association

创新 · 产业化 · 国际化

INDUSTRIALIZATION

INTERNATIONALIZATION

2015-2016 会刊

ASSOCIATION JOURNAL

会长寄语
Message from Chairman of PhIRDA

发挥社会团体优势　促进创新驱动发展

蒋华良

To leverage the strength of PhIRDA and promote the innovation-driven development

Jiang Hualiang

当前，全球范围内生物医药技术和产业呈现快速发展的态势，主要发达国家和新兴经济体纷纷对发展生物医药产业作出战略调整和前瞻部署，将其作为获取未来科技经济竞争优势的一个重要领域。在这种形势下，大力发展健康科技和产业，积极开展科技成果创新与转化，构建以创新药物研发和先进医疗设备制造为龙头的规模化医药研发产业链，提高生物医药产业技术水平，提高健康科技和健康服务水平已经成为我国刻不容缓的国家发展战略。

中国医药创新促进会作为一家以研发为核心、创新为宗旨、临床需求为导向、“政产学研用资”紧密结合为建设目标的社会团体，在促进生物医药技术的创新化、产业化、资本化和国际化方面发挥着不可替代的推动作用。在新的一年中，中国医药创新促进会将继续认真贯彻国家有关方针、政策和改革精神，提高中国医药创新能力，加强医药科研与生产的紧密结合，促进中国医药创新领域的国际合作，加快中国医药及相关行业的技术进步，提高经济效益，维护会员单位的合法权益，为医药卫生事业、经济社会发展做出更大的贡献。

我将竭尽所能，与广大同仁一起携手并肩，推动中国医药创新促进会各项工作的均衡、全面发展，为实现我们共同期盼已久的“新药梦”而不懈努力。

蒋華良

Nowadays, with the global booming of biopharmaceutical technology and industry, both the leading developed countries and the emerging economies have made the strategic adjustment and deployment for the development of biopharmaceutical industry, which is considered as a major competitive field in future technological and economic edges. Therefore, it has become an imperative national development strategy for China to vigorously develop healthcare industry, to advance the innovation and commercialization of scientific results, to establish the large-scale industry chain for drug research and development with innovative drug discovery and the advanced medical device manufacture taking the leading role, to enhance the technical level of biopharmaceutical industry, and to improve the standards of healthcare technology and service.

China Pharmaceutical Innovation and Research Development Association (PhIRDA) is a non-profit organization playing an irreplaceable role in driving innovation, industrialization, capitalization and internationalization of biopharmaceutical technology, with the core of R&D, the aim of innovation, the orientation of clinical demands, and the target of synergistic effects by “Government-Industry-University-Institute-Customer-Funding” alliance. In the forthcoming year, PhIRDA will continue to implement the relevant state principles, policies and spirit of reform, to enhance the capabilities of pharmaceutical innovation in China, to strengthen the communication between scientific research and manufacturing, to promote the international cooperation in pharmaceutical innovation field, to accelerate the technical improvement of Chinese pharmaceutical and related industries, to boost economic benefits, and to safeguard the lawful rights of the association members. PhIRDA aims to make greater contributions to national pharmaceutical and healthcare industry as well as its social and economic development.

As the chairman of PhIRDA, I will spare no effort working together with all of the colleagues to promote the balanced and all-round development of PhIRDA, and endeavor unremittingly in pursuit of our common “Dream of New Drugs”.

目录

中国医药创新促进会简介
Brief Introduction of PhIRDA

中国医药创新促进会（简称“中国药促会”），英文名称：China Pharmaceutical Innovation and Research Development Association；缩写：PhIRDA。成立于1988年，是经国家民政部登记注册的非营利性全国性一级社会团体组织。

中国医药创新促进会原名“中国医药工业科研开发促进会”，2014年10月23日经国家民政部批准更名。目前，中国药促会有会长及会员单位60多家，主要由三方面的成员构成：一是，在医药创新方面具有代表性的民族医药企业；二是，从事医药创新研发的高等院校和科研院所；三是，在新药临床研究领域具有较高水平、特别是承担“重大新药创制”科技重大专项新药临床评价研究技术平台的临床医疗机构。中国药促会是以“创新、产业化、国际化”为宗旨，以临床需求为导向，“产学研用”紧密结合的促进医药创新发展的社会团体。

中国药促会的工作内容主要包括：一是，通过举办各种论坛、发布会、大型会议等促进会员单位乃至整个医药产业互相交流、创新发展；二是，通过与国外医药行业协会、企业、科研机构和外国驻华使馆合作，共同寻求推动中外医药产业领域的合作交流，为会员单位搭建国际交流平台；三是，为会员单位提供医药信息搜集、整理、评价、咨询的服务，包括编辑双月刊刊物《医药科研开发信息》和每日《医药信息简报》、每周《国际医药产业发展动态与研发信息简报》、《行业热点评析》等内部电子刊物以及建设中国药促会官方网站等内容；四是，开展医药政策研究工作，在卫生计生委、商务部、工信部、食品药品监督管理总局等有关政府部门、医药科研学术机构和企业的支持下，为医改事业和医药产业发展建言献策。

中国药促会将围绕“创新、产业化、国际化”的宗旨，加强行业自律，推动我国医药产业的创新发展和可持续发展，为加快我国经济社会发展、保障人民群众健康不断做出贡献！

Founded in 1988, China Pharmaceutical Innovation and Research Development Association (PhIRDA) is registered as a non-profit organization by the Ministry of Civil Affairs of China at the first national level.

Formerly named China Pharmaceutical Industry Research and Development Association, the association was approved to rename into PhIRDA by Ministry of Civil Affairs on October 23, 2014. At current stage, PhIRDA has more than 60 members, mainly consist of three major categories: First, national pharmaceutical enterprises excelling at innovation; Second, universities, colleges and research institutions conducting pharmaceutical research and development; Third, clinical institutions featuring high skills in applicable research on new drugs, especially those undertake “major new drug innovation” technological platform for good clinical practice. PhIRDA will exert great effort to grow into a social organization featuring “academia-industry collaboration”, which centers on research and development, persists in innovation to achieve unmet clinical requirements.

Major work of PhIRDA includes: First, to promote communication and innovative development of our members and even the whole pharmaceutical industry through forums, press-conferences, summits, etc; Second, to make efforts to establish an international exchange platform for our members through cooperation with foreign embassies and foreign associations to stimulate communication between China and foreign countries in pharmaceutical field; Third, to improve the website of PhIRDA and provide collecting, arranging, revising and consulting service of pharmaceutical information, which includes the following internal e-magazines such as the bimonthly journal Scientific and Technological Development Information on Pharmacy, Pharmaceutical Information Brief, International Pharmaceutical Development Tendency and Research Information Brief, Comments on Industrial Hot Issues; Fourth, to conduct pharmaceutical policy researches, propose valuable suggestions on healthcare reform and the development of pharmaceutical industry , with supports from NHFPC, Ministry of Commerce, Ministry of Industry and Information Technology, CFDA and other related government departments.

Centering on the principle of “innovation, industrialization, internationalization”, PhIRDA will strengthen self-discipline, promote healthy development of Chinese pharmaceutical industry, making constant contributions to the greater economic development of the country and public health.

中国医药创新促进会章程

第一章 总 则

第一条 本团体的名称：中国医药创新促进会，英文名称：China Pharmaceutical Innovation and Research Development Association；缩写：PhIRDA。

第二条 本团体是由医药生产企业、相关的科研院所、大专院校等有关单位和机构自愿结成的全国性、专业性、非营利性社会组织。

第三条 本团体的宗旨：高举中国特色社会主义伟大旗帜，以邓小平理论、三个代表重要思想、科学发展观为指导，贯彻国家有关方针、政策和改革精神，提高中国医药工业的科研创新能力，加强医药科研与生产的紧密结合，推动中国医药创新的国际步伐，加快中国医药及相关行业的技术进步，提高经济效益，维护会员单位的合法权益，为医药卫生事业、经济社会发展做出更大的贡献。

本团体遵守宪法、法律、法规和国家政策，遵守社会道德风尚。

第四条 本团体接受业务主管单位国务院国有资产监督管理委员会和社团登记管理机关民政部的业务指导和监督管理。

第五条 本团体的住所：北京市。

第二章 业务范围

第六条 本团体的业务范围：

（一）认真贯彻执行党中央、国务院有关中国医药创新各项政策，深入研究新药研发政策和中国医药体系创新的相关问题，科学预测新药研发的走向，及时提出中国医药创新发展的政策建议，切实反映会员单位合理的愿望和要求，协助会员单位解决实际问题；

（二）组织和参加有关医药行业发展的交流活动，增强中国医药行业的创新能力。组织和参加有关学术交流，组建中国医药行业发展、创新智库，推动医药行业产学研的结合，积极开展新药科研和技术协作及科技成果的推广，组织技术转让与协作，促进医药高科技的产业化，专业化；

（三）发挥自身优势、充分利用现代化手段，搜集、整理、研究、传递医药科技研发信息，聚焦医药行业重点问题，并开展咨询服务；

（四）推动中国医药行业的国际交流，组织开展各种形式的中外医药行业信息、技术、人员的交流与合作。

第三章 会 员

第七条 本团体的会员为单位会员。

第八条 申请加入本团体的会员，必须具备下列条件：

（一）拥护本团体的章程；

（二）有加入本团体的意愿；

（三）在本团体的业务领域内具有一定的影响。

第九条 会员入会的程序是：

（一）提交入会申请书；

（二）经会员大会讨论通过；

（三）由会员大会或会员大会授权的机构发给会员证。

第十条 会员享有下列权利：

（一）本团体的选举权、被选举权和表决权；

（二）参加本团体的活动；

（三）获得本团体服务的优先权；

（四）对本团体工作的批评建议权和监督权；

（五）按规定有获得本团体发出的信息资料和刊物权；

（六）有对本团体提出保护合法权益不受侵害的权利；

（七）入会自愿，退会自由。

第十一条 会员履行下列义务：

（一）遵守本团体章程，执行本团体决议；

（二）维护本团体合法权益；

（三）完成本团体交办的工作；

（四）按规定交纳会费；

（五）向本团体反映情况，提供有关资料。

第十二条 会员退会应书面通知本团体，并交回会员证。会员如果 2 年不履行义务，视为自动退会。

第十三条 会员如有严重违反本章程的行为，经会员大会表决通过，予以除名。

第四章 组织机构和负责人产生、罢免

第十四条 本团体的最高权力机构是会员大会。会员大会的职权是：

（一）制定和修改章程；

（二）选举和罢免会长、副会长和秘书长；

（三）审议本团体的工作报告和财务报告；

（四）制定并修改会费标准；

（五）决定名誉职务的设立和人选；

（六）决定办事机构、分支机构、代表机构和实体机构的设立、变更和注销；

（七）决定副秘书长、各机构主要负责人的聘任；

（八）决定本团体终止事宜；

（九）决定其他重大事宜。

第十五条 会员大会须有 2 ／ 3 以上的会员出席方能召开，其决议须经到会会员半数以上表决通过方能生效。

第十六条 会员大会每年至少召开 1 次。特殊情况下，可以采用通讯方式召开，但修改章程、领导人变更及会费标准等重大事项不得以通讯方式表决。

第十七条 本团体的会长、副会长、秘书长必须具备下列条件：

（一）坚持党的路线、方针、政策、政治素质好；

（二）在本团体业务领域内有较大影响；

（三）会长、副会长最高任职年龄不超过 70 周岁，秘书长最高任职年龄不超过 60 周岁且为专职；

（四）身体健康，能坚持正常工作；

（五）未受过剥夺政治权利的刑事处罚；

（六）具有完全民事行为能力。

第十八条 本团体会长、副会长、秘书长如超过最高任职年龄的，应当办理离职手续。

第十九条 本团体实行年度轮值会长制度；会长从会员中经选举产生，任期 1 年。

副会长、秘书长每届任期 4 年，连任不超过两届。

第二十条 会长为本团体法定代表人。因特殊情况，经会长委托，会员大会同意，报业务主管单位审查、社团登记管理机关批准后，可以指定一名副会长或秘书长担任法定代表人。

法定代表人代表本团体签署有关重要文件。

本团体法定代表人不兼任其他团体的法定代表人。

本团体会长、副会长、会员代表离开所属单位的，自动失去会长、副会长、会员代表资格，由原单位推荐新的人选，报会员大会选举备案。

第二十一条 本团体会长行使下列职权：

（一）召集和主持会员大会；

（二）检查会员大会决议的落实情况。

（三）副会长受会长的委托，可以代行会长的部分职权。

第二十二条 本团体设立秘书处，秘书长行使下列职权：

（一）主持办事机构开展日常工作，组织实施年度工作计划；

（二）协调各分支机构、代表机构、实体机构开展工作；

（三）提名副秘书长以及各机构主要负责人，交会员大会决定；

（四）决定办事机构、代表机构、实体机构专职工作人员的聘用；

（五）处理其他日常事务。

第五章 资产管理、使用原则

第二十三条 本团体经费来源：

（一）会费；

（二）捐赠；

（三）政府资助；

（四）在核准的业务范围内开展活动和服务的收入；

（五）利息；

（六）其他合法收入。

第二十四条 本团体按照国家有关规定收取会员会费。

会费由秘书处负责管理，并在会员大会期间向全体会员单位公布经费使用情况。

第二十五条 本团体经费必须用于本章程规定的业务范围和事业的发展，不得在会员中分配。

第二十六条 本团体建立严格的财务管理制度，保证会计资料合法、真实、准确、完整。

第二十七条 本团体配备具有专业资格的会计人员。会计不得兼任出纳。会计人员必须进行会计核算，实行会计监督。会计人员调动工作或离职时，必须与接管人员办清交接手续。

第二十八条 本团体的资产管理必须执行国家规定的财务管理制度，接受会员大会和财政部门的监督。资产来源属于国家拨款或者社会捐赠、资助的，必须接受审计机关的监督，并将有关情况以适当方式向社会公布。

第二十九条 本团体换届或更换法定代表人之前必须接受财务审计。

第三十条 本团体的资产，任何单位、个人不得侵占、私分和挪用。

第三十一条 本团体专职工作人员的工资和保险、福利待遇，参照国家和本团体的有关规定执行。

第六章 章程的修改程序

第三十二条 对本团体章程的修改，须经会员大会审议。

第三十三条 本团体修改的章程，须在会员大会通过后 15 日内，报业务主管单位审查，经同意，报社团登记管理机关核准后生效。

第七章 终止程序及终止后的财产处理

第三十四条 本团体完成宗旨或自行解散或由于分立、合并等原因需要注销的，由会员大会提出终止动议。

第三十五条 本团体终止动议须经会员大会表决通过，并报业务主管单位审查同意。

第三十六条 本团体终止前，须在业务主管单位及有关机关指导下成立清算组织，清理债权债务，处理善后事宜。清算期间，不开展清算以外的活动。

第三十七条 本团体经社团登记管理机关办理注销登记手续后即为终止。

第三十八条 本团体终止后的剩余财产，在业务主管单位和社团登记管理机关的监督下，按照国家有关规定，用于发展与本团体宗旨相关的事业。

第八章 附 则

第三十九条 本章程经 2015 年 9 月 24 日第十届会员大会第二次会议表决通过。

第四十条 本章程的解释权属本团体的会员大会。

第四十一条 本章程自社团登记管理机关核准之日起生效。

Constitution of PhIRDA

Chapter One: General Principle

Article 1. Name of the Association: China Pharmaceutical Innovation and Research Development Association (the abbreviated name is PhIRDA).

Article 2. PhIRDA is a nationwide non-governmental and non-profit industrial organization composed of pharmaceutical scientific research institutions, enterprises, relevant universities and colleges on the basis of voluntariness.

Article 3. The objectives of the Association include:

Holding the great banner of Socialism with Chinese characteristics, taking Deng Xiaoping Theory, Three Represents and Scientific Outlook of Development as our guide, to implement the relevant general and specific policies and the reform spirit of the government, enhance research and innovation capacity of China's pharmaceutical industry, strengthen the combination between the scientific research institutions and pharmaceutical enterprises, promote international cooperation on research and development of China's pharmaceutical industry, expedite the technological development in pharmaceutical industry, enhance the economic efficiency in enterprises and provide better service for healthcare and economic developments.

The Association follows the China's related constitution, laws, regulations and policies, as well as the ethical code of the society.

Article 4. The Association undertakes administration by Ministry of Civil Affairs and State-owned Assets Supervision and Administration Commission of the State Council.

Article 5. The Association's residence is in Beijing.

Chapter Two: Business Range

Article 6. Business range of the Association

(1) To carry out and implement relevant general and specific policies on Chinese pharmaceutical industry development made by the Central Committee of CPC and the State Council, perform in-depth research on new drug development and Chinese pharmaceutical innovation system, scientifically forecast the direction of new drug development, timely propose the recommendations for development of Chinese pharmaceutical industry, reflect members' reasonable wishes and demands, and assists members to solve practical problems.

(2) To organize and participate in the relevant exchange programs to enhance Chinese pharmaceutical industry development. To organize and participate in the relevant academic exchanges, set up a think tank for Chinese pharmaceutical industry development and innovation, promote the pharmaceutical industry combination of scientific research and practices, operate the relevant research cooperation and academic-achieve promotion, and assist to industrialization and specification of the high technology.

(3) Using our advantages and modern technologies to collect, study and publish the medical information, to focus on the key issues of industry and provide consultancy.

(4) To promote the international communication of Chinese pharmaceutical industry, and organize different kinds of cooperation and exchanges on information, technologies and personnels.

Chapter Three: Members

Article 7. Members of the Association: Institutional members.

Article 8. Applicant members should fulfill the following requirements:

(1) Upholding the constitution of the Association;

(2) Be willing to join the Association;

(3) Possessing certain influences in the professional (industrial, academic) realm of our Association.

Article 9. Procedure of joining the Association

(1) Submitting application;

(2) Being approved through discussion on PhIRDA General Assembly;

(3) PhIRDA General Assembly or authorized agency issuing certificate to approved members.

Article 10. Rights and duties of members

(1) The rights of election, being elected and vote;

(2) Participate in the Association activities;

(3) The priorities of obtaining services from Association;

(4) The rights of supervision, suggestion and criticizing the issues of Association;

(5) The rights of obtaining the information and publications by Association;

(6) The right of protecting legitimate rights and interests.

(7) Enjoying freedom of joining and quitting the Association;

Article 11. Duties of the members

(1) Follow the Constitution of PhIRDA, implement the decision of the Association;

(2) Protect the legal rights and interests of the Association;

(3) Complete the work entrusted by the Association;

(4) Pay membership dues on time as per the stipulation;

(5) Provide various information requested by the Association.

Article 12. Quitted members should notify the Association with a written statement and return the membership certificates. If members don't carry out their duties for 2 years, they are regarded as withdrawing from the Association automatically.

Article 13. Members with serious breach of the Constitution will be cancelled with their membership by vote of the PhIRDA General Assembly on the basis of consensus.

Chapter Four: Generation and Recall of Organization Leadership

Article 14. The PhIRDA General Assembly is the highest powerful organization of the Association. Functions of the PhIRDA General Assembly include:

(1) Composing and revising the Constitution of the association;

(2) Electing and recalling of the Chairman, Vice-President and Secretary-General;

(3) Reviewing working report and financial report of this association;

(4) Establishing and modifying the membership fee standard;

(5) Making decision on the establishment and nomination of honorary position;

(6) Deciding the establishment, alteration and cancellation of offices, branches, agencies and entities of the Association;

(7) Appointing Deputy Secretary-General and other major responsible persons;

(8) Deciding termination of the Association;

(9) Deciding other important issues.

Article 15. The PhIRDA General Assembly should require a participation of more than two thirds of all members. The effectiveness of its decision should require acquire approval vote of more than half members.

Article 16. The PhIRDA General Assembly shall be convened at least once a year; it can be convened through telecommunication under certain conditions, except the decisions on important issues, including constitution emendation, major responsible person and fee standard changes, etc.

Article 17. The Chairman, Vice-Presidents and Secretary-General of the association must meet the following requirements:

(1) Persist in the CCP political direction, decisions, policies and good political qualities.

(2) Strong influence in the professional work field.

(3) An age of no more than 70 for the Chairman, Vice-President. An age of no more than 60 for the Secretary-General. The Secretary-General should be in full-time position.

(4) Being healthy enough to do normal daily work.

(5) Never deprived of political rights for criminal punishment.

(6) With ability of complete civil behavior.

Article 18. The Chairman, Vice-Presidents and Secretary-General of the association exceeds the maximum age shall conduct demission procedures.

Article 19. The Association applies system of annual Chairman rotation; the Chairman shall be elected from association members, and the term lasts for 1 year.

The Vice-President and Secretary-General are in position for a 4-year term, while their maximum tenure in office shall not surpass 2 terms.

Article 20. The Chairman is the legal representative of the Association. Under special circumstances, with the Chairman's commission and approval from Members General Assembly, subject to the review and approval from the related registration and administration authority, a Vice-President or the Secretary-General can be appointed as the legal representative.

The legal representative is not allowed to hold a concurrent post in other associations.

The Chairman, Vice-President and members of the Association will automatically lose their representative qualification when leaving their member units, and new election from candidates for their posts will be invoked.

Article 21. Function and powers executed by the President:

(1) Calling for and hosting the General Assembly.

(2) Examining the implementation of decisions made by General Assembly.

(3) In the case of being authorized by the Chairman, Vice-Presidents can perform parts of Chairman's responsibilities.

Article 22. The PhIRDA General Assembly establishes the Secretariat, and the functions executed by the Secretary-General include:

(1) In charge and to organize administrative sectors to do routine work and implement annual work plan.

(2) To coordinate the work of sub-branches, representatives and entities.

(3) To nominate the Deputy Secretary-General and representatives of sub-branches for the General Assembly's approval.

(4) To manage the employment of full-time working staffs for the Association.

(5) In charge of executing other routine affairs.

Chapter Five: Principle of Assets Management and Utilization

Article 23. Funds resources of the Association:

(1) Member annual fee;

(2) Donation;

(3) Government subsidies;

(4) Income from approved business activities and services;

(5) Interests;

(6) Other income from legitimate sources.

Article 24. Members pay fees to the Association according to the relevant state regulation.

The secretariat is responsible to manage the dues and the financial revenue and expenditure will be reported to all members during the General Assembly.

Article 25. The funds of the Association shall be used in the business range and career development regulated in the constitution and shall not be distributed among members.

Article 26. The Association sets up strict financial management rules and regulations, in order to ensure that the accounting data is legitimate, true, accurate and complete.

Article 27. The Association employs accounting staff with professional qualifications. An accountant cannot be a cashier at the same time. Accountants must perform accounting and accounting supervision. If accountants leave the posts or are transferred to other work, they must go through connecting procedures with the managing staff and shifting persons.

Article 28. Management of assets of the Association shall be executed according to the financial regulations stipulated by the state, and shall accept supervision of the members' Conference and the financial department. The assets that come from the government subsidies and social contribution shall be subjected to supervision by the audit organ, and shall be also promulgated to the public by the proper means.

Article 29. Before the legal person of the Association is replaced or is at the expiration of his term of office, he must be subjected to the financial audit by the relevant registration administration organ and the professional administration unit.

Article 30. The assets of the Association cannot be embezzled, diverted and distributed in private by any unit or any person.

Article 31. The wages, insurance and welfare of full-time staffs should comply with relevant regulations for government institutions in China.

Chapter Six: Revision Procedure of the Constitution

Article 32. The right of interpreting this Constitution belongs to the General Assembly.

Article 33. The Constitution comes into force on the date when it is ratified by social registration administration organ.

Chapter Seven: Procedure of disbanding the Association and handling the Assets

Article 34. Association cancelled due to organization structure changes or other reasons will be firstly proposed by the General Assembly.

Article 35. The proposal needs to be submitted and passed by the General Assembly and approved by administration department.

Article 36. Before disbanding the Association a clearing group shall be formed, under the direction of the professional administrative unit and the relevant organ, settle claims and debts, and to deal with the aftermath. During the clearing period any activities except clearing work will not be in progress.

Article 37. The Association is terminated after cancelling its registration in Social Organization Registration Administration.

Article 38. The left assets, after the Association is terminated, will be used to develop the business concerned about the Association's aim under the supervision of the professional administrative unit and the mass organization registration administration, in accordance with the relevant state regulations.

Chapter Eight: Appendix

Article 39. This Constitution was approved by 2nd Meeting of 10th PhIRDA General Assembly on September 24th, 2015.

Article 40. The right of interpreting this Constitution belongs to PhIRDA General Assembly.

Article 41. The Constitution comes into force on the date when it is approved by the authority of social organization registration & administration.

ORGANIZATIONAL STRUCTURE OF ASSOCIATION 机构设置



2015-2016

会领导介绍 | INTRODUCTION OF PhIRDA LEADERSHIP

第九届会员大会以来历任会长照片
Chairmen of PhIRDA Since 9th General Assembly

桑国卫
中国药促会会长（2009-2012） 中国药促会荣誉会长（2012-2014）
十一届全国人大常委会副委员长 中国工程院院士

Sang Guowei
Chairman of PhIRDA (2009-2012) Honorary Chairman of PhIRDA (2012-2014)
Vice Chairman of the Standing Committee of Eleventh National People's Congress
Academician of Chinese Academy of Engineering

陈启宇
2012-2013 年度会长
上海复星医药（集团）股份有限公司董事长

Chen Qiyu
Annual Chairman 2012-2013
Chairman of the Board, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

闫希军
2013-2014 年度会长
天士力控股集团董事局主席

Yan Xijun
Annual Chairman 2013-2014
Chairman of the Board,
Tasly Holding Group

孙飘扬
2014-2015 年度会长
江苏恒瑞医药股份有限公司董事长

Sun Piaoyang
Annual Chairman 2014-2015
Chairman of the Board,
Jiangsu Hengrui Medicine Co., Ltd.

蒋华良
2015-2016 年度会长
中国科学院上海药物研究所所长

Jiang Hualiang
Annual Chairman 2015-2016
Director, Shanghai Institute of Materia Medica,
Chinese Academy of Sciences

现任会领导
Current Leadership of PhIRDA

会长 蒋华良
中国科学院上海药物研究所所长

Jiang Hualiang, Chairman of PhIRDA
Director, Shanghai Institute of Materia Medica,
Chinese Academy of Sciences

执行会长 宋瑞霖
中国医药创新促进会

Song Ruilin, Executive President
China Pharmaceutical Innovation and Research Development Association

副会长 陈启宇

上海复星医药（集团）股份有限公司董事长

Chen Qiyu, Vice President
Chairman of the Board, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

副会长 闫希军

天士力控股集团董事局主席

Yan Xijun, Vice President
Chairman of the Board, Tasly Holding Group

副会长 孙飘扬

江苏恒瑞医药股份有限公司董事长

Sun Piaoyang, Vice President
Chairman of the Board, Jiangsu Hengrui Medicine Co., Ltd.

副会长 丁列明

贝达药业股份有限公司董事长兼 CEO

Ding Lieming, Vice President
Chairman of the Board & CEO, Betta Pharmaceutical Co., Ltd.

副会长 张伯礼

天津中医药大学校长，中国工程院院士

Zhang Boli, Vice President
President,Tianjin University of Traditional Chinese Medicine, Academician,Chinese Academy of Engineering

副会长 蔡东晨

石药集团有限公司董事长

Cai Dongchen, Vice President
Chairman of the Board, China Shijiazhuang Pharmaceutical Group Co., Ltd.

副会长 楼定波

上海医药集团股份有限公司董事长、党委书记

Lou Dingbo, Vice President
Chairman of the Board, Secretary of the Party Commission, Shanghai Pharmaceuticals Holding Co., Ltd.

副会长 任晋生

先声药业有限公司董事长

Ren Jinsheng, Vice President
Chairman of the Board, Simcere Pharmaceutical Group

副会长 石晟怡

中国医药集团总公司董事会秘书、中国国际医药卫生公司董事长

Shi Shengyi, Vice President
Secretary of the Board of Sinopharma Group Corporation, Chairman of the Board of China Sinopharm International Corporation

副会长 蒋建东

中国医学科学院药物研究所所长

Jiang Jiandong, Vice President
Director, Institute of Materia Medica, Chinese Academy of Medical Sciences

副会长 柯尊洪

成都康弘药业集团股份有限公司董事长

Ke Zunhong, Vice President
Chairman of the Board, Chengdu Kanghong Pharmaceutical Group Co., Ltd.

秘书长 冯　岚

中国医药创新促进会

Feng Lan, Secretary-General
China Pharmaceutical Innovation and Research Development Association

中国医药创新促进会工作报告

2015 年 9 月 24 日在第十届会员大会第二次会议上

（摘要）

执行会长 宋瑞霖

第一部分 2014-2015 年度主要工作回顾

2014 年 10 月 23 日，国家民政部正式批准我会更名申请，我会会名由“中国医药工业科研开发促进会”变更为“中国医药创新促进会”，会名变更标志着我会的工作重点从过去的促进工业科研开发转向推动医药创新；以医药创新为核心，团结医药产业、科研机构和临床研发机构及广大药物创新研究人员，成为我国医药创新政策研究、成果转化、国际交流的重要平台。2014 年 10 月 27 日我会召开了更名后第一次会员大会——第十届会员大会第一次会议，会议选举了我会第十届领导班子，确定了工作要求，明确了工作重点。换届以来的主要工作特点体现在以下四个方面：

一是，坚持民主办会，规范管理，促进我会科学发展、创新发展、改革发展。

二是，配合国家有关部门落实创新驱动战略，从产、学、研、用各个方面来促进医药创新。

三是，充分考虑和满足会员单位的需求，充分发挥社会各界专家和会员单位的力量、智慧和积极性来开展工作。

四是，加强信息化建设，运用网络、自媒体等多种形式，打造线上线下沟通平台，表达行业和会员单位的合理诉求。

具体工作如下：

一、加强我会建设

（一）切实发挥会长会议的作用，坚持民主决策。

由会长、副会长、秘书长组成的会长会议制度自 2012 年建立以来，就轮值会长候选人的推举、企业入会申请、会员大会的筹备等重大事项进行研究，在我会的发展和运转中发挥了重要作用。

今年 1 月 9 日，孙飘扬会长主持召开会长会议扩大会议，听取秘书处关于 2014 年换届大会以来的工作情况汇报，讨论了 2015 年我会的工作计划；研究了由我会帮助起草并将由国家卫计委报请国务院发布的《关于促进药物创新发展的指导意见（草案）》。

此外，经会长会议投票表决通过，深圳信立泰药业股份有限公司、华领医药（技术）上海有限公司、歌礼生物科技（杭州）有限公司以及信达生物制药（苏州）有限公司正式成为我会会员。

（二）成立专业委员会，搭建沟通交流平台。

我会分别于今年 4 月、7 月成立了药物临床研究专业委员会、药物研发专业委员会、医药政策专业委员会。专委会集中了临床研究、药物研发和医药政策等方面近 200 位专家，是第一批集临床、科研和产业研发人员于一体的专业委员会，已经成为我会工作的重要智力支持。

二、加强医药政策研究工作

围绕“研究我国医药创新发展的政策环境、市场环境和搭建医药创新发展交流平台”这个工作重点，我们主要开展了以下医药政策研究工作：

（一）接受有关部门的委托，为完善我国鼓励医药创新政策、药品招标采购政策、药品审评审批政策、专利强制许可政策等建言献策。

1、关于完善鼓励医药创新的政策。

受国家卫计委科教司（重大新药专项办）的委托，我会参与起草拟报国务院发布的《关于促进创新药物发展应用的指导意见》（以下称“指导意见”）的相关工作，参加了卫计委科教司征求各部委意见的研讨会，并组织了企业和专家征求意见的座谈会。目前，卫计委正在征求各部委对草案的意见，并将上报国务院。

“指导意见”草案的主要内容有：科学合理地界定创新药物；优化新药的审评、监管制度 完善医疗保险制度，加快推进创新药物进入国家医疗保障体系；完善新药专利保护制度，研究建立药品专利期限补偿制度和专利链接制度；加大国家对新药创制的投入和财税激励力度，切实减轻新药研发企业税收负担。我会的起草工作得到了重大新药专项办的肯定；许多观点已经在近期国务院出台的相关文件中得到体现。

2、关于完善我国药品招标采购政策。

（1）接受国家卫计委药政司委托，对基本药物可及性进行研究，同时针对药品招标采购制度中 “最低价中标”规定的弊端和危害做了大量工作，形成研究报告报送国务院领导和国家卫计委、国务院医改办等部门。

今年 2 月国务院发布了《关于完善公立医院药品集中采购工作的指导意见》（以下称国办 7 号文）。在该文件起草过程中，我会积极参与研究并主动拜访相关部门，提出修改意见与建议；该文有关招采合一、量价挂钩、完善双信封制、分类采购的指导思想是我会与医药行业同仁共同呼吁的结果。

（2）受农工党中央委托，撰写了《关于完善我国药品集中采购机制的研究报告》。报告中指出满足人民群众医疗服务的可获得性和可支付性，需要医疗、医保、医药三项改革系统性推进，共同联动；借鉴国际经验，明确医疗机构的采购主体地位，进一步提高医院在药品采购中的参与度和谈判能力提高采购效率等建议。

此报告的主要内容作为农工党中央《关于建立医疗卫生机构核心用药制度及做好药品集中采购工作的建议》的核心部分，由农工党中央主席、全国人大常委会副委员长陈竺院士上报国务院领导同志。国务院领导作出重要批示：请国家卫生计生委、人社部阅研，在药品采购中要充分调动各方力量真正实现招采合一，量价挂钩，切实压缩药价高水分，并在整合和修订医保目录中考虑。对此，陈竺副委员长特别对我会的工作表示感谢。

（3）受国家卫计委药政司委托，开展“公立医院基本用药配备模式研究”课题研究。我们对 700 家样本公立医院药品配备、使用数据进行收集及定量分析，针对公立医院基本用药目录的遴选，目录内药品的采购、报销方式等相关问题进行深入研究分析，最终提出完善我国公立医院基本用药配备及采购政策的建议。

3、关于完善药品审评审批政策。

（1）今年以来，我会多次接受国家食品药品监管总局药品化妆品注册司（以下称“注册司”）的委托，就完善药品注册分类问题进行研究，组织专家，对改革化学药品注册分类的迫切性及如何分类的建议、具体技术要求等进行研讨，并将书面意见报送注册司。我会建议：药品注册分类可按照药物的新颖性，将药品分为创新药、新药和仿制药三大类。该建议在 8 月 18 日国务院发布的《关于改革药品医疗器械审评审批制度的意见》（国发〔2015〕44 号）中得到体现。

（2）针对国家食品药品监管总局公开征求意见的《关于征求加快解决药品注册申请积压问题的若干政策意见的公告》（2015 年第 140 号），我会进行了认真研究，形成意见稿。我会提出，对质量一致性评价问题，应明确参比制剂的遴选原则，建立中国仿制药参比制剂目录；组织制定具有可操作性的仿制药分类别、分品种的一致性评价技术指南。药品研制资料“不完整”与“不真实”属于两种性质，应该区别对待，不能一概简单退审。对于国内有临床急需的药物，应鼓励国内企业研究挑战原研药的外围专利。针对专利问题，我会提出 CFDA 不对药品专利是否侵权做出判断，建立专利链接制度，因药品申报所引发的专利纠纷案件应当由司法途径解决等等。我会意见提交两天后，毕井泉局长、吴浈和孙咸泽副局长召开会议并特别邀请我会到会发表意见，我会在会上的多条意见和建议被采纳。

（3）国家食品药品监管总局注册司委托我会开展“特殊情形下药品批准制度课题研究”，按照有关部委“共同提出、共担风险”的原则，起草了适合我国国情的、特殊情形下多部门联合会商授权使用药品的程序规定。

4、关于知识产权保护政策研究。

受国家知识产权局保护协调司委托，我会开展国家紧急状态下专利强制许可程序实务研究，将针对紧急状态或为公共利益目的，研究制定专门的、明确和可操作的专利强制许可法律规范和实施机制。

（二）独立开展其他医药政策课题研究。

1、从 2014 年底开始，我会与中国药科大学合作，研究编撰“中国制药企业政策环境评估蓝皮书”（以下称“蓝皮书”）。蓝皮书对 2009 年新医改实施后国家和地方层面出台的相关医药政策（包括审批、价格、医保、招标、产业扶持等）进行综述，着重评价各省出台的有关医保、价格、招标、产业扶持等具体措施与国家层面出台的相关政策的契合度；设立合理的医药政策友好度评价指标和标准，形成各省医药政策环境友好度排名。

2、其他医药政策课题研究。我会始终坚持围绕我国医药政策领域热点问题进行专题研究，为我国民族医药产业的健康发展、医药卫生体制改革提出独立的见解。我会在研的课题十余项，涉及药品招标采购、药品审评收费制度、药品价格管理体制改革、仿制药产业发展、创新药相关政策等主题。

（三）通过召开研讨会、开展调研等方式促进医药健康产业创新发展。

1、2015 年 4 月 21 日，我会在徐州召开了“中国创新药物研发研讨会”，来自国家食药监管总局药品化妆品注册管理司的领导，我会药物临床、药物研

发专委会委员等 100 余人参与了本次会议。会议围绕中国创新药物研发环境与展望进行研讨。

2、2015 年 7 与 3 日，我会在北京召开了“药品招标采购政策研讨会”，来自医药政策专委会的 60 余名委员参加了本次会议。与会代表就我国药品招标采购的现状及发展趋势、GPO 采购通行做法等议题进行了集中讨论，并就如何完善我国现行药品招标采购制度进行了探讨。

3、2015 年 7 月 24 日，我会与中国药学会、中国药师协会共同举办了第六届医院药学政策论坛，来自国家卫计委药政司、医院管理研究所等单位的相关同志，以及全国各地医疗机构的药剂科主任及临床专家共计 500 多人参加了会议。会议就“加强药师队伍培养，促进以基本药物为重点的药品合理使用”、“医改的变化对医院、药剂科的冲击所引发的思考”等热点议题进行讨论，激发了广大药学工作者提高能力建设的积极性。

（四）坚决维护会员单位和行业的合法权益，为医药产业健康发展不断呼吁。

今年以来国家和各地的药品招标采购政策频繁出台，一直是社会热点问题。我会密切关注各地的药品招标采购相关政策，在各地征求相关意见时进行研究并及时提出建议，对一些违反产业发展规律和国家政策，漠视企业合法权益的做法在第一时间做出郑重回应。

1、针对浙江省药品招标采购工作的研究。2014 年 11 月 19 日浙江省公布了 2014 年药品集中采购（第一批）部分资料评审结果。2015 年 5 月 18 日，浙江省公布《关于创新全省药品集中采购机制的意见（征求意见稿）》。我会分别对这两个文件进行了研究并提出书面意见。我们建议：公开药物经济学评价专家的名单、程序和结果；对药品采购清单实行负面清单制度；浙江省应当以在本省实际执行的药品采购最低价作为本省集中采购和制定医保支付标准的依据。浙江有关方面专门给我会回函，表示将认真研究我会提出的意见。

2、2015 年 1 月，针对湖南省在药品集中采购工作的不当做法公开提出意见。我们认为：湖南有关部门在药品招标采购工作中采取专家在电脑前与企业即时确定交易价格的议价做法，科学依据不足；不够公开透明；没有充分考虑到我国药品质量存在差异的现状；受到“唯低价是取”等老旧思维方式的影响。这种做法与党中央、国务院关于全面深化改革、促进市场公平竞争、维护市场正常秩序的精神不符。

为此，湖南省药品招标办负责人致电我会，对我会进行批评和指责并扬言起诉我会。我会通过门户网站，摆事实、讲道理，向湖南省药品招标办重申了我会的观点和意见，并对湖南省的药品招标工作和中标品种的质量状况，持续进行监督。此举在业界和全国药品招标部门引起了较大反响；我会敢于坚持真理、敢于仗义执言的精神赢得了各界的赞赏。

3、与业界一起努力协助有关部门纠正安徽省蚌埠市卫计委在药品采购工作中的错误做法。今年 4-5 月，安徽省蚌埠市卫计委在公立医疗卫生机构药品带量采购工作中，强制要求相关企业在省级招标价格的基础上再降价 25%，并对不愿意降价的企业采取永远禁止其所有产品进入当地公立医院销售的惩罚措施，同时将不愿意降价的企业列入不良记录。

我会经研究认为，蚌埠的这一做法存在两个方面的问题：一是，与中央鼓励创新、简政放权、让市场在资源配置中发挥决定性作用并更好地发挥政府作用的精神不一致；二是，涉嫌违反《民法通则》、《合同法》、《反垄断法》等法律。我会形成专门的研究报告，报送给包括国务院医改办在内的有关部委并抄送安徽省卫生计生委；在未得到有关部门回应的情况下，就蚌埠市卫计委涉嫌违反《反垄断法》有关规定的问题依法向国家发展改革委、国家工商总局举报。

8 月 17 日，国家发改委向安徽省政府办公厅发出《国家发展改革委办公厅关于建议纠正蚌埠市卫生计生委滥用行政权力排除限制竞争有关行为的函》（发改办价监 [2015]2175 号，以下称“2175 号文”），并要求安徽省政府在 8 月 31 日前将整改情况报告给国家发改委。2175 号文是对包括中国药促会在内的业界强烈反应的回应，实质上是对蚌埠市卫计委组织的药品采购工作错误做法的否定。这是国家发展改革委依法启动的全国第一例涉及医改的反垄断调查，对全国各地的药品采购工作具有指导、示范作用，将促使各级药品招标主管部门依法履行对招标工作的监管职责，在制定药品招标政策时要科学论证，充分征求相关方面的意见，听取不同的声音，使各地的药品招标采购工作朝着合法、理性与良性的方向发展。

三、广泛开展国际交流活动

（一）组织或者参加重要的国际会议

1、2014 年 10 月 27-28 日，受国家卫生计生委委托，承办了“2014 国际医药创新合作论坛——金砖国家面临的挑战与机遇”。此次会议是金砖国家首次召开的有关促进医药创新合作方面的会议，也是在金砖国家卫生部长会议框架下第一次专门就医药创新和产业发展问题召开的会议，具有开创性的意义。巴西联邦共和国驻华大使馆、世界卫生组织驻华处代表、联合国艾滋病规划署的代表，以及金砖国家医药界、我会会员单位的代表、学者共 230 多人参加了本次论坛。

2、2014 年 11 月 10 日，我会和台湾国家生技医疗产业策进会（以下称“生策会”）在台北市共同主办了“2014 两岸生技新药产业合作论坛”。来自海峡两岸生物医药产业界的 300 余位代表参加了论坛。会上，生策会与我会签署了双方《合作备忘录》，旨在促进两岸医药产业合作，共同推动医药产业创新发展。本次论坛的召开推动了两岸创新医药产业间在新药研发方面的交流与协作。

3、2014 年 12 月 2-4 日，我会会长孙飘扬、执行会长宋瑞霖应邀作为中国政府卫生代表团成员出席在巴西召开的金砖国家卫生部长会议，会议主题为药物研发和可获得药物。我会代表在会上提出的建议获得金砖国家与会代表的一致认可，并被写入金砖国家第四次卫生部长会议的最终报告。这是中国医药相关协会第一次参加政府间国际会议并参与会议文件起草和讨论，具有非常积极的意义。会议期间，孙飘扬会长等我会代表与国家卫计委李斌主任就我国药物创新政策、专利强制许可以及药品招标采购等问题进行了交流，增进了卫计委领导对医药产业的理解。

4、2015 年 4 月 9 日，应日本制药工业协会（JPMA）邀请，我会陈昌雄秘书长出席了在日本东京举办的“如何促进新药研发及市场化”及“如何打击假药”为主旨的“亚洲医药创新联盟会议”（APAC）。

5、2015 年 5 月 13 日，根据国家卫计委建议，我会与生物技术工业组织（BIO）、中国外商投资企业协会药品研制和开发行业委员会（RDPAC）在美国洛杉矶共同主办了“中美生物医药创新合作研讨会”。国家重大新药创制科技重大专项行政负责人、国家卫生计生委副主任刘谦出席会议并发表讲话。

6、2015 年 8 月 19-20 日，我会派员应邀参加了在马尼拉举行的 2015 亚太经合组织医药产业伦理准则会议（2015 APEC Business Ethics Forum）。此次活动是自 2013 年吉隆坡会议以来，我会连续第三次受邀派员参加 APEC 医药产业伦理准则会议。

（二）就药品采购制度和医疗保险制度等政策问题开展国外调研。

1、为了完善我国药品招标采购制度，2015 年 5 月我会组织调研组访问了 LEK（艾意凯咨询）洛杉矶公司，就美国药品集团采购组织（Group Purchasing Organization，GPO）的相关问题开展调研。

2、结合我会的政策研究课题，2015 年 7 月，我会调研组赴柏林和布鲁塞尔进行调研，详细了解德国的医疗保险体制和欧盟鼓励医药创新的政策。

调研组了解到：在德国，新药上市后，医保基金即将其纳入医保报销范围；与此同时，要求企业开展临床效果评价，收集证明其优于其他药品的证据。这一制度设计，不仅促使企业从重视审评向注重药品的疗效和质量转变，也使得药品支付方在开展价格谈判中找到了谈判依据。

欧盟的药物创新模式对我国当前实行大众创业、万众创新的战略有着一定的借鉴作用。

3、为了完善我国鼓励新药创制的相关政策，应日本制药工业协会（JPMA）的邀请，2015 年 7 月 27-29 日，我会代表团赴日本开展医药政策调研活动。代表团访问了 JPMA、日本最大的批发物流公司 ALFRESA 公司总部、日本厚生劳动省和 PMDA，就日本的药品审评制度、药品知识产权制度、医保体系及医保药品定价、医药分业、医院药品采购等内容进行了深入调研，获得了丰富的第一手资料。

四、不断提高医药信息服务水平

1、加强门户网站的建设。为适应我会工作内容的不断拓展并增强用户体验，我们对我会门户网站进行了全新改版，提高了用户对网站推送信息的浏览感受及浏览便利性。网站每日更新的行业热点，包括国家政策法规、行业动态、我会工作进展与行业市场研究报告等信息，获得了较高的关注度。

2、运用微信自媒体表达心声，传递信息。今年我们开通了微信公众账号，利用微信自媒体传播便捷和多样化的特点，广泛宣传我会对医药政策研究的意见、建议，并推送行业热点信息。我们还通过建立、维护会员 QQ 群、专业委员会微信群，为大家提供即时交流与对话平台。

3、为医药政策研究提供数据支持。为了提高我会政策研究的质量与水平，增强政策建议的预见性与科学性，我会的医药信息工作也逐步拓展至为我会政策研究提供信息数据参考，通过对有效数据的正确分析作出科学、合理的政策分析。

过去的一年，是国家医药相关改革政策密集出台的一年，在孙飘扬会长的正确领导以及广大会员单位和各专委会专家的大力支持参与下，中国药促会积极参与到改革的进程中，发挥了积极主动的作用。中国药促会与相关部门建立了较好的沟通、交流与合作关系，工作和努力也得到了有关部门的认可；针对各地药品招标以及医保报销等具体实施工作，药促会认真研究问题，勇于提出问题和建议；对个别地方出台的与国家法律政策不一致损害医药产业发展的政策，敢于提出批评并提出具体建议。中国药促会起到了专业社会团体应当起到的作用，不仅在国内医药界得到认可，也引起国际医药界瞩目。中国药促会在业界的向心力和凝聚力进一步增强。今年又有 8 家创新型企业申请加入中国药促会。我们深深体会到，作为医药专业社会团体只有充分发挥自己的专业优势，主动发现、研究问题，提出可行、合理的建议和意见才能赢得各方的理解和尊重；只有医药界真正地团结起来，才能将医药协会做大做强，才能切实代表成员单位的合理利益，维护会员单位的合法权益。

第二部分 关于 2015-2016 年度的工作建议

党的十八大以来，国家关于社团发展的总体要求是：加快形成政社分开、权责明确、依法自治的现代社会组织体制，引导社会组织健康有序发展。今年以来，党中央、国务院又出台了具体的政策。2015 年 7 月初，中共中央办公厅、国务院办公厅印发了《行业协会商会与行政机关脱钩总体方案》，要求理清政府、市场、社会关系，促进行业协会商会成为依法设立、自主办会、服务为本、治理规范、行为自律的社会组织。

另一方面，党的十八大以来，党中央、国务院一直强调保障和改善民生及创新发展，在改善民生和创新管理中加强社会建设，实施创新驱动发展战略，加快建设国家创新体系。今年国家相继出台了多个实施创新驱动战略的文件：3 月，《中共中央国务院关于深化体制机制改革加快实施创新驱动发展战略的若干意见》发布，指出要破除一切制约创新的思想障碍和制度藩篱，激发全社会创新活力和创造潜能，营造大众创业、万众创新的政策环境和制度环境。5 月，国务院印发了《中国制造 2025》，明确指出要发展针对重大疾病的化学药、中药、生物技术药物新产品。6 月，国务院发布了《关于大力推进大众创业万众创新若干政策措施的意见》（国发〔2015〕32 号），要求充分发挥市场在资源配置中的决定性作用，实现创业便利化，激发创造活力，发展创新型创业，形成有利于创业创新的良好氛围。

前不久，国家发布了《中共中央国务院关于构建开放型经济新体制的若干意见》提出，要进一步破除体制机制障碍，使对内对外开放相互促进，引进来与走出去更好结合，以对外开放的主动赢得经济发展和国际竞争的主动，以开放促改革、促发展、促创新，建设开放型经济强国。

基于上述大的政策背景，我会在 2015-2016 年度要为会员单位和医药行业提供优质服务，促进国家医药创新体系的构筑，探索并推动建立符合中国国情、行之有效的创新药物发展的新模式和新机制。为此，提出以下具体工作建议：

（一）继续围绕医药行业生态环境建设问题开展政策研究。

1、与国家食品药品监管总局有关司局密切配合，继续开展修改《药品管理法》、《药品注册管理办法》的研究工作，重点研究如何从法律机制上来鼓励创新，包括如何在法律中完善药品审评机制和仿制药管理制度，建立上市许可人制度和药品专利链接制度等内容。

2、与国家新药重大专项办、国家卫计委、人社部研究新药研发、医疗保险制度、药品价格形成机制等相关政策，继续推动优化鼓励医药创新的政策环境。

3、与农工党中央密切合作，就提高我国药品质量标准、完善我国的药品采购制度进行深入研究，为党中央、国务院及有关部委提供政策建议。

4、密切关注各地出台的药品政策，发挥社会组织的第三方监督职能，维护医药行业的合法权益。

（二）继续加强国际交流，为我国的医药创新发展提供服务。

继续加强与美国 PhRMA、JPMA、BIO、DIA 等国际组织以及医药发达国家、新兴市场国家的医药创新型企业和研究机构的单边与多边合作，围绕“医药创新合作”主题，开展以下三个方面的交流：

一是，探讨国内外医药创新政策的最新动态，借鉴国外鼓励创新的政策法规，促进我国相关政策的完善。

二是，加强国内外的医药信息技术交流，分析医药创新国际发展趋势和最新突破，推动我国药物创新与研发。

三是，为国内外医药研发机构、生产企业和投资机构提供项目交流平台，将我国的资金优势和产能优势与国际优秀的研发项目结合。

（三）进一步加强能力建设，更好地为会员单位服务。

1、深入调研，了解会员单位的需求，并充分发挥会员单位的积极性与优势，使我会的各项工作与会员单位的要求紧密结合，为会员单位的创新项目以及产品推广提供平台服务。

2、在国家推行质量疗效一致性评价以及生物等效性试验工作中，探索发挥药促会自身优势的方式与路径，为会员单位服务。

3、充分发挥专业委员会的作用，通过各种形式，利用外脑，为会员单位和医药行业提供全方位的服务。我们将做好新发起成立的投资专委会的筹备工作，进一步提高药促会的服务能力。

4、加强医药信息服务，努力提高对医药信息数据的收集、遴选、分析能力，为我会和会员单位的政策研究和发展提供支持。

各位代表，时代赋予了中国发展兴盛的历史机遇，我会的发展也面临着同样的历史机遇。让我们以党中央有关社团改革与创新驱动的精神为指导，凝神聚力，开拓创新，奋发向上，为实现医药创新的中国梦、把我国建成富强民主文明和谐的社会主义现代化国家、实现中华民族伟大复兴的中国梦作出新的更大贡献！

PhIRDA Annual Work Report of 2014-2015

The Second Meeting of 10th PhIRDA General Assembly, September 24, 2015 (Abstract)

Song Ruilin, Executive President of PhIRDA

Session One. Review of Work during 2014-2015

On October 23,2014, The Ministry of Civil Affairs formally approved the our application to rename from “China Pharmaceutical Industry Research and Development Association” into “China Pharmaceutical Innovation and Research Development Association”, indicating our focus change from promoting industrial research and development into promoting pharmaceutical innovation; centering on pharmaceutical innovation as the core, unit the industry, research institutions and clinical research institutions as well as the vast number of drug innovation researchers, becoming an important platform of the innovation policy research, technology transfer and international exchange for pharmaceutical industry in China. The First Meeting of 10th PhIRDA General Assembly was held on October 27, 2014, which elected the tenth leadership team, identified the work goals with clear focus points. The major work The First Meeting of 10th PhIRDA General Assembly are summarized in four aspects as below:

Firstly, adhered to the democratic and standardized management, promoted the scientific innovative reform and development.

Secondly, cooperated with relevant departments to implement the innovation driven strategy, utilizing all aspects to promote pharmaceutical innovation, including industry, academic, research and application.

Thirdly, fully considered to meet the needs of members, full utilized the strength, wisdom and enthusiasm of experts and members to carry out work.

Fourthly, strengthened information construction, utilized internet, media and other forms of online and offline communication platform to express reasonable needs from the industry and members.

Details are summarized as following:

Part One. Improved The Association’s Construction

(I) Held Presidential Board Meeting for democratic decision-making.

Since 2012, PhIRDA established Presidential Board Meeting consisting of Chairman, Vice Presidents and Secretary-General. The Presidential Board Meeting has discussed about important topics, including Chairman candidates, membership application, General Assembly, etc, playing vital role during the development and operation of the association.

On January 9, 2015, Chairman Sun Piaoyang held the Presidential Board Meeting, listened to the Secretariat’s work report since The First Meeting of 10th PhIRDA General Assembly, discussed the work plan in 2015, studied “The Guidance on Promoting Drug Innovation and Development (Draft)”, which was drafted by PhIRDA and to be submitted to State Council by NHFPC.

Moreover, the Presidential Board Meeting approved Innovent Biologics, Inc., Shenzhen Salubris Pharmaceuticals Co., Ltd., Hualing Medicine (Shanghai) Ltd., Ascletis Bioscience Co., Ltd. to become members of PhIRDA.

(II) Established Specialty Committees, built communication platform.

PhIRDA established Medicinal Policy, Drug R&D, Clinical Research Specialty Committees in April and July 2015, consisting of nearly 200 experts on the clinical research, drug R&D and medicinal policy, which have become an important intellectual support to our work.

Part Two. Enhanced Medicinal Policy Research

Focusing on the study of policy environment, market environment and the establishment of drug innovation and development platform in China, research work on the following medicinal policies were carried out:

(I) Entrusted by relevant departments, to provide policy advice on pharmaceutical innovation encouragement, drug bidding and procurement, review and approval, patent compulsory licensing.

1. On improving the policy to encourage drug innovation. Entrusted by NHFPC, PhIRDA drafted “The Guidance on Promoting Drug Innovation and Development” and participated in related meetings for views. The NHFPC is now seeking the views of related departments and will submit the draft to State Council.

The main contents of this drafted guidance are: scientific and reasonable definition of innovative drugs, optimizing the new drug review, supervision system, improving the medical insurance system, accelerating their entry into the national medical insurance system, improving the patent protection

system of new drugs, establishing the compensation system of drug patent and the patent link system. Many opinions and advice from PhIRDA have been reflected in relevant documents recently issued by State Council.

2. On improvement of drug bidding and procurement policy in China.

(1) Entrusted by NHFPC, PhIRDA carried out research on availability of essential drugs, focusing on the abuse and harm of "the lowest bid" provisions in drug bidding and purchasing system, submitted report to State Council leadership, NHFPC and Health Reform Office of State Council.

In February this year, the State Council issued "The Guidance on Improvement of Centralized Drug Purchasing Work in Public Hospitals" (hereinafter referred to as the State Article No.7). In the process of drafting the document, we actively participated in the research and visited relevant departments to propose amendments views and suggestions; the guidance contents in the article about the combination of bidding and procurement, linkage of amount and price, improvement of the dual envelope system and procurement classification are the results of the voice from PhIRDA together with our colleagues in pharmaceutical industry.

(2) Entrusted by Central Committee of Chinese Peasants And Workers Democratic Party, we wrote "Report on the Improvement of Centralized Drug Purchasing Mechanism". The reports pointed out that to meet the needs of availability and affordability of medical services, it is necessary to systematically promote common linkage of three reforms on healthcare, medical insurance and medicine; learn from international experience, clarify the center position of procuring medical institutions to further improve the hospitals' participation and negotiation skills during drugs procurement, and improve procurement efficiency, etc.

With the main contents of this report as its core, report "Proposal on the establishment of core administration system and centralized drug procurement in medical institutions" by the Central Committee of Chinese Peasants And Workers Democratic Party, was submitted to the State Council by Chen Zhu, Chairman of Chinese Peasants And Workers Democratic Party, Vice Chairman of NPC Standing Committee. The State Council leadership made important instructions: Forward to NHFPC and MOHRSS for reading and research, to fully utilize all forces to combine the bidding and procurement with linkage between amount and price, effectively compressing high drug prices, this should be considered during the integration and revision of health insurance directory. In this regard, Vice Chairman Chen Zhu expressed special thanks to our work.

(3) Entrusted by NHFPC Pharmaceutical Affairs Division, we carried out research "Equipped model of essential medicines in public hospitals". Our obtained 700 samples of public hospitals with medicine data and performed quantitative analysis, carried out deep research and analysis on selection of essential medicines for public hospitals directory, related issues within the directory medicines procurement and reimbursement methods, and ultimately provided policy recommendations to improve essential medicines procurement in public hospitals in China.

3. Improved drug evaluation and approval policies

(1) Entrusted by Department of Drug and Cosmetics Registration in China Food and Drug Administration (abbreviated in Registration Department) this year, PhIRDA organized experts to have a discussion on issues of improving drugs registration classification; researched on the urgency of reform on chemical drugs registration classification, suggestions on how to classify and the specific technological requirements, and eventually submitted the research report to Registration Department. PhIRDA's suggestions is that drugs registration classification could be processed in accordance with drug novelty, and drugs should be divided into three categories, including innovative drugs, new drugs and generic drugs, which was reflected on Approval System Reform for Drugs, Medical Devices issued by State Council on August 18 (No.2015.44).

(2) Regarding the Notice issued by China Food and Drug Administration, PhIRDA carried out research and drafted a report. Regarding the quality consistency evaluation, PhIRDA proposed that selected principle of reference preparation should be clarified, and establish a generic drugs reference preparation catalog in China. Organize to develop practical generic drugs catalogs on consistent evaluation by categories and species. Pharmaceutical research data "incomplete" and "untrue" belongs to two properties, it should be treated differently. For domestic clinically needed drugs, domestic companies should be encouraged to challenge patent periphery of the foreign original drug. Regarding patent issues, PhIRDA proposed CFDA not to judge whether drugs patent belongs to infringement; establish patent link system; drug declaration triggered because of patent disputes should be resolved by judicial means, etc. Minister Bi Jingquan, Vice Ministers Wu Zhen and Sun Xianze, held a meeting and invited representative from PhIRDA to attend and share ideas. Many suggestions proposed by PhIRDA representatives were adopted.

(3) Entrusted by Department of Drug and Cosmetics Registration in China Food and Drug Administration, PhIRDA carried out the research on Drug approval regulations under special circumstances. According to the principle "Co-Sponsor, Co-Risk" proposed by related authorities, PhIRDA drafted procedural requirements of multi-sectoral federation's authorized use of drugs under special circumstances with Chinese characteristics.

4. Research on intellectual property rights protection policy. Entrusted by Protection Coordination Division at State Intellectual Property Office, we carried out research on patents compulsory licensing procedures under national emergency, study and formulate specific, clear and workable legal norms and implementation mechanisms of compulsory patent licensing.

(II) Carried out research on other medicinal policy topics.

1. Since end of 2014, PhIRDA has been working with China Pharmaceutical University on "Blue book on policy environment assessment for pharmaceutical enterprises in China" (hereinafter referred to as the "Blue Book"). The Blue Book reviews relevant pharmaceutical policies at national and local levels since the new health reform in 2009 (including approval, pricing, health care, bidding, support, etc.), focusing on evaluation of the policy fitness between provinces and the central government on pricing, health care, bidding, support; establishing reasonable evaluation standards factors of medical policy friendship, ranking the provincial environmental friendship for pharmaceutical industry.

2. Research on other medicinal policies. We always focus on studies about the hot issues in pharmaceutical policy areas to provide independent views for the healthy development of China's pharmaceutical industry, medical and health system. There are more than 10 on-going research subjects, involving drug bidding and procurement, drug evaluation fee system, drug price management system, development of generics and innovative drug-related policies.

(III) Held seminars and investigations to promote the healthy development of the pharmaceutical industry.

1. On April 21, 2015, PhIRDA held "Seminar on innovative drug R&D in China" in Xuzhou. More than 100 people, including leaders from the CFDA and PhIRDA Specialty Committees, participated in the meeting. Topics around innovative drug R&D environment and prospects in China were discussed.

2. On July 3, 2015, PhIRDA held "Seminar on pharmaceutical bidding and procurement policy" in Beijing, more than 60 members from PhIRDA Specialty Committees attended the meeting. Delegates discussed on the current situation and development trend of China's drug bidding, GPO procurement prevailing practices, and shared views on how to improve the existing drug bidding procurement system.

3. On July 24, 2015, together with CPA and Chinese Pharmacists Association, PhIRDA jointly organized the 6th Hospital Pharmacy Policy Forum. More than 500 people, including officials from NHFPC and related pharmacy directors and clinical experts across the country, attended the meeting. Topics on "Strengthening the pharmacist team culture, promote rational use of drugs centering essential medicines", "Impacts of health reform on hospitals, pharmacies" were discussed, stimulating people's enthusiasm to improve ability construction.

(IV) Safeguarded the legitimate rights and interests of members and industry, continuously appealing for the healthy development of pharmaceutical industry.

The frequent introductions of drug bidding and procurement policies at national and provincial levels have been hot social topics this year. We paid close attention to related policies, conducted research when the government was seeking advice and timely made suggestions for some violation of industrial development rules and national policies, making timely responses.

1. Research on the bidding and procurement work in Zhejiang Province. Zhejiang Province centralized drug procurement results (first part) were announced on November 19, 2014.Then, on May 18, 2015, Zhejiang Province announced "Guidance on innovation of provincial centralized drug procurement mechanisms (draft)." PhIRDA carried out research on these files and submitted written comments. We recommend: publish name list of pharmacoeconomic evaluation experts, procedures and results; implement negative list system for drug procurement, the lowest procurement price in practice in Zhejiang should be used as the standard basis for provincial centralized procurement and insurance payment. Related departments in Zhejiang replied to carefully study these suggestions.

2. In January 2015, PhIRDA submitted public comments on Hunan inappropriate centralized drug procurement practices. We believe that Hunan authorities' bidding method to determine the transaction price lacked of scientific evidence and transparency, did not adequately take into account the differences in drug quality under current situation, and was affected by "cheap-buying" old way of thinking. This practice violated the policy spirit to comprehensively deepen the reform, promote fair market competition and maintain normal market order by CPC Central Committee and State Council.

For this reason, Hunan Provincial Drug Bidding Office criticized, accused and threatened to sue PhIRDA. We reiterated our views and opinions, stated the facts and the truth through website, carried out continuous supervision on Hunan status. This attracted great attention among the industry and drug bidding offices across the country; Our spirit, to dare to uphold the truth and speak out, received appreciation from the community.

3. Worked together with industry to help relevant departments correct its erroneous ways in drug purchasing in Bengbu, Anhui Province. From April to May this year, Bengbu Health and Family Planning Commission forced relevant enterprises to make a 25% reduction on the government bidding price in drug purchasing. And as a punishment to the companies refused to lower their prices, all of their products will be declined by the local public hospitals, together with poor record.

Two problems were found through our studies: one is that it goes against the central government guidance which encourages innovation, streamlining administration and letting the market determine the distribution of resources. Another is that it is an allegation of lawbreaking, including General Principles of Civil Law, Contract Law and Antitrust Law, etc. We sent the research report to relevant Ministries including State Council Health Reform Office and also copied to Anhui Health and Family Planning Commission. In the absence of responses from the relevant departments, we reported the problem to National Development and Reform Commission and State Administration of Industry and Commerce for alleged violations of the Antitrust Law.

On August 17, National Development and Reform Commission issued a letter (No. 2175) to Anhui Provincial General Office on the recommendation to correct the abuse of administrative power to eliminate and restrict competition, and required Anhui government to report rectification progress by August 31. No. 2175 is a response to the industry's strong reaction including PhIRDA. Essentially, it is a denial of the purchasing practice of the Bengbu Health and Family Planning Commission. This is the first case for NDRC, which involves the anti-monopoly investigation of health reform and plays a guiding role to drug purchasing in China. It urges the related departments to fulfill their duties of supervision and administration on bidding work. Making drug bidding policy requires the scientific argument, wide range of opinions and different voices, so to make the drug bidding work develop legally, rationally and virtuously.

Part Three. Carried Out Extensive International Exchange Activities

(I) Organized or participated in important international events.

1. 2014 International Pharmaceutical Innovation Collaboration Forum - Challenges and Opportunities for BRICS Countries was hosted by NHFPC and organized by PhIRDA in Beijing on October 27-28, 2014. This forum is the first meeting of the BRICS countries in the field of pharmaceutical innovation, which provided a dialogue platform for BRICS countries to exchange experience. The Ambassador Extraordinary and Plenipotentiary, Embassy of the Federative Republic of Brazil,WHO Representative in China and representative from UNAIDS together with more than 230 participants attended this forum.

2. On November 10, 2014, PhIRDA together with and Taiwan Institute for Biotechnology and Medicine Industry (hereinafter referred to as "IBMI") co-hosted "2014 biotechnology new drugs forum" in Taipei. More than 300 delegates attended the forum. At the forum, a bilateral "Memorandum of Cooperation" was signed between PhIRDA and IBMI, aiming to promote cross-strait cooperation, and jointly enhance the innovation and development of pharmaceutical industry. This forum promoted cross-strait exchanges and cooperation on new drug R&D innovation in pharmaceutical industry.

3. On December 2-4 2014, Chairman Sun Piaoyang and Executive President Song Ruilin were invited as members of Chinese government delegation to attend the BRICS health Ministers Meeting in Brazil, on the theme of drug development and availability. Our suggestions were agreed by BRICS delegates and written into the final report of the fourth BRICS Health Ministers Meeting. This is the first time for a Chinese pharmaceutical association to participate in international intergovernmental conferences and participated in drafting and discussions, which was highly positive. During the Forum, Chairman Sun Piaoyang and other representatives also discussed drug innovation policy, compulsory patent licensing, bidding and procurement policies, together with Minister I Bin from NHFPC, enhancing the understanding from NHFPC leadership.

4. On April 9, 2015, Secretary-General Chen Changxiong was invited by JPMA for APAC event on promoting new drug innovation and combating counterfeit drugs in Tokyo.

5. On May13, 2015, according to suggestion by NHFPC, PhIRDA together with BIO and RDAC co-hosted "Sino-US Biopharmaceutical Innovation Cooperation Forum" in Los Angeles. Vice Minister Liu Qian from NHFPC attended the forum.

6. On August 19-20, 2015, Senior Director Wang Xin attended 2015 APEC Business Ethics Forum in Manila, Philippines. It has been the third year since the association's leadership was invited to attend APEC Business Ethics Forum in Kuala Lumpur in 2013.

(II) Carried out foreign investigations on drug procurement and medical insurance policies.

1. In May 2015, to improve the drug bidding and procurement regulations in China, PhIRDA delegates visited LEK Consulting Office in LA for investigation on US Group Purchasing Organization (GPO) .

2. In July 2015, PhIRDA delegates visited Berlin and Brussels to conduct research to learn more about health insurance systems and policies to encourage pharmaceutical innovation in Germany and European Union.

It was learned that in Germany, after the listing of new drugs, the health insurance fund will soon include the drug into the reimbursement list; meanwhile, it requires companies to conduct clinical effect evaluation, collecting evidence to prove their superior to other drugs. This system design, not only encourages enterprises to focus on the efficacy and quality of drugs, but also finds basis for the payers during price negotiations.

The EU drug innovation model has a certain reference for our current implementation of public innovative strategy in China.

3. In order to improve China's relevant policies to encourage new drug innovation, PhIRDA delegates was invited by Japan Pharmaceutical Manufacturers Association (JPMA) for policy research activities during July 27-29, 2015. The delegation visited the JPMA, corporate headquarter of Japanese largest wholesale and logistics company ALFRESA , MHLW and PMDA, deeply discussed about the drug approval regulation, intellectual property system, healthcare system, medicare drug pricing, hospital drug procurement system, while obtained a wealth of first-hand information.

Part Four. Continuously Enhance Informative Service Standards

1. Strengthened the construction of the gateway website. To adapt to our association's constant expansion and to enhance user experience, we've made a whole new revision of our gateway website, increased users' browsing experience of website's push notification and browsing convenience. Industry hotspots updated by our website, including national policy and laws, industry dynamics, our working process and research reports of industrial market, etc., has attracted high attention.

2. Used Wechat-media. We opened our Wechat public service account this year. The convenient and diverse communication models of we-media allow us to publicize our ideas and suggestions on medical policy research and push industry news updates in large scale. We also have provided exchange mechanisms by building and maintaining the members' QQ group and Wechat group for special commissions.

3. Data support for drug policy study. In order to improve the quality and standard of policy study, and to enhance the predictability and scientific of our policy advice, our information work gradually develops to provide data reference for policy study, by making scientific and rational policy analysis of the effective data.

During the past year, the national pharmaceutical reform policies were published intensively. Under the leadership of Chairman Sun Piaoyang, the strong support of the members of PhIRDA and the experts of Specialty Committees, PhIRDA played a proactive and positive role in the pharmaceutical reform process. PhIRDA was well known by hard working and formed a good relationship with the relevant departments. We did lots of research to propose the critical questions and made advanced suggestions on drug biding and the implementation of medicare reimbursement. We proposed issues and suggestions on the local policies which had bad influence on the development of pharmaceutical industry. PhIRDA, as a professional and social organization, plays an important role both in the domestic pharmaceutical industry and the international pharmaceutical industry. Its influence and cohesion have been increased step by step. We know that deeply, as a professional society group, we should win the understanding and respect by discovering issues and proposing reasonable suggestions. The pharmaceutical industry area should be united tightly in order to make the PhIRDA stronger and bigger to protect the legal rights and interests of its members.

Session Two. Suggested Work Plan for 2015-2016

In the 18th National Congress of Communist Party of China, social associations are required to develop healthily and orderly. Associations should be modern social organizations, which are self-controlled and independent from government and have clear rights and responsibilities. The Central Committee of CPC and State Council issued specific policies this year. At the beginning of July 2015, The CPC Central Committee General Office and State Council published "Strategy of Industry Association Independent from Administrative Organization" in order to promote associations to become legal, independent, professional service and self-disciplined social organization by clarifying the relationship among government, market and associations.

On the other hand, during the 18th National Congress of Communist Party of China, The CPC Central Committee and State Council emphasized to improve citizen life and innovative development. The national innovation system should be promoted by innovation development strategy. There are many innovation improvement documents this year: In March, "Deepening the Reform of Institution to Improve Innovation Strategy by State Council" was published and it pointed that we should take over all of the difficulties from mind and institution to stimulate the potential creativity of the whole society to create an innovation policy and institution environment; In May, State Council published "China Manufacturing in 2025" which stated clearly that it is important to develop the new chemical entities, traditional Chinese medicines and biotech drugs to cure serious diseases; In June, State Council published "The Comments on Promoting Entrepreneurial and Innovative Measures" (State Council 2015, No. 32) which required that market to play a decisive role in the allocation of resources to create a good entrepreneurial and innovational atmosphere, so as to stimulate innovative and creative activities.

Recently, "Comments on construction of a new and open economy system" was published by State Council. It stated that we should break the institutional obstacles to promote opening of internal and external market and technique-knowledge exchange. We would be a winner during economic development and international competition by opening market. Our country would be an opening country by revolution, development and innovation.

Based on these backgrounds above, PhIRDA will provide good services to its members and the pharmaceutical industry from 2015 to 2016, so as to promote the establishment of national pharmaceutical innovation system, to explore an effective new drug innovation system. For this prospective, we propose the following specific work:

(I) To continuously carry out policy research of pharmaceutical eco-system..

1. PhIRDA will work closely with relevant departments of CFDA to revise the "Drug Administration Law" and "Drug Registration Regulations", focusing on the legal mechanisms to encourage innovation, including how to improve drug approval mechanism and generic drugs management system, establish MAH and drug patent link system, etc.

2. PhIRDA will work together with NHFPC, MOHRSS on medical insurance system, drug pricing mechanism and related policies to continuously encourage pharmaceutical innovation.

3. PhIRDA will work together with Central Committee of Chinese Peasants And Workers Democratic Party on drug quality and procurement system in China, providing suggestions to CPC Central Committee, State Council and related departments.

4. PhIRDA will closely follow regulations by local governments, playing the supervision role as a NGO and protect the legal rights of pharmaceutical industry.

(II) To continuously strengthen international exchanges to promote pharmaceutical innovation and development.

PhIRDA will continue to strengthen the unilateral and multilateral cooperation with PhRMA, JPMA, BIO, DIA and other international organizations as well as innovative pharmaceutical companies and research institutions in developed countries and emerging markets. Focusing on "pharmaceutical innovation cooperation", we will carry out exchange activities mainly in the following three aspects:

Firstly, to discuss the latest developments in domestic and foreign policies on pharmaceutical innovation, learn from foreign policy experience to improve relevant policies in China.

Secondly, to strengthen information exchanges all over the world, analyze international drug innovation trend and the latest breakthroughs, to promote drug innovation and R&D in China.

Thirdly, to build communication platform for domestic and foreign pharmaceutical research institutions, manufacturing companies and investment capitals, so as to link the financial strength and capacity advantage in China together with the promising research projects worldwide.

(III) To further improve the service ability to the members.

1. PhIRDA will deeply investigate members' needs, link members' advantages and needs together with our daily work, providing service platform to members' innovative projects and products.

2. During the implementation of quality efficacy consistency evaluation and bioequivalence tests, PhIRDA will utilize our own ways and advantages to serve for our members.

3. PhIRDA will give full play to the role of Specialty Committees through various forms, utilizing outside resources, providing a full range of services to our members and the pharmaceutical industry. The establishment of Investment Specialty Committee will be well-prepared, so as to further improve own service ability.

4. PhIRDA will improve informative service, making efforts to enhance capabilities for data collection, selection and analysis, so as to support policy research and development of the association and its members.

Dear representatives, the era gave our nation great historical development prosperity, while PhIRDA is facing the same historical development opportunity. Guided by the CPC Central Committee's spirit of NGO reform and innovation-driven strategy, let's work together with efforts for innovation, making greater contributions to achieve the Chinese dream on pharmaceutical innovation, to build China into a prosperous, democratic, civilized and harmonious modern socialist country, and ultimately to achieve the great rejuvenation our nation!

中国医药创新促进会
第十届会员大会第二次会议纪要

2015 年 9 月 24 日，中国医药创新促进会（以下称中国药促会）在北京召开了第十届会员大会第二次会议。本次大会，应到会员单位数 66 家，实到会员单位数 64 家，符合我会章程关于“会员大会须有 2/3 以上会员出席方能召开”的规定。

会议主要内容如下：

本次会议分为两个阶段，第一阶段是工作会议阶段，由中国药促会 2014-2015 年度会长、江苏恒瑞医药股份有限公司董事长孙飘扬主持。第二阶段是专题报告阶段，由中国药促会执行会长宋瑞霖主持。

一、工作会议阶段

在开幕式上，主持人孙飘扬会长介绍了本次大会的主要来宾。民政部民间组织管理局社团管理一处刘晓贵副处长，中国工业经济联合会经团部汪富亮处长，以及来自中国药促会会员单位、中国药促会药物研发、药物临床研究、医药政策专委会的 100 度位代表和专家出席会议。

（一）大会审议事项

本次大会对《中国药促会 2014-2015 年度工作总结暨 2015-2016 年度工作安排》、《中国药促会 2014-2015 年度会费收支情况报告》、《企业入会申请》、《会费标准修订案》、《中国药促会章程修订案》以及《关于设立中国药促会医药创新投资专业委员会的议案》等重要内容进行了审议。

1、大会审议通过了宋瑞霖执行会长做的《中国药促会 2014-2015 年度工作总结暨 2015-2016 年度工作安排》报告。

报告从加强我会建设、加强医药政策研究工作、广泛开展国际交流活动、不断提高医药信息服务水平等四个方面总结了中国药促会过去一年的工作。

报告指出，过去的一年，是国家医药相关改革政策密集出台的一年，在孙飘扬会长的正确领导以及广大会员单位和各专委会专家的大力支持参与下，中国药促会秉承“创新、产业化、国际化”的宗旨，积极参与到改革的进程中，发挥了积极主动的作用。

中国药促会与国家卫计委、CFDA、国家新药重大专项办公室、人社部和国家知识产权局等相关部门建立了较好的沟通、交流与合作关系，我们的工作和努力也得到了有关部门的认可；针对各地药品招标以及医保报销等具体实施工作，我们认真研究问题，勇于提出问题和建议；对个别地方出台的与国家法律政策不一致、损害医药产业发展的政策，敢于提出批评并提出了具体建议。中国药促会起到了专业社会团体应当起到的作用，不仅在国内医药界得到了认可，也引起了国际医药界的瞩目。在自身建设上，通过不断创新内部治理结构和体制机制，提升了为会员单位服务的能力与水平，包括举办了各种论坛、发布会、大型会议等促进会员单位乃至整个医药产业互相交流、创新发展，与外国驻华使馆、国外行业组织和企业合作，共同推动了中外医药产业界合作交流，为会员单位搭建了国际交流平台，提供了医药信息搜集、整理、评价、咨询服务，在有关政府部门和医药企业的支持下，开展了国内外重大医药政策问题研究，为政府提供决策参考。通过过去一年的努力，药促会在机构建设、会员服务、公共服务等方面都取得了较大进展，形成了结构合理、功能完善、政社分开、责权明确、依法自治、诚信自律的现代社会组织体制。

报告还提出了 2015-2016 年度工作的总体要求与具体建议。中国药促会今年工作的总体要求是：坚决贯彻国家关于社团改革和创新驱动的精神和要求，加强和完善内部治理结构，为会员单位和医药行业提供优质服务，促进国家医药创新体系的构筑，探索并推动建立符合中国国情、行之有效的创新药物发展新模式和新机制。报告针对中国药促会在 2015-2016 年度的工作提出了以下具体建议：（1）继续围绕医药行业生态环境建设问题开展政策研究：主要包括与国家食品药品监管总局密切配合，继续开展修改《药品管理法》、《药品注册管理办法》的研究工作，重点研究如何从法律机制上来鼓励创新，包括如何在法律中完善药品审评机制和仿制药管理制度，建立上市许可人制度和药品专利链接制度等内容；与国家新药重大专项办、国家卫计委、人社部研究新药研发、医疗保险制度、药品价格形成机制等相关政策；与农工党中央密切合作，就提高我国药品质量标准、完善我国的药品采购制度进行深入研究，为党中央、国务院及有关部委提供政策建议；密切关注各地出台的药品政策，发挥社会组织的第三方监督职能，维护医药行业的合法权益。（2）继续加强国际交流，为我国的医药创新发展提供服务：继续加强与美国 PhRMA、JPMA、BIO、DIA 等国际组织以及医药发达国家、新兴市场国家的医药创新型企业和

研究机构的单边与多边合作，围绕“医药创新合作”主题，开展交流。

2、大会审议通过了《中国药促会 2014-2015 年度会费收支情况报告》。

3、大会审议追认了会员大会闭会期间会长会议通过的 4 家企业的入会申请，4 家企业是：深圳信立泰药业股份有限公司、华领医药技术（上海）有限公司、歌礼生物科技（杭州）有限公司、信达生物制药（苏州）有限公司；另外，经过本次大会现场审议，通过了江苏亚盛医药开发有限公司、再鼎医药（上海）有限公司、方恩（天津）医药发展有限公司、药明康德新药开发有限公司 4 家企业的入会申请。

4、审议通过了《关于进一步修订会费标准的议案》（以下称“议案”）。随着我会工作重心进一步向促进医药创新工作转移，中小规模的创新药物研发型企业以及致力于医药创新投资的企业积极申请加入我会。考虑到上述企业均非药品生产型企业，根据我会《章程》，对我会会费标准作如下修改：对没有医药产品上市销售的非生产型企业会员单位、副会长单位实行会费减免政策。关于会费标准修订案，发出表决票 65 张，收回 65 张，有效票数 65 张，赞成票 62 张，反对票 1 张，弃权票 2 张。同意票数超过参加投票人数的三分之二。根据中国药促会《章程》的相关规定，“议案”顺利通过。

5、审议通过了《中国医药创新促进会章程修订案》（以下称“修订案”）。为了配合民政部批准我会更名，实现新的办会宗旨与功能定位，根据《社会团体登记管理条例》（国务院令〔1998〕第 250 号）、《国务院办公厅转发民政部关于清理整顿社会团体意见的通知》（国办发〔1997〕11 号）、《国务院办公厅关于加快推进行业协会商会改革和发展的若干意见》（国办发〔2007〕36 号）等有关规定，结合我会《章程》的相关规定，对《章程》中关于协会名称、协会负责人等规定做出了修改。关于《章程》修订案，发出表决票 65 张，收回 65 张，有效票数 65 张，赞成票 65 张，反对票 0 张，弃权票 0 张。同意票数超过参加投票人数的三分之二。根据中国药促会《章程》的相关规定，“修订案”顺利通过。

6、大会审议通过了《关于设立中国药促会医药创新投资专业委员会的议案》。去年的会员大会审议通过了关于成立药物研发、药物临床研究、医药政策等专业委员会的决议。在各位专家的支持下，这三个专委会今年陆续成立并分别开展工作，产生了很好的效果，对中国药促会的相关工作有很大的支持和促进作用。从大的环境来看，资本与创业投资的支持和参与对医药产业的创新发展有着越来越重要的意义，有必要将投资界代表纳入医药创新的链条。因此，中国药促会拟成立“医药创新投资专业委员会”。再鼎医药（上海）有限公司董事长兼首席执行官杜莹女士作为医药创新投资专业委员会发起人代表宣读了《关于发起成立中国药促会“医药创新投资专业委员会”的倡议》。

（二）选举 2015-2016 年度轮值会长、2016-2017 年度候任轮值会长、秘书长

本次大会按照国资委和民政部相关文件的要求，以无记名投票的方式选举中国医学科学院上海药物研究所所长蒋华良为中国药促会 2015-2016 年度轮值会长；选举贝达药业股份有限公司董事长兼首席执行官丁列明为 2016-2017 年度候任轮值会长；选举中国药促会副秘书长冯岚女士为第十届秘书长。具体投票结果如下：

关于 2015-2016 年度轮值会长选举，发出选票 65 张，收回 65 张，有效票数 65 张，赞成票 64 张，反对票 1 张，弃权票 0 张。

关于 2016-2017 年度候任轮值会长选举，发出选票 65 张，收回 65 张，有效票数 65 张，赞成票 63 张，反对票 0 张，弃权票 2 张。

关于秘书长选举，发出选票 65 张，收回 65 张，有效票数 65 张，赞成票 64 张，反对票 1 张，弃权票 0 张。

以上各候选人的同意票数均超过参加投票人数的三分之二。根据《国务院国有资产监督管理委员会行业协会换届选举暂行办法》第十六条之规定以及中国药促会《章程》的相关规定，三位候选人成功当选。

（三）新当选年度会长蒋华良讲话

新当选中国药促会 2015-2016 年度会长、中国科学院上海药物研究所所长蒋华良发表了当选感言。蒋华良会长指出，在过去的一年中，深切地感受到中国药促会为我们会员单位以及整个医药行业的创新发展做出了不少可圈可点、实实在在的贡献，药物研发、药物临床研究与医药政策专委会的成立，使得中国药促会如虎添翼，各专委会的专家在药品的招标采购、促进药物创新发展应用、药品审评制度改革和注册管理办法修订等方面为中国药促会最终提交各个部门的研究报告给出了许多宝贵的意见和建议，使中国药促会的建议和报告受到了国家有关部门领导以及社会各方的高度认可，影响力在行业中不断提升。展望新的一年，蒋华良会长非常赞同宋会长工作报告中提出的关于下一个年度的工作部署，也非常期待新成立的医药创新投资专委会能够发挥它在早期药物研发、项目投资方面专家咨询的优势。在新的一年里，蒋华良会长建议中国药促会按照党中央、国务院关于社团的管理要求，继续团结依靠广大资源，保持与政府组织、专家群的紧密联系，做政府、企业和行业之间的纽带，为国家服务、为会员单位服务、为行业服务。

就具体工作而言，蒋华良会长建议，一是继续加强药物政策研究，积极为国家和地方相关医药政策的制定建言献策，尤其在加快药品审评制度改革、解决审评积压、改革药品注册分类、创新药物鼓励政策等方面，多提可操作性建议，以取得实在的绩效；第二，维护会员单位的正当权益；第三，通过与国内外产业的交流，参与国际医药市场的竞争。

（四）领导讲话

在会员大会的各项议程圆满完成后，民政部民间组织管理局社团管理一处副处长刘晓贵代表民政部民间组织管理局发表了重要讲话。刘处长首先对本次会员代表大会的顺利召开表示热烈的祝贺，并对中国药促会的工作予以充分肯定。关于社团管理体制改革，刘处长认为，中国药促会正在面临一个重大的改革机遇，中共中央办公厅、国务院办公厅联合下发的《行业协会商会与行政机关脱钩总体方案》（以下简称“方案”）指出，要建立一种新型的管理体制，推动我国的行业协会商会由原来的业务主管单位和机关双重管理转向多部门综合管理，建立起一种权责明确、运行清晰的体系。“方案”同时强调，今后各级行政机关在研究重大问题、制定国家法律法规时，一定要主动听取行业协会商会的意见建议。

最后，刘处长表示，希望中国药促会能够探索社团管理体制改革的新体制、新机制，强化行业自律，提高服务于医药创新的能力，在今后做出更大的贡献。

二、专题报告阶段

大会第二阶段由中国药促会执行会长宋瑞霖先生主持，国家食品药品监督管理总局（以下称“CFDA”）孙咸泽副局长到会就药品安全监管与改革做了专题报告并与参会企业代表和专家交换了意见。

孙咸泽副局长首先结合我国现状，介绍了药品审评审批机制改革的背景。孙局长指出，为进一步解决我国药品审评审批积压现状，加快审评效率，2015 年 8 月 9 日国务院发布的《国务院关于改革药品医疗器械审评审批制度的意见（国发〔2015〕44 号）》（以下简称“44 号文”），标志着药品审评审批制度改革的全面启动。按照中央全面深化改革的统一部署，CFDA 在起草药品医疗器械审评审批制度综合改革方案的同时，已经会同有关部委启动了一系列改革措施，包括：（1）加强审评队伍建设；（2）提高药品、医疗器械产品注册收费标准；（3）开展药物临床数据自查核查；（4）征求各方建议，为解决药品积压，提出具体意见等。结合上述已经启动的改革，按照 44 号文的精神，针对以下重点问题，他给出了相关解读：

（一）审评队伍建设与免责机制

孙局长指出，目前药品审评积压严重，药品审评中心（以下称“CDE”）审评人员数量有限、任务重，加之待遇过低，导致 CDE 人才流失严重，审评队伍建设亟待提高。为加快建立一支专业化的审评队伍，CDE 采取聘用外部审评人员、增加内部编制等途径扩大审评队伍。目前，CDE 已经从上海、江苏、山东、广东、重庆等地聘用了 70 多名技术骨干，参加技术审评工作。同时 CDE 增加编制 70 人，总编制人员达到 190 人。如何建立编制内外人员合理、平衡的薪酬体系将是审评队伍改革的进一步重点。

审评人员去行政化，建立首席专家负责制，按主审、主审员、高级审评员、审评员四个序列建立专业审评队伍。为了鼓励审评人员勇于担当、大胆工作、提高效率，将建立免责机制。凡是非主观故意、不触及廉政底线，属于科学认知、能力水平等出现的一些工作瑕疵，经甄别，查明原因，总结教训，改进工作，将对审评员免于追责。

（二）统筹兼顾，严格把控增量，管好存量

严控增量。（1）将药品进行重新分类，分为创新药、改良型新药、仿制药；仿制药分为首仿药和一般仿制药。（2）简化临床审批。创新药临床审批，从Ⅰ、Ⅱ、Ⅲ分期改为一次性批准，对临床申报资料只审查涉及安全性和受试者保护（即医院伦理委员会的要求）内容，对前期药学研究资料作简易审查，申报注册生产时将对所有的数据进行真实性核查。（3）实施仿制药生物等效试验备案制。CFDA 目前正在筹建仿制药生物等效试验申报平台，届时凡申报仿制药的企业，通过备案平台获得备案号，即可开展临床生物等效试验。（4）进一步加大临床数据核查力度，对临床数据造假行为一律严查，绝不姑息。（5）集聚审评资源，搭建创新药审评沟通平台。CFDA 将通过数据资源共享平台对申报药品进行网上受理，在 5 日受理期内完成立卷审查。创新药受理之前，加强与申报企业的沟通，符合条件的企业才能进行申报。受理审查不完善的，允许一次性补充资料。仿制药进入技术审评后，不再发补，符合标准的，进行批准；不符合标准的，不批准。创新药可随时进行补充。（6）推行上市许可持有人制度。将对创新药推行上市许可制度试点。上市许可持有人要对研发过程数据真实性负责，要监督受托生产企业严格按照 GMP 要求生产出符合质量要求的产品，药品上市后还应对临床医生进行合理用药方面的指导。

管好存量。要进一步加强药品质量评价。计划用 10-15 年时间进行仿制药一致性评价。第一阶段：2015-2018 年，完成 2007 年 10 月 1 日前批准的国家基本药物目录中化学仿制药口服固体制剂的一致性评价。据中检院统计，上述品种总计 300 个通用名，涉及 1897 个商品名，药品生产企业 1883 家；第二阶段：对所有固体制剂进行一致性评价；第三阶段：用 10-15 年的时间对所有仿制药包括中药注射剂进行一致性再评价。未来将对质量和疗效不一致的，分期分批开展评价。鼓励企业对评价目录之外的品种开展一致性评价。

CFDA 将在中检所设立仿制药一致性评价办公室，负责具体组织工作。目前由中检院牵头，已经起草完成仿制药一致性评价指导意见，并征求有关部委意见，即将报国务院。其中参比制剂遴选原则、溶出曲线研究、生物等效性

指导原则已经征求过社会意见，即将发布。无参比制剂开展临床试验的指导原则还在起草中。

孙局长指出，对 2007 年 10 月 1 日前批准的，国家基本药物目录中 300 个通用名化学仿制药口服固体制剂分三批进行一致性评价，推出已经选定的参比制剂。另外，不局限于这 300 个品种，只要能够找到原研药，就可以尽早开展一致性评价，并同样享受相关政策优惠。仿制药一致性评价的主体是企业。参比制剂优先选择原研品种；国内找不到的可以一次性进口，供一致性评价使用; 首仿药（原 3.1 类）找不到原研药开展临床试验的同样适用此政策。国际原研药已经停产的，采用美国、欧盟监管机构批准的国际公认替代品种。找不到参比制剂的，开展大规模临床试验。CFDA 推荐两种一致性评价方法：体外溶出度试验以及体内生物等效性试验。允许企业采用体外溶出度试验，鼓励企业采用生物等效性试验进行一致性评价；采用体外溶出度试验进行一致性评价的药品，将来还可以研究采用体内生物等效性试验进行后续评价。

国家对通过仿制药一致性评价的药品将采取一系列鼓励措施，包括：（1）改处方、工艺的补充申请，可一并向仿制药一致性评价办公室报批；（2）在标签标识上予以标注，便于医生患者识别；（3）考虑凡通过一致性评价的品种均进入药品招标采购目录；（4）可以参加药品上市许可持有人试点，进行委托加工；（5）与医保部门协调，对通过一致性评价的药品在医保报销方面予以支持；（6）与工信部协商，在药品储备、技术改造上予以资金支持，并将在产业结构调整政策上予以倾斜。

（三）药品申报审评分流运转，提高科学性

孙局长指出，为了提高药品审评工作的效率与科学性，CFDA 将建立四灯制度，将药品申报审评分流运转：

1）无灯区：创新药，进入无灯区，即报即审。

2）绿灯区：临床急需的重大传染病用药如艾滋病，肺结核以及肿瘤、孤儿药、短缺产品、儿童用药等，单独排队，加快审批。

3）黄灯区：对于临床应用较多的仿制药申报，予以公示，公开已受理、已审评、已批准、再评价的仿制药名单，引导理性申报，科学审评。

对于多年未生产、已注销批准文号的低价药，将联合工信部、人社部等部门采取国家储备、提价、收购、鼓励仿制或医保报销，甚至允许实行上市许可持有人制度等政策鼓励企业生产。

4）红灯区：将限制审批品种归入“红灯”区，及时公布限制类审批目录。

孙局长指出，将推行阳光审评政策，将所有审评标准、指导原则、审评过程及结果全部公开。同时建立复审委员会，凡对审评结果有异议者可以申请由第三方组成的复审委员会进行复审。

（四）加强相关部门的合作

孙局长指出，按照改革意见的要求，CFDA 将会同中央编办、发改委、科技部、工信部、财政部、人社部、卫计委、中医药局和总后卫生部建立部际联席会议，及时研究解决改革中遇到的问题。

药品审评审批制度改革是党中央、国务院的重大决策，对促进制药业结构调整，增强中国制造药品国际竞争力，保障人民群众身体健康意义重大，影响深远。

本次会员大会内容丰富，安排紧凑，既圆满完成了各项议程，又为会员提供了了解国家药品审评审批政策改革动态的机会。此次会议，强化了中国药促会的领导机构建设，完善了内部治理结构，确定了下一年度的发展方向和主要任务；同时新会员的加入和医药创新投资专业委员会的成立为中国药促会推动医药创新和发展注入了新的血液和动力，彰显中国药促会在医药创新领域凝聚力和向心力的进一步增强！

二〇一五年九月二十四日

Summary of The Second Meeting of 10th PhIRDA General Assembly

In the morning of 24 September 2015, China Pharmaceutical Innovation and Research Development Association (PhIRDA) held the Second Meeting of 10th PhIRDA General Assembly in Beijing. Representatives from 64 members out of 66 in total attended this meeting, which met the requirement by Article 15 of PhIRDA Constitution.

The main contents are as follow:

The meeting consisted of two sessions. First is the work meeting session, which was hosted by Mr. Sun Piaoyang (PhIRDA Annual Chairman 2014-2015, Chairman of Jiangsu Hengrui Medicine Co., Ltd). Second is the report session, which was hosted by Mr. Song Ruilin (PhIRDA Executive President).

Session One. Work Meeting Session

On the opening ceremony, Chairman Sun Piaoyang introduced the distinguished guests. Liu Xiaogui, Deputy Director of Department of Social Organization Management, Wang Fuliang, Director of China Federation of Industrial Economics, almost 100 representatives from PhIRDA members and PhIRDA Specialty Committees of Drug R&D, Clinical Research, Medicinal Policy attended this meeting.

(I) Approved Items by the Meeting

The meeting approved 2014-2015 PhIRDA Annual Work Report and 2015-2016 Work Plan, PhIRDA's Annual Financial Report for Year 2014-2015, Amendment to Membership Fee Standard, Amendments of Standards for Member Annual Fee, Amendments of PhIRDA Constitution and the establishment of Pharmaceutical Innovation Investment Specialty Committee, etc.

1. The meeting approved 2014-2015 PhIRDA Annual Work Report and 2015-2016 Work Plan delivered by Executive President Song Ruilin.

The report summarized PhIRDA's work during the past year in four areas, including construction of the association, healthcare policy research, international cooperation, pharmaceutical information service, etc.

The report pointed out that during the past year, national pharmaceutical related policies were published intensively. Led by Chairman Sun Piaoyang, with the support and cooperation by members and experts of Specialty Committees, centering on the goal of “Innovation, Industrialization, Internationalization”, PhIRDA play an active role in the progress of the reforms.

Cooperating with NHFPC, China Food and Drug Administration, National Science and Technology Major Project “Innovation and Development of New Drug” Office, Ministry of Human Resources and Social Security, the State Intellectual Property Office and other related departments, efforts made by PhIRDA got positive feedbacks; regarding provincial biding for medicine and healthcare reimbursement, PhIRDA seriously studied the problems and raised questions and suggestions; in terms of policies issued by some provinces which is not in accordance with national laws and harmful to the development of pharmaceutical industry, PhIRDA proposed comments and suggestions. As a professional social organization, PhIRDA was not only accepted in domestic pharmaceutical industry, but also attracted great attention from international pharmaceutical industry. On self-construction, PhIRDA continued to improve innovative internal management structure and construction, enhance the service capacity and standards to members; promote communication and cooperation through organizing forums, press-conferences and summits; build international cooperation platform for members through work with embassies, foreign organizations and enterprises; provide services on information collection, summarizing, review and consulting; carry out research on major healthcare policies and provide decision references to government. During the past year, PhIRDA made great progress in structure construction, member service and public service through efforts, initially forming a modern social organization with reasonable structure, complete functions, government-separated position, clear responsibilities and rights, self-administration with law and self-discipline.

The report also pointed out the overall requirements and suggestions for PhIRDA's 2015-2016 annual work. The overall requirements is to implement the requirements and spirits concerning reforms of social organizations and innovation-driven, strengthen internal management structure, provide quality services to members and the pharmaceutical industry, promote the construction of national pharmaceutical innovation system, to explore and promote the establishment of new models and mechanisms for innovative pharmaceutical development. Proposal of PhIRDA's work during 2015-2016 is made as below: (1) PhIRDA plans to closely cooperate with related departments of CFDA to continuously carry out researches on the revision of “Medicine Registration Regulation” and “Drug Administration Law”, researches on encouragement of innovation from law mechanism, including improvements of drug evaluation mechanism, generic drug management regulations, MAH and patent link system, etc. Carry out related researches on new drug R & D, medical insurance system, drug pricing mechanism with National Science and Technology Major Project “Innovation and Development of New Drug” Office, NHFPC and MOHRSS; have a close cooperation with Chinese Peasants and Workers Democratic Party Central and study how to improve quality standard of drugs and medicine purchasing system in China, in order to provide decision references to the party central committee, state council and related departments; give more attention on new medicine policies, play the supervising role as a third-party , safeguard the rights and interests of

pharmaceutical companies. (2)Enhance international cooperation to provide service for pharmaceutical innovative development in China; strengthen unilateral and multilateral collaboration with many international organizations and pharmaceutical innovative companies and institutions in developed countries and emerging market countries, including PhRMA, BIO, EFPIA, IFPMA, JPMA, WHO, DIA, etc..

2. The meeting approved 2014-2015 Annual Financial Report.

3. The meeting confirmed Innovent Biologics, Inc., Shenzhen Salubris Pharmaceuticals Co., Ltd., Hualing Medicine (Shanghai) Ltd., Ascletis Bioscience Co., Ltd. to become members of PhIRDA; and approved Ascentage Pharma Group Corp Ltd., ZAI Lab (Shanghai) Co., Ltd., Fountain Medical Development Ltd., WuXi AppTec Co., Ltd. to become members of PhIRDA.

4. The meeting approved “The Proposal to Revise PhIRDA Membership Fee Standards”. As the focus is moving towards pharmaceutical innovation, more and more research-based SMEs expressed their interests to join the association. Considering that these companies are not manufactures, according to the Constitution, it is proposed to reduce the fee standard for research-based non-manufacturing SMEs within PhIRDA member companies and Vice-President level members. 65 votes were issued, and this proposal was passed with 62 favored votes.

5. The meeting approved “The Amendment to PhIRDA Constitution” (hereafter referred as “The amendment”). To fulfill PhIRDA’s new goal and function after the rename approved by the Ministry of Civil Affairs, according to related regulations and policies issued by the State Council (1998-250, 1997-11, 2007-36, etc.), regulations about the name and leadership of the association were revised. 65 votes were issued, and the amendment was passed with 65 favored votes.

6. The meeting approved “The Proposal to Establish Specialty Committees of PhIRDA”. The General Assembly approved the establishment of Drug R&D, Clinical Research and Drug Policy Specialty Committees last year. These three specialty committees carried out activities with great outcomes this year, which provided strong support and promotion to the association’s work. From overview on the large environment, the support and participation of funds and venture capitals have become more and more important to the innovation and development of the pharmaceutical industry. It is necessary to include representatives from the investment community into the chain of pharmaceutical innovation. Thus, PhIRDA proposed to establish Drug Innovation and Investment Specialty Committee. Mrs. Du Ying, Chairwoman & CEO of ZAI Lab (Shanghai) Co., Ltd., announced “The Proposal to Establish Drug Innovation and Investment Specialty Committee of PhIRDA” as a representative of the promoters.

(II) Elected 2015-2016 Annual Chairman, 2016-2017 Annual Chairman, Secretary-General of PhIRDA.

According to requirement of related policies by Ministry of Civil Affairs, the meeting elected Mr. Jiang Hualiang, Director, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, as 2015-2016 Annual Chairman (64 favored out of 65 votes); Ding Lieming, Chairman of the Board, Beta Pharmaceutical Co., Ltd., as 2016-2017 Annual Chairman (63 favored out of 65 votes); Mrs. Feng Lan as Secretary-General of PhIRDA by anonymous votes (64 favored out of 65 votes).

All three candidates received more than 2/3 favored votes. According to Article 16 of Election Regulation of Associations by SASAC and Constitution of PhIRDA, all three candidates were elected as the new leadership of the association.

(III) Speech by Chairman Jiang Hualiang

Chairman Jiang Hualiang Jiang, Director of Shanghai Institute of Materia Medica, Chinese Academy of Sciences, gave speech. Chairman Jiang pointed out that PhIRDA made remarkable contributions to its members and the entire pharmaceutical industry in the last year. Drug R&D, clinical research and drug policy specialty committees were established. The experts of various special committees gave a lot of valuable comments and suggestions on research report of PhIRDA about drug bidding, drug development and application of innovation, the drug system reform, registration regulation amendment and etc. PhIRDA submitted research report to relevant departments and was highly evaluated by the national leaders of relevant departments and all sectors of society. PhIRDA plays a more and more important role in pharmaceutical industry. Chairman Jiang can’t agree more with Executive President Song on the work arrangement of next year. He is also looking forward that the new drug innovation & investment specialty committee can play an important role on supplying expert advice of drug development and projects investment as soon as possible. In the New Year, Chairman Jiang suggests that PhIRDA should follow the community management requirement of the CPC Central Committee and State Council, continue to unite the majority resources, and to be the ties of the government, business and industry by keeping the close connection on government organizations and experts groups. By this way, PhIRDA supplies the services to our country, its members and industries.

To the specific works, Chairman Jiang suggested that: First, we should continue to strengthen the drug policy research, supply advices and suggestions positively to national and local policies, especially on the aspects of speeding up the reform of the drug review system to address the backlog of review, the reform of Drug Registration Categories, drug innovation incentives policies and etc. By providing more workable proposals, we would achieve real good performance. Second, we should protect the legitimate rights and interests of our members. Third, by communication between domestic and foreign industry, PhIRDA will participate more and more in international pharmaceutical market competition.

(IV) Government Speech

After the successful completion of the agenda, Liu Xiaogui, Deputy Director of Association Management Department I, Ministry of Civil Affairs, made an important speech. Director Liu expressed warm congratulations to the successful meeting and made high evaluation to the work of PhIRDA. To community management system reform, Director Liu believes that PhIRDA is facing an important reform opportunity. The CPC Central Committee and State Council jointly issued the "Chamber of commerce and industry association independent from the administrative organization strategy" (hereinafter referred to as “strategy”). In the strategy, it is pointed out that a new management system should be established to promote chamber of commerce and industry association from management by both the original competent business organization and organ to multisectoral management in order to establish a clear responsibilities and running well system. “Strategy” also stressed that in the future, administrative organs should listen to advices and suggestions from industry association and chamber of commerce initiatively when administrative organs research important issues and make national laws and regulations.

Finally, Director Liu expressed his hope that PhIRDA would make a greater contribution in the future by exploring to reform new system of social organization management, strengthening industry self-discipline and improving the service of medical innovation.

Session Two. Report Session

The second session was chaired by PhIRDA Executive President Song Ruilin, Vice Minister Sun Xianze from China Food and Drug Administration (hereinafter referred to as "CFDA") made a speech on the drug safety supervision and reform. He exchanged his views with the business representatives and experts in the meeting.

Vice Minister Sun Xianze introduced the background of the drug review and approval mechanism reform in China. He pointed out that to solve the review of drug approval backlog and improve the review efficiency, on August 9, 2015, the State Council published “Comments on the reform of the drug and medical devices review and approval system” (published in [2015] No.44) (hereinafter referred to as No. 44). It is the sign of the beginning of the drug review and approval system reform. According to the instructions by Party Central Committee, CFDA and the relevant ministries have jointly launched a series of reform measures at the time of drafting a comprehensive drugs and medical devices review and approval system strategy, including: (1) strengthen the review team building; (2) increase drug, medical device product registration fees; (3) carry out drug clinical data checking and verification; (4) make specific comments on solving the backlog of drugs and so on. According to these reforms has been launched, with the spirit of the "No. 44", he gave interpretations on the following key issues:

(I) Review Mechanism Team Building and Disclaimer System

Vice Minister Sun Xianze pointed out: The backlog of drug evaluation is a serious problem. The number of staffs in Center of Drug Evaluation (hereafter referred to as "CDE") is limited, but the task is heavy. In this condition, the staffs’ treatment is too low to stop the serious brain drain from CDE. We need to improve review team building. To speed up the establishment of a professional review team, CDE hires outside reviewers and increases internal review workers, meanwhile finds some other ways to expand the review team. Currently, CDE has hired more than 70 technical experts from Shanghai, Jiangsu, Shandong, Guangdong, Chongqing and other places to participate in the technical review. At the same time, CDE is increasing 70 workers and the total number of workers is increasing to 190. How to build the reasonable internal and external salary system will be the important work of the review team reform.

Review staffs should be independent from administration. The chief expert responsibility system should be built. The professional review team should be built by four sequences: chief reviewers, principal reviewers, senior reviewers and reviewers. To encourage reviewers to work bravely and effectively, exemption system would be established. Reviewers would be exempt from responsibility if their work flaws are non-subjective intent, does not break the bottom line of honest policies, belong to scientific knowledge, due to their ability level limitation and etc.

(II) Control Increment Strictly and Manage Inventory Integrally

Control Increment Strictly. (1) Reclassify drugs into new category, including innovative drugs, improved drugs and generic drugs; generic drugs have two types: the first generic drugs and general generic drugs. (2) Simplify the clinical approval. Innovative drugs clinical approval changed to one-time approval from I, II, III three stages approval. We only review the part of clinical application materials related to safety and person protection content (which is the requirements of the hospital ethics committee) and preliminary material of pharmaceutical research. When applying for registration of the production, we will review the authenticity of all data. (3) Carry out generic drugs bioequivalence test filing system. CFDA are planning to build the generic drug bioequivalence test platform currently. After that when enterprises declare generic drugs, they would get the record number by filing platform and then they could carry out clinical bioequivalence test. (4) Improve the review of clinical data. Clinical data fraud would not be tolerated. (5) Gather review resources and build innovative drug review communication platform. CFDA would complete review in the 5 days through data sharing platform. Before accepting innovative drugs application, enhance communication with the reporting companies. Qualified enterprises can be applied. Allow enterprises update the additional information at once. But after entering the technical review of generic drugs, enterprises could not update the additional information. If generic drug meets the standards, it could be allowed; If generic drug does not meet the criteria, it could not be approved. The information material of innovative drugs can be supplemented at any time. (6) Implement marketing authorization holder system. We will pursue innovative drug marketing authorization system pilot. Marketing authorization holder should be responsible for the authenticity of the data on research and development process, supervise the company to product good quality products, which are in strict accordance with the GMP requirements, guide clinicians to use the drugs rationally after the drug entering the market.

Manage Inventory Integrally. It is necessary to further strengthen drug quality evaluation. We plan to use 10-15 years to make the consistent evaluation of generic drugs. The first stage: 2015-2018, we will complete the consistent evaluation of the national approved essential generic drugs before October 1,

2007 on the national essential drugs List of chemical generic oral solid drugs. According to collection of national institutes for food and drugs control, there are 300 varieties of the common names drugs. It concerns to 1897 products and 1883 drug manufacturers; the second stage: to make the consistent evaluation of all solid drugs; the third stage: to make the consistent re-evaluation of all generic drugs including traditional Chinese medicine injections in 10-15 years. The inconsistent quality and efficacy products will be evaluated by different times and stages. Encourage enterprises to carry out consistent evaluation of products outside the evaluation directory list.

CFDA will set up a consistent evaluation office on national institutes for food and drug control. Leading by national institutes for food and drug control, it has been drafted generics conformance assessment guidance and solicited the views of relevant ministries currently and will give to the State Council for approval soon. The reference formulation selection principle, curve of dissolution research and bioequivalence guidelines for biological community has received comments from the society, and will be published soon. Non-reference clinical guidelines are currently being drafted.

Vice Minister Sun Xianze pointed out that it will be evaluated consistence by three times for the 300 common generic chemical oral solid preparations on the National Essential Drug List approved before the October 1, 2007. In addition, not limited to these 300 species, if the brand-name drug can be found, it can be carried out consistent assessment as soon as possible and has the same preferential policies. The main workforce of consistent assessment of generic drugs is enterprises. Reference preparation is better to select the original research varieties; if it cannot be found in China, we should import at one-time for consistent evaluation; first generic drugs (formerly 3.1 Class) which could not find the original drugs to make the clinical tests are also apply to this policy. For international original drugs that already stopped producing, it could be replaced by the internationally recognized alternative species approved by the United States and European Union regulators. If it still cannot find the reference drugs, large-scale clinical trials should be made. CFDA recommends two consistent evaluation methods: in vitro dissolution tests and in vivo bioequivalence tests. Allowing enterprises to use in vitro dissolution test and encourage enterprises to adopt bioequivalence tests to evaluate consistence; if the drug consistent evaluation is used the methods in vitro dissolution test, this drug could also be studied in vivo bioequivalence tests for follow-up evaluation in the future.

Generic drugs passed the consistent evaluation will have a series of incentive measures, including: (1) The prescription change and supplementary applications can be submit to generic drugs consistent evaluation office at the same time; (2) To be identified on the label labels for easy identification of patients and doctor; (3) Generic drugs passed the consistent evaluation will on the pharmaceutical bidding directory list; (4) Generic drugs passed the consistent evaluation may on post marketing license holder pilot and can be commissioned to be produced; (5) In coordination with the health insurance sector, generic drugs passed the consistent evaluation should be supported in terms of Medicare reimbursement; (6) In consultation with Ministry of Industry and Information Technology, generic drugs passed the consistent evaluation would be funded in the drugs reserve, technological innovation and will be inclined in the industrial structural adjustment policies.

(III) Drugs Application Review Shunt Operation

Vice Minister Sun Xianze pointed out that in order to improve the efficiency and scientific of drug evaluation, CFDA will establish four light systems for the drug application review shunt operation:

1) No Light Zone: innovative drugs in the non-light zone would be reviewed as soon as applied.

2) Green Light Zone: major infectious clinical drugs for AIDS, tuberculosis and cancer, as well as rphan drugs, the shortage products and children's medication, etc., are in the separate queues which would speed up their review.

3) Yellow Light Zone: The common use generic drug of clinical application should be publicized and accepted openly. To the reviewed and re-evaluation generic drugs list, rational declaration and scientific review should be guided.

The low-price drugs, which are without production many years and canceled approval numbers, will be encouraged to produce by joint efforts by MIIT, MOHRSS and other departments to take national reserves, to increase price, acquisitions, encourage imitation and insurance reimbursement, and even allow the implementation of marketing authorization holder system and other favorable policies.

4) Red Light Zone: the limit approval species are classified in the "Red Light" Zone. We would disclosure the list of Red Light Zone on time.

Vice Minister Sun Xianze said that it would implement Sunshine Policy. Information will be published on all the evaluation criteria, guidelines, the entire disclosure of the review process and results. Meanwhile, to establish a re-evaluation committee, who disagrees with the results of the review may apply for re-evaluation by a third party.

(IV) Strengthen Cooperation with Relevant Departments

Vice Minister Sun Xianze pointed out that in accordance with the requirements of reform, CFDA would have an inter-ministerial meeting with SCOPSR, NDRC, MOST, MIIT, MOF, MOHRSS, NHFPC, SATCM and Medical Department of Central Logistics Department of PLA to research and solve problems during the reform.

Drug evaluation and approval system reform is an important decision of CPC Central Committee and State Council, to promote the restructuring of pharmaceutical industry, to enhance the international competitiveness of Chinese-made drugs, and to protect people's health. It has the great significance and deep influence.

The General Assembly Meeting was successful completed with good contents and opportunities for members to learn about national drug review and approval policy reform. The meeting strengthened PhIRDA leadership and internal management structure, meanwhile clarified PhIRDA's development direction and major tasks in next year. At the same time, new members and Drug Innovation & Investment Specialty Committee will further promote the development of PhIRDA as new blood and power, enhancing the association's important role and strength in pharmaceutical innovation!

September 24, 2015

专业委员会介绍
Introduction of Specialty Committees

为了给会员单位提供全方位、多层次的服务，借助相关领域专家的智慧和资源，中国医药创新促进会（以下简称“中国药促会”）经第十届一次、二次会员大会审议通过，批准成立医药政策、药物研发、药物临床研究、生物医药和医药创新投资五个专业委员会。

药物研发专业委员会旨在通过为中国药促会会员单位的创新研发活动提出意见和建议，提升会员单位的创新研发能力。

药物临床研究专业委员会旨在通过为中国药促会会员单位的临床研究活动提供试验设计、试验过程指导、试验数据处理等方面的意见和建议，促进会员单位临床研究能力与水平的提升。

医药政策专业委员会旨在研究国内外医药政策领域的重大理论与实践问题，为政府提供决策参考。

生物医药专业委员会旨在通过为中国药促会会员单位建立生物医药产业相关政策、研发、技术创新、临床试验等方面沟通交流平台，提供生物医药产业方面的指导。

医药创新投资专业委员会旨在吸纳对于医药创新有经验、有实力的投资界代表加入，激发中国药促会会员单位的创新活力和创造潜能，提升医药创新的效率和效益，在医药领域推动营造大众创业、万众创新的政策环境和制度环境。

各专业委员会吸纳相关专家以个人身份加入，为中国药促会会员单位在政策、研发、技术创新、临床试验、生物医药等方面提供指导与咨询，为会员单位切实提供服务。

In order to provide comprehensive, multi-level services to members, with intelligence and resources of experts in related fields, the first and second Meeting of 10th PhIRDA General Assembly, China Pharmaceutical Innovation and Research Development Association (PhIRDA) approved the establishment of five Specialty Committees: Medicinal Policy, Drug R&D, Clinical Research, Biopharmaceutical and Pharmaceutical Innovation Investment.

Drug R&D Specialty Committee aims to enhance the innovative R&D capability of PhIRDA's members through providing suggestions and comments on their innovative R&D activities.

Clinical Research Specialty Committee aims to promote clinical research capability and level of PhIRDA's members through providing experimental design, guidance of test processing and data, as well as other aspects of clinical research activities of PhIRDA's member.

Medicinal Policy Specialty Committee aims to research major theoretical and practical issues in medicinal policies, providing references for government.

Biopharmaceutical Specialty Committee aims to provide guidance to PhIRDA's members through building communication platforms on related policies of biopharmaceutical industry, R&D, technological innovation, clinical trials, etc.

Pharmaceutical Innovation Investment Specialty Committee aims to attract representatives from investment communities with rich experience in pharmaceutical innovation, in order to stimulate innovative vitality and creative potential of the members, enhance the efficiency and effectiveness of innovation, promote entrepreneurship and create a highly innovative public policy and regulatory environment in pharmaceutical field.

Each specialty committee absorbed related experts to join personally and provide guidance and consultation to PhIRDA members on policies, R&D, technological innovation, clinical trials and biopharmaceutical.

药物研发专业委员会
Drug R&D Specialty Committee

名誉主任委员 蒋建东

中国医药创新促进会副会长
中国医学科学院药物研究所所长
Honorary Chairman, Jiang Jiandong
Vice President of China Pharmaceutical Innovation and Research Development Association (PhIRDA)
Director, Institute of Materia Medica, Chinese Academy of Medical Science

主任委员 张　丹

方恩（天津）医药发展有限公司董事长兼 CEO
Chairman, Zhang Dan
Chairman of the Board & CEO, Fountain Medical Development Ltd.

候任主任委员 王印祥

贝达药业股份有限公司总裁兼首席科学家
Elect Chairman, Wang Yinxiang,
President & Chief Scientist Officer (CSO) of Betta Pharmaceutical Co., Ltd.

副主任委员 房健民

同济大学生命科学与技术学院常务副院长
Vice - Chairman, Fang Jianmin
Executive Deputy Dean of School of Life Science and Technology, Tongji University

副主任委员 何　伟

浙江导明医药科技有限公司总经理
Vice - Chairman, He Wei
General Manager of DTRM Biopharma



副主任委员 鲁先平

深圳微芯生物科技有限责任公司总裁兼首席科学官
Vice - Chairman, Lu Xianping
President & Chief Scientist Officer (CSO) of Shenzhen Chipscreen Biosciences Co., Ltd.

副主任委员 王　鹏

亚宝药业集团股份有限公司北京药物研究院院长
Vice - Chairman, Wang Peng
President of Beijing Research Institute, Yabao Pharmaceutical Group Co., Ltd.

副主任委员 徐希平

深圳奥萨制药有限公司董事长
Vice - Chairman, Xu Xiping
Chairman of the Board, Shenzhen AUSA Pharmaceuticals Ltd.

副主任委员 杨大俊

江苏亚盛医药开发有限公司董事长
Vice - Chairman, Yang Dajun
Chairman of the Board, Ascentage Pharma Group Corp., Limited

副主任委员 俞德超

信达生物制药（苏州）有限公司董事长兼总裁
Vice - Chairman, Yu Dechao
President & CEO, Innovent Biologics (Suzhou) Co., Ltd.

药物临床研究专业委员会
Clinical Research Specialty Committee

名誉主任委员 孙　燕

中国工程院院士
中国医学科学院肿瘤医院国家新药临床研究中心主任
Honorary Chairman, Sun Yan
Academician of the Chinese Academy of Engineering
Director of National New Drugs Clinical Research Center, Cancer Hospital Chinese Academy of Medical Science

名誉主任委员 葛均波

中国科学院院士
复旦大学附属中山医院心内科主任
Honorary Chairman, Ge Junbo,
Academician of the Chinese Academy of Sciences
Director of Cardiology Department, Zhongshan Hospital Fudan University

主任委员 王拥军

首都医科大学附属北京天坛医院副院长
Chairman, Wang Yongjun
Vice President of Beijing Tiantan Hospital, Capital Medical University

候任主任委员 霍　勇

北京大学第一医院心内科及心脏中心主任
Elect Chairman, Huo Yong
Director of Cardiology and Heart Center, Peking University First Hospital

副主任委员 季加孚

北京大学肿瘤医院院长
Vice - Chairman, Ji Jiafu
President of Beijing Cancer Hospital

副主任委员 王宁利

北京同仁医院党委书记、副院长
Vice - Chairman, Wang Ningli,
Secretary of the Party Committee & Vice President of Beijing Tongren Hospital

副主任委员 陈　方

北京安贞医院副院长
Vice - Chairman, Chen Fang
Vice-President of Beijing Anzhen Hospital

副主任委员 纪立农

北京大学人民医院内分泌科主任
Vice - Chairman, Ji Linong
Director of Department of Endocrinology, Peking University People's Hospital

副主任委员 王广发

北京大学第一医院呼吸科主任
Vice - Chairman, Wang Guangfa
Director of Department of Respiration, Peking University First Hospital

副主任委员 侯　健

上海长征医院血液科主任
Vice - Chairman, Hou Jian
Director of Department of Hematology, Shanghai ChangZheng Hospital



副主任委员 崔一民

北京大学第一医院药剂科主任
Vice - Chairman, Cui Yimin
Director of Department of Pharmacy, Peking University First Hospital

医药政策专业委员会
Medicinal Policy Specialty Committee

主任委员 史录文

北京大学药学院药事管理与临床药学系主任
Chairman, Shi Luwen
Director, Pharmacy Administration and Clinical, Peking University School of Pharmaceutical Sciences

候任主任委员 邵　蓉

中国药科大学研究生院常务副院长
Elect Chairman, Shao Rong
Executive Deputy Dean of China Pharmaceutical University Graduate School

副主任委员 张清奎

原国家知识产权局医药生物审查部部长
Vice - Chairman, Zhang Qingkui
Former Director-General of Pharmaceutical and Biotech Examination Department, State Intellectual Property Office of the P.R.C.

副主任委员 朱恒鹏

中国社会科学院经济研究所公共政策研究中心主任
Vice - Chairman, Zhu Hengpeng
Director, Public Policy Research Center, Institute of Economics of Chinese Academy Social Science

副主任委员 胡　欣

北京医院药学部主任
Vice - Chairman, Hu Xin
Director of Department of Pharmacy, Beijing Hospital

副主任委员 刘军帅

山东省青岛市社会保障研究会副会长
Vice - Chairman, Liu Junshuai
Vice-President of Qingdao Social Security and Research Association

副主任委员 陈　川

北京华康管理咨询有限公司董事长
Vice - Chairman, Chen Chuan
Chairman of Beijing HuaKang Healthcare Consulting Co., Ltd.

副主任委员 武志昂

沈阳药科大学工商管理学院院长
Vice - Chairman, Wu Zhi'ang
Dean of School of Business Management, Shenyang Pharmaceutical University

副主任委员 陈　文

复旦大学公共卫生学院院长
Vice - Chairman, Chen Wen
Dean of School of Public Health, Fudan University

副主任委员 王　波

北京秦脉医药咨询有限责任公司董事长
Vice - Chairman, Wang Bo
Chairman of Beijing CHNMED Pharmaceutical Technology Development Co., Ltd.

副主任委员 邵　颖

上海复星医药（集团）股份有限公司副总裁兼研发中心主任
Vice - Chairman, Shao Ying
Vice President & Director of R&D Center, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

生物医药专业委员会发起人
Sponsors of Biopharmaceutical Specialty Committee

彭红卫 Peng Hongwei	苏州金盟生物技术有限公司董事长 President of Genemen Biotech Co., Ltd.
刘世高 Liu Shigao	上海复宏汉霖生物技术有限公司总裁兼首席执行官 CEO & President of Henlius Biopharmaceuticals Co., Ltd.
孙奇威 Sun Qiwei	上海源培生物科技有限公司总经理 Manager-General of BasalMedia Biotech Co., Ltd.
裘霁宛 Qiu Jiwan	江苏泰康生物医药有限公司总裁 President of Jiangsu T-mab BioPharma Co., Ltd.
李　晶 Li　Jing	上海张江生物技术有限公司副总经理 Vice Manager-General of Zhang Jiang Biotechnology Co., Ltd.
黄应峰 Huang Yingfeng	宝船生物医药科技（上海）有限公司副总经理 Vice Manager-General of Dragonboat Biopharmaceutical Co., Ltd.

医药创新投资专业委员会发起人
Sponsors of Pharmaceutical Innovation Investment Specialty Committee

杜　莹 Du Ying	再鼎医药（上海）有限公司董事长兼首席执行官 Chairman of the Board & CEO, ZAI Lab (Shanghai) Co., Ltd.
储慧斌 Chu Huibin	海捷投资控股集团首席合伙人 Chief Partner of Hiyeild Capital Holding Group
易诺青 Yi Nuoqing	高瓴资本集团合伙人 Partner of Hillhouse Capital Group
张　勇 Zhang Yong	上海建信康颖创业投资管理有限公司总经理 General Manager of Shanghai Jianxin Health Venture Capital Management Co., Ltd.
朱晋桥 Zhu Jinqiao	深圳市倚锋投资管理企业（有限合伙）创始合伙人 Founding Partner of EFung Capital Co., Ltd.

重要活动
Important Events

中国药促会在江苏省连云港市召开 2015 年会长会议扩大会议
PhIRDA held extended meeting of 2015 President Board Meeting in Lianyungang, Jiangsu Province

参会代表合影（2015 年 1 月 9 日•连云港）
Group photo of representatives (January 9, 2015, Lianyungang)

第十届会员大会第二次会议

（2015年9月24日 • 北京）

The Second Meeting of 10th PhIRDA General Assembly (September 24, 2015, Beijing)

参会代表合影

Group photo of representatives

会场全景

Plenary Meeting

2014–2015 年度会长孙飘扬主持会议
Address by Sun Piaoyang, PhIRDA's Annual Chairman 2014-2015

执行会长宋瑞霖做工作报告
Address by Executive President Song Ruilin

新任会长蒋华良讲话
Address by Jiang Hualiang, PhIRDA's Annual Chairman 2015-2016

副秘书长冯岚宣读 2014–2015 年度会费收支情况报告
Feng Lan, Deputy Secretary-General announced PhIRDA's Annual Financial Report for Year 2014-2015

CFDA 副局长孙咸泽围绕我国最新药品安全监管与改革相关政策作专题报告
Vice Minister Sun Xianze from China Food and Drug Administration made a speech on the drug safety supervision and reform

CFDA 副局长孙咸泽和执行会长宋瑞霖与参会代表互动讨论
Vice Minister Sun Xianze from China Food and Drug Administration together with PhIRDA Executive President Song Ruilin held Q&A discussion with representatives

中国医药创新促进会药物研发专业委员会成立大会暨中国创新药物研发研讨会

（2015 年 4 月 21 日 • 徐州）

The establishment ceremony of PhIRDA Drug R&D Specialty Committee and Seminar on Innovative Drug R&D in China (April 21, 2015, Xuzhou)

参会代表合影

Group photo of representatives

中国医药创新促进会药物临床研究专业委员会成立大会暨中国创新药物研发研讨会

（2015 年 4 月 21 日 • 徐州）

The establishment ceremony of PhIRDA Clinical Research Specialty Committee and Seminar on Innovative Drug R&D in China (April 21, 2015, Xuzhou)

参会代表合影

Group photo of representatives

中国医药创新促进会医药政策专业委员会成立大会暨药品招标采购政策研讨会

（2015 年 7 月 3 日 • 北京）

The establishment ceremony of PhIRDA Medicinal Policy Specialty Committee and Seminar on Drug Bidding and Procurement Policies (July 3, 2015, Beijing)

参会代表合影

Group photo of representatives

第六届中国医院药学政策论坛

（2015 年 7 月 24 日 • 成都）

The 6th Chinese Hospital Pharmacy Policy Forum (July 24, 2015, Chengdu)

本次论坛由中国医药创新促进会、中国药学会与中国药师协会联合主办，会议主题为：政府简政放权后，药师如何在医药卫生体系中发挥作用。来自国家卫计委药政司、中国医药创新促进会、中国药师协会、卫计委医院管理研究所等单位的相关同志，和北京朝阳医院、北京大学第一医院、北京同仁医院、北京大学人民医院等医疗机构的药剂科主任及临床专家，以及来自全国各地药学领域的代表共计 500 多人参加了会议。

Co-hosted by PhIRDA, China Pharmaceutical Association and Chinese Pharmacists Association, the forum was under the theme “The role of pharmacists in the new healthcare system and regulation”. More than 500 people, including officials from NHFPC, Chinese Pharmacists Association and related pharmacy directors and clinical experts across the country from Beijing Chaoyang Hospital, No.1 Hospital of Peking University, Beijing Tongren Hospital, Peking University People’s Hospital, etc., attended this event.

会场全景

Plenary Meeting

开展政策研讨 积极建言献策

Making discussions on medical policies & Providing suggestions

2014-2015 年度，中国药促会先后承接了农工党中央、卫计委科教司、药政司，国家食品药品监管总局、国家知识产权局等部委及企业委托的政策研究课题十余项，涉及完善我国药品集中采购机制研究、创新药物的政策研究、公立医院常用药品配备管理模式研究、特殊情形下药品批准制度研究、国家紧急状态等公共利益目的依据下专利强制许可程序实务研究等方面。另外，截至 2015 年 9 月初，中国药促会召开了 4 个课题项目结题会，分别对“大医改背景下药师的地位与作用”、“我国现有药品招标采购制度”、“国家医保谈判药品目录”、“基本药物可及性及合理性”四个方面的研究成果进行了总结。

During 2014-2015, PhIRDA had made more than 10 researches on policies authorized by Central Committee of Chinese Peasants and Workers Democratic Party, National Health and Family Planning Commission (NHFPC), China Food and Drug Administration (CFDA), State Intellectual Property Office (SIPO) and companies, including researches on centralized drug procurement system, policies on encouraging pharmaceutical innovation, equipped model of essential medicines in public hospitals, drug approval regulations under special circumstances, patents compulsory licensing procedures under national emergency and etc. Moreover, until early September, 2015, PhIRDA held four closing seminars, including studies on pharmacists' role and effect under the background of healthcare reform , current drug biding and procurement regulations in China, accessibility and rationality of essential medicines and healthcare negotiating drug list.

“我国现有药品招标采购制度研究”课题结题会
（2015 年 1 月 27 日 • 北京）
Closing Seminar on “Current Drug Biding and Procurement Regulations in China” (January 27, 2015, Beijing)

“基本药物可及性与合理性研究”结题会
（2015 年 7 月 8 日 • 北京）
Closing Seminar on “Study of Accessibility and Rationality of Essential Medicines” (July 8, 2015, Beijing)

2015 年以来，中国药促会多次针对国家食品药品监管总局（CFDA）关于完善化学药品注册分类、加快解决药品注册申请积压等问题组织专家进行反复研讨并形成书面意见报送 CFDA，中国药促会关于创新药的定义及分类，关于仿制药质量一致性评价中参比制剂的选择原则及创新药专利补偿政策等的相关建议获得 CFDA 肯定，大部分意见建议被采纳。

另外，中国药促会密切关注全国各地出台的药品招标采购相关政策，在各地公开征求意见时进行研究并及时提出建议，对一些违反产业发展规律和国家政策，漠视企业合法权益的做法在第一时间做出郑重回应。中国药促会敢于坚持真理、敢于仗义执言的精神赢得了各界的赞赏。

Since 2015, regarding issues on improving drugs registration classification and how to accelerate drug application for registration proposed by China Food and Drug Administration (CFDA), PhIRDA organized experts to have a discussion and eventually submitted the research report to CFDA. Suggestions on definition and classification of new drugs, the selected principle of reference preparation in quality consistency evaluation of generic drugs, new drug patent term restoration all got positive feedbacks from CFDA and were adopted finally.

In addition, PhIRDA always focus on related policies, conducted researches when the government was seeking advice and timely made suggestions for some violation of industrial development rules and national policies, making timely responses. PhIRDA's spirit, to dare to uphold the truth and speak out, received appreciation from the community.

来访外宾的会见与交流
Meeting with foreign guests

执行会长宋瑞霖会见 BioCentury 公司主席 Karen Bernstein 一行（2015 年 2 月 9 日 • 北京）
Executive President Song Ruilin met with Karen Bernstein, Chairman of BioCentury and other representatives (February 9, 2015, Beijing)

执行会长宋瑞霖与美国安进公司 Bradway 董事长兼首席执行官合影（2015 年 5 月 21 日 • 北京）
Executive President Song Ruilin met with Bradway, President & CEO of Amgen Co., Ltd. (May 21, 2015, Beijing)



执行会长宋瑞霖会见加拿大阿尔伯塔大学医学院院长 Richard Fedorak 一行（2015 年 6 月 25 日 • 北京）
Executive President Song Ruilin met with Richard Fedorak, Dean of the Faculty of Medicine & Dentistry at the University of Alberta and other representatives (June 25, 2015, Beijing)

执行会长宋瑞霖会见法国益普生公司（Ipsen Pharma）副首席执行官 Christel Bories 一行（2015 年 9 月 16 日 • 北京）
Executive President Song Ruilin met with Christel Bories, Vice CEO of Ipsen Pharma and other representatives (September 16, 2015, Beijing)

中国药促会代表团赴台湾考察访问
（2014 年 11 月 10 日 –12 日 • 台湾）

PhIRDA Delegation visited Taiwan (November 10-12, 2014, Taiwan)

中国药促会执行会长宋瑞霖与台湾生策会陈维昭会长签署《合作备忘录》
Executive President Song Ruilin from PhIRDA and Chairman Chen Weizhao from IBMI signed the Memorandum of Cooperation

代表团参加第一届两岸生技新药产业合作论坛
PhIRDA delegates attended "the 2014 Cross Strait Biotech Industry Development Forum"

代表团受邀访问台湾国家生技医疗产业策进会
PhIRDA Delegation visited Taiwan Institute for Biotechnology and Medicine Industry (IBMI)

代表团访问杏辉医药集团研发中心、癌症制剂中心
PhIRDA Delegation visited R&D Center and Cancer Preparation Center of Sinphar Group

中国药促会代表团出席金砖国家第四次卫生部长会议

（2014 年 12 月 2 日 –5 日 • 巴西）

PhIRDA delegates attended the IV BRICS Health Ministers Meetings (December 2-5, 2014, Brazil)

2014 年 12 月 2-4 日，会长孙飘扬、执行会长宋瑞霖应邀作为中国政府卫生代表团成员出席在巴西召开的金砖国家卫生部长会议，会议主题为药物研发和可获得药物。我会代表在会上提出的建议获得金砖国家与会代表的一致认可，并被写入金砖国家第四次卫生部长会议的最终报告。这是中国医药相关协会第一次参加政府间国际会议并参与会议文件起草和讨论，具有非常积极的意义。

On December 2-4 2014, Chairman Sun Piaoyang and Executive President Song Ruilin were invited as members of Chinese government delegation to attend the BRICS Health Ministers Meeting in Brazil, on the theme of drug development and availability. Our suggestions were agreed by BRICS delegates and written into the final report of the fourth BRICS Health Ministers Meeting. This is the first time for a Chinese pharmaceutical association to participate in international intergovernmental conferences and participated in drafting and discussions, which was highly positive.

会场全景
Plenary Meeting

中国药促会主办“中美生物医药创新研讨会”

（2015 年 5 月 13 日 • 美国）

PhIRDA hosted the China-US Biopharmaceutical Innovation Forum (May 13, 2015, United States)

由中国药促会（PhIRDA）、生物技术工业组织（BIO）、中国外商投资企业协会药品研制和开发行业委员会（RDPAC）共同主办的“中美生物医药创新研讨会”在美国洛杉矶召开。国家重大新药创制科技重大专项行政负责人、国家卫生计生委副主任刘谦率领国家卫生计生委代表团一行、中国药促会会长孙飘扬、执行会长宋瑞霖共同出席了会议。此次活动是中美两国的生物医药产业界举行的首次研讨会，必将在促进中美生物医药产业界互利合作、共同发展等方面产生积极而深远的影响。

PhIRDA together with BIO and RDPAC co-hosted “Sino-US Biopharmaceutical Innovation Cooperation Forum” in Los Angeles. Vice Minister Liu Qian from NHFPC, PhIRDA Chairman Sun Piaoyang and Executive President Song Ruilin attended the forum. As the first forum of the Sino-US biopharmaceutical industries, this event will greatly promote the cooperation and development of biotech between the two sides.

国家卫生计生委副主任刘谦致辞
Address by Vice Minister Liu Qian from NHFPC

中国药促会 2014–2015 年度会长孙飘扬致辞
Address by Sun Piaoyang, PhIRDA Annual Chairman 2014-2015

BioCentury 总裁兼首席执行官 David Flores 介绍金融创新和法规监管创新以及病人的参与对生物医药创新的重要意义
David Flores, President & CEO of BioCentury, made speech about the importance of capital and regulatory innovation to biopharmaceutical development

美国公共利益医药中心高级副总裁 Robert M. Goldberg 介绍新药对科技和经济的影响
Robert M. Goldberg, Vice President of US Center for Medicine in the Public Interest, made speech about the new drugs' effects on technology and economy



中国药促会执行会长宋瑞霖围绕“中美促进生物医药创新研发的政策环境”做主题报告

Song Ruilin, Executive President of PhIRDA, made speech about the Ecosystem to encourage biopharmaceutical innovation

中国药促会副会长蒋建东介绍中国生物药的发展情况和相关学术研究情况以及相关的政策与监管等内容

Jiang Jiandong, Vice President of PhIRDA, made speech about the update on new drugs innovation and policies in China

南加州大学国际管理科学中心主任Frances J. Richmond 强调法规变革和适应生物医药技术发展的重要性

Frances J. Richmond, Director of International Center for Regulatory Science at University of Southern California, made speech on the importance of adaption between regulation reform and biotech development



神州细胞工程有限公司首席执行官谢良志介绍中国生物医药技术发展的历史及现状

Xie Liangzhi, CEO of Sinocelltech Ltd., made speech about the history and status of biotech development in China

中国药促会调研组赴德国、比利时调研

（2015 年 7 月 13 日 –16 日）

PhIRDA delegation visited Germany and Belgium (July 13-16, 2015)

2015 年 7 月，中国药促会调研组赴德国柏林和比利时布鲁塞尔进行调研，详细了解德国的医疗保险体制和欧盟鼓励医药创新的政策。

On July, 2015, PhIRDA research group conducted in-depth researches on medical insurance system in Germany and policies encouraging pharmaceutical innovation in EU.

调研组在布鲁塞尔拜耳欧洲大区办公室调研

PhIRDA Delegation visited Bayer European Regional Office

调研组拜访欧洲制药工业协会联合会

PhIRDA Delegation visited the European Federation of Pharmaceutical Industries and Association (EFPIA)

调研组在欧洲亚洲事务研究所调研

PhIRDA Delegation visited European Institute for Asian Studies

中德双方代表合影

Group photo of PhIRDA delegates and German representatives

中国药促会代表团考察日本医药制度及政策

（2015 年 7 月 27 日 –29 日 • 日本）

PhIRDA Delegation investigated medicine policies and regulations in Japan (July 27-29, 2015, Japan)

为了完善我国鼓励新药创制的相关政策，应日本制药工业协会（JPMA）的邀请，2015 年 7 月 27-29 日，中国药促会调研组赴日本开展医药政策调研活动。调研组访问了 JPMA、日本厚生劳动省、日本药品与医疗器械审评中心（PMDA），就日本的药品审评制度、药品知识产权制度、医保体系及医保药品定价、医药分业、医院药品采购等内容进行了深入调研，对相关政策有了更深的了解。

In order to improve relevant policies to encourage pharmaceutical innovation in China, upon the invitation from Japan Pharmaceutical Manufacturers Association (JPMA), PhIRDA research group went to Japan to carry out policy research on July 27-29, 2015. During the event, the research group visited Japan Pharmaceutical Manufacturers Association (JPMA), MHLW and PMDA, conducting in-depth research on drug evaluation system, pharmaceutical intellectual property system, medical insurance system and drug pricing, separation of dispensing from prescription and the drug procurement in hospitals and so on, obtaining deep understanding on related policies.

代表团赴日本制药工业协会考察

PhIRDA Delegation visited JPMA

第十届会员单位及其代表

Members & Representatives of 10th PhIRDA General Assembly

蒋华良 Jiang Hualiang	中国科学院上海药物研究所所长 Director, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
陈启宇 Chen Qiyu	上海复星医药（集团）股份有限公司董事长 Chairman of the Board, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
闫希军 Yan Xijun	天士力控股集团董事局主席 Chairman of the Board, Tasly Holding Group
孙飘扬 Sun Piaoyang	江苏恒瑞医药股份有限公司董事长 Chairman of the Board, Jiangsu Hengrui Medicine Co., Ltd.
丁列明 Ding Lieming	贝达药业股份有限公司董事长兼 CEO Chairman of the Board & CEO, Betta Pharmaceutical Co., Ltd.
张伯礼 Zhang Boli	天津中医药大学校长，中国工程院院士 President,Tianjin University of Traditional Chinese Medicine, Academician,Chinese Academy of Engineering
蔡东晨 Cai Dongchen	石药集团有限公司董事长 Chairman of the Board, China Shijiazhuang Pharmaceutical Group Co., Ltd.
楼定波 Lou Dingbo	上海医药集团股份有限公司董事长、党委书记 Chairman of the Board, Secretary of the Party Commission, Shanghai Pharmaceuticals Holding Co., Ltd.
任晋生 Ren Jinsheng	先声药业有限公司董事长 Chairman of the Board, Simcere Pharmaceutical Group
石晟怡 Shi Shengyi	中国医药集团总公司董事会秘书、中国国际医药卫生公司董事长 Secretary of the Board of Sinopharma Group Corporation, Chairman of the Board of China Sinopharm International Corporation
蒋建东 Jiang Jiandong	中国医学科学院药物研究所所长 Director, Institute of Materia Medica, Chinese Academy of Medical Sciences
柯尊洪 Ke Zunhong	成都康弘药业集团股份有限公司董事长 Chairman of the Board, Chengdu Kanghong Pharmaceutical Group Co., Ltd.
徐镜人 Xu Jingren	扬子江药业集团董事长 Chairman of the Board, Yangtze River Pharmaceutical Group
白礼西 Bai Lixi	太极集团有限公司董事长 Chairman of the Board, Taiji Group Co., Ltd.
胡季强 Hu Jiqiang	浙江康恩贝制药股份有限公司董事长 Chairman of the Board, Zhejiang Conba Pharmaceutical Co., Ltd.
李振江 Li Zhenjiang	神威药业集团董事长 Chairman of the Board, Shineway Pharmaceutical Group
李春波 Li Chunbo	浙江医药股份有限公司董事长 Chairman of the Board, Zhejiang Medicine Co., Ltd.
白　骅 Bai Hua	浙江海正药业股份有限公司董事长 Chairman of the Board, Zhejiang Hisun Pharmaceutical Co., Ltd.
高任龙 Gao Renlong	华北制药集团有限责任公司党委常委 Member of Standing Committee of CPC Committee, North China Pharmaceutical Group Corporation
汲　涌 Ji Yong	东北制药集团股份有限公司总经理 General Manager, Northeast Pharmaceutical Group Co., Ltd.
刘革新 Liu Gexin	四川科伦药业股份有限公司董事长 Chairman of the Board, Sichuan Kelun Pharmaceutical Co., Ltd.
李　聪 Li Cong	通化东宝药业股份有限公司总经理 General Manager, Tonghua Dongbao Pharmaceutical Co., Ltd.
李安平 Li Anping	山西振东制药股份有限公司董事长 Chairman of the Board, Shanxi Zhendong Pharmaceutical Co., Ltd.
刘殿波 Liu Dianbo	绿叶制药集团董事长 Chairman of the Board, LUYE Pharma Group
张成海 Zhang Chenghai	美罗药业股份有限公司董事长 Chairman of the Board, Merro Pharmaceutical Co., Ltd.
顾浩亮 Gu Haoliang	上海信谊药厂有限公司总经理 General Manager, Shanghai SINE Pharmaceutical Co., Ltd.
李　昕 Li　Xin	华润双鹤药业股份有限公司总裁 President, China Resources Double-Crane Pharmaceutical Co., Ltd.
陶德胜 Tao Desheng	丽珠医药集团股份有限公司总裁 President, Livzon Pharmaceutical Group Inc.
郭殿武 Guo Dianwu	杭州民生药业有限公司副总经理 Deputy General Manager, Hangzhou Minsheng Pharmaceutical Co., Ltd.

董弘宇 浙江佐力药业股份有限公司总经理
Dong Hongyu General Manager, Zhejiang Jolly Pharmaceutical Co., Ltd.

许淑清 广西梧州中恒集团股份有限公司董事长
Xu Shuqing Chairman of the Board, Guangxi Wuzhou Zhongheng Group Co., Ltd.

王　勇 南京圣和药业股份有限公司董事长
Wang Yong Chairman of the Board, Nanjing Sanhome Pharmaceutical Co., Ltd.

张观福 贵州信邦制药股份有限公司董事长
Zhang Guanfu Chairman of the Board, Guizhou Xinbang Pharmaceutical Co., Ltd.

赵　涛 山东步长制药股份有限公司董事长
Zhao Tao Chairman of the Board, Shandong Buchang Pharmaceutical Co., Ltd.

于伟仕 悦康药业集团有限公司董事长
Yu Weishi Chairman of the Board, Youcare Pharmaceutical Group Co., Ltd.

陈庆才 江苏奥赛康药业股份有限公司董事长
Chen Qingcai Chairman of the Board, Jiangsu Aosaikang Pharmaceutical Co., Ltd.

王晓琳 重庆植恩药业有限公司总经理
Wang Xiaolin General Manager, Zein Pharmaceutical Co., Ltd.

冯　鹤 正大青春宝药业有限公司总裁
Feng He President, Chiatai Qingchunbao Pharmaceutical Co., Ltd.

徐希平 深圳奥萨制药有限公司董事长
Xu Xiping Chairman of the Board, Shenzhen AUSA Pharmaceuticals Ltd.

娄　竞 沈阳三生制药有限责任公司总裁
Lou Jing President, Shenyang Sunshine Pharmaceutical Co., Ltd.

任武贤 亚宝药业集团股份有限公司董事长
Ren Wuxian Chairman of the Board, Yabao Pharmaceutical Group Co., Ltd.

葛啸虎 常州方圆制药有限公司董事长
Ge Xiaohu Chairman of the Board, Changzhou Fangyuan Pharmaceutical Co., Ltd.

郑效东 上海东富龙科技股份有限公司董事长
Zheng Xiaodong Chairman of the Board, Shanghai Tofflon Science and Technology Co., Ltd.

李伯涛 齐鲁制药有限公司董事长
Li Botao President, Qilu Pharmaceutical Co., Ltd.

王锦刚 北京科信必成医药科技发展有限公司总经理
Wang Jingang General Manager, CoSci Med-Tech Co., Ltd.

王俊林 上海中信国健药业股份有限公司总裁
Wang Junlin President, Shanghai CP Guojian Pharmaceutical Co., Ltd.

鲁先平 深圳微芯生物科技有限责任公司董事、总裁、首席科学官
Lu Xianping Director, President & Chief Scientific Officer, Shenzhen Chipscreen Biosciences, Ltd.

王泽楷 青岛黄海制药有限责任公司董事长
Wang Zekai Chairman of the Board, Qingdao Huanghai Pharmaceutical Co., Ltd.

钟慧娟 江苏豪森医药集团有限公司董事长、总裁
Zhong Huijuan Chairman of the Board & President, Jiangsu Hansoh Pharmaceutical Group

叶宇翔 深圳信立泰药业股份有限公司总经理
Ye Yuxiang General Manager, Shenzhen Salubris Pharmaceuticals Co., Ltd.

俞德超 信达生物制药（苏州）有限公司董事长兼总裁
Yu Dechao President & CEO, Innovent Biologics (Suzhou) Co., Ltd.

陈　力 华领医药技术（上海）有限公司董事长、总经理
Chen Li President & CEO, Hua Medicine (Shanghai) Ltd.

吴劲梓 歌礼生物科技（杭州）有限公司董事长
Wu Jinzi Chairman of the Board, Ascletis Bioscience Co., Ltd.

杨大俊 江苏亚盛医药开发有限公司董事长
Yang Dajun Chairman of the Board, Ascentage Pharma Group Corp Limited

杜　莹 再鼎医药（上海）有限公司董事长兼首席执行官
Du Ying Chairman of the Board & CEO, ZAI Lab (Shanghai) Co., Ltd.

张　丹 方恩（天津）医药发展有限公司董事长兼 CEO
Zhang Dan Chairman of the Board & CEO, Fountain Medical Development Ltd.

李　革 药明康德新药开发有限公司董事长兼首席执行官
Li　Ge Chairman of the Board & CEO, WuXi AppTec Co., Ltd.

王善春 正大天晴药业集团股份有限公司总裁
Wang Shanchun President, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

孔　泰 北京泰德制药股份有限公司总裁
Kong Tai President, Beijing Tide Pharmaceutical Co., Ltd.

吴晓明 中国药科大学原校长
Wu Xiaoming Former President, China Pharmaceutical University

高思华 北京中医药大学原校长
Gao Sihua Former President, Beijing University of Chinese Medicine

吴春福 沈阳药科大学党委书记
Wu Chunfu Secretary of the Party Committee, Shenyang Pharmaceutical University

刘俊义 北京大学药学院院长
Liu Junyi Dean, Peking University School of Pharmaceutical Sciences

陆伟跃 复旦大学药学院党委书记
Lu Weiyue Secretary of the Party Committee, School of Pharmacy Fudan University

刘克良 军事医学科学院毒物药物研究所原所长
Liu Keliang Former Director, Institute of Pharmacology and Toxicology Academy of Military Medical Sciences

汤立达 天津药物研究院院长
Tang Lida Director, Tianjin Institute of Pharmaceutical Research

李卓荣 中国医学科学院北京协和医学院医药生物技术研究所副所长
Li Zhuorong Deputy Director, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College

王拥军 首都医科大学附属北京天坛医院副院长
Wang Yongjun Deputy Dean, Beijing Tiantan Hospital, Capital Medical University

第十届会员单位简介（排名不分先后）
Brief Introduction of Members of 10th PhIRDA General Assembly

中国科学院上海药物研究所
Shanghai Institute of Materia Medica, Chinese Academy of Sciences

中国科学院上海药物研究所是我国历史最悠久的综合性药物研究机构。其前身是国立北平研究院药物研究所，创建于 1932 年，首任所长为赵承嘏。1933 年南迁上海，后将武康路作为所址，1953 年后陆续搬迁至岳阳路，2003 年落户浦东张江高科技园区。

建设以来，上海药物所秉承着“寻找治疗疾病的新药，为人民解除病痛”的办所宗旨，共研制开发新药 100 余种并投入生产，创制了蒿甲醚、二巯基丁二酸、石杉碱甲等一批在国内外具有影响的创新药物。近年来又研制了现代中药丹参多酚酸盐、抗菌新药盐酸安妥沙星等新药，一批新药正处于临床研究阶段。

中国科学院开展“知识创新工程”以来，上海药物所确立了“出新药”战略，瞄准国际生命科学发展的前沿领域以及药物研究的重要科学问题，开展创新药物基础和应用基础研究，发展药物研究新理论、新方法和新技术。

重点围绕治疗恶性肿瘤、心脑血管系统疾病、神经精神系统疾病、代谢性疾病、自身免疫性疾病及感染性疾病等开展新药研发，并加强现代中药的研发。

经过几代人的努力，上海药物所已发展成为学科齐全、成就卓著、人才荟萃、在国内外享有较高声誉的综合性药物研究机构。

Shanghai Institute of Materia Medica (hereafter referred as SIMM), Chinese Academy of Sciences (hereafter referred as CAS), has the longest history as a comprehensive research institution for drug discovery in China. SIMM was evolved from Peking Institute of Materia Medica, Academia Sinica, founded in 1932 by Professor Chenggu Zhao (T. Q. Chou). It was relocated to Wukang Road, Shanghai in 1933, then to Yueyang Road in 1953, and settled down in Zhang Jiang Hi-Tech Park, Pudong New District in 2003.

In line with the mission of “Discovering new drugs to relieve patients suffering from various diseases”, SIMM has developed and commercialized over 100 new drugs. Among them, a number of innovative drugs such as Artemether, Dimercaptosuccinic acid, and Huperzine A gained recognition both home and abroad. Recent years have witnessed the development of some novel drugs from SIMM, including Depsides salts, a modern Traditional Chinese Medicine (TCM), and Antofloxacin Hydrochloride, a novel fluoroquinolone antibacterial agent. SIMM has currently a number of candidates in clinical stages.

Since the implementation of the Knowledge Innovation Program of CAS, developing novel drugs has become a paramount research focus of SIMM in recent years. In line with frontiers in life sciences and aiming at solving key scientific problems in drug discovery, SIMM carries out both basic and applied studies and develops new theories, methods and technologies. Research priorities are given to treat major diseases, such as cancer, cardio-cerebrovascular disease, neuropsychiatric disease, metabolic disease, autoimmune disease, and infectious disease. SIMM pays also attention to the development of modern Traditional Chinese Medicine (TCM).

Through several generations’ efforts, SIMM has become one of the leading interdisciplinary centers of excellence in China. It is recognized worldwide by its outstanding achievements and distinguished research team.

上海复星医药（集团）股份有限公司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

上海复星医药（集团）股份有限公司成立于 1994 年，是在中国拥有领先地位的医药健康产业集团。复星医药战略性地覆盖医药健康产业链的多个重要环节，主要从事的业务包括制药、药品分销及零售、医学诊断与医疗器械以及医疗服务。公司拥有国家级企业技术中心及国际化的研发团队，持续专注于新陈代谢及消化道、心血管、中枢神经系统、抗肿瘤、抗感染等治疗领域的创新研发。在中国，复星医药已取得肝病、糖尿病、结核病、临床诊断产品等细分市场的竞争优势；在全球市场，复星医药也已成为抗疟药物的领先者。

复星医药在聚焦发展核心制药业务的同时，积极发展医疗服务领域，并进一步巩固在医学诊断、医疗器械等领域的竞争优势。目前，复星医药已在国内高端和专科医疗服务领域建立坚实基础。复星医药亦是国药控股的第二大股东，国药控股是中国最大的药品及保健品分销商及领先供应链服务提供商，并拥有国内最大的药店零售体系。

复星医药奉行可持续发展的原则，追求人才与产品的可持续发展，将履行社会责任纳入到企业发展的长期战略。在企业的经营发展过程中，复星医药始终怀着感恩的心态，积极履行社会责任，致力于成为医药健康领域最受尊敬的企业公民之一。

面向未来，复星医药将秉承持续创新，共享健康的品牌理念，继续坚持“内生式增长、外延式扩张、整合式发展”的发展战略，致力于成为全球主流医药健康市场的一流企业。

Shanghai Fosun Pharmaceutical (Group) Co., Ltd,established in 1994 is a leading company in China’s pharmaceutical and healthcare industry.Fosun Pharma’s business covers the whole value-chain of the pharmaceutical and healthcare industry which includes pharmaceutical R&D and manufacture, distribution and retailing, diagnosis and medical devices, as well as healthcare services. We owns a national-level Technology Center and has a R&D team with international perspective. We have been focusing on innovative research and development in therapeutic areas such as metabolism and alimentary tract, cardiovascular system, central nervous system, anti-tumor as well as anti-infective treatment. In China, Fosun Pharma has competitive advantage in the market segments for liver disease, diabetes, central nervous system, tuberculosis and in-vitro diagnostic products. Fosun Pharma is also the global market leader in anti-malarial drugs.

While focusing on pharmaceutical manufacturing, Fosun Pharma has built a leading position in diagnosis and medical devices as well as actively developing its presence in healthcare services. Fosun Pharma has a solid foundation in domestic high-end and specialty services now and is the second largest shareholder of Sinopharm, which is the largest pharmaceutical and healthcare products distributor and leading supply chain service provider in China. Fosun Pharma strongly believes in the principle of sustainable development and has put CSR into its long-term corporate strategy while persisting in such principle in human resources and products. Fosun Pharma actively fulfills its CSR in the operation and aims to become one of the most respected corporate citizens in the pharmaceutical and healthcare industry.

In future, Fosun Pharma will continue its commitment to “Innovation for Good Health” and implement its strategy of organic growth with external expansion and integrated business operation. We are dedicated to becoming a first class enterprise in the major global healthcare market.

天士力控股集团
Tasly Holding Group

天士力控股集团创建于 1994 年，是以大健康产业为主线，以生物医药产业为核心，以健康保健产业和医疗康复、健康养生管理与服务产业为两翼的高科技国际化企业集团。

天士力成立以来，始终秉承“追求天人合一，提高生命质量”的企业理念和“创造健康，人人共享”的企业愿景，坚持打造中药现代化、国际化第一品牌，大健康产业领先品牌，不断推进大健康产业持续快速发展。2014 年资产总额 344 亿元，销售额 263 亿元，实现利润 31.1 亿元。

天士力积极倡导、推动和实践大健康五大体系的建设，即：树立大健康理念体系、普及大健康教育体系、创新大健康技术体系、发展大健康产业体系、完善大健康服务体系，围绕让人们“生得优、育得好、活得长、病得少、走得安”的目标，全力打造“六个一”工程，即：做好“一盒药、一瓶水、一杯茶、一樽酒，规划设计一套健康管理方案，打造一个少儿教育与健康管理平台；努力成为大健康产品的创造者、大健康管理方案的设计者、大健康文化的践行者。

企业先后承担国家 863 计划、973 计划、“十一五”、“十二五”重大新药创制专项等重大科研课题近百项。连续三届获得“全国精神文明建设先进单位”，先后获得“高新技术企业”、“创新型企业”、“全国劳动关系和谐企业”、“全国创建学习型组织先进单位”、“全国民主管理厂务公开先进单位”等荣誉称号。

面向未来，天士力控股集团将继续发展壮大“一个核心带两翼”的大健康产业格局，为实现“创造健康，人人共享”的目标，锐意创新，科学发展。

Tasly Holding Group was founded in 1994, it is a technological and international enterprise that develops great health industry as it main business; biological pharmaceutical industry as its core business; health care industry, health management and service industry as its supporting businesses.

The corporate philosophy of Tasly is ‘To pursue harmonization between human and nature, to improve life quality’; the corporate mission is ‘To share the joy of health with all’. Tasly is committed to build the best modern and international TCM brand, and to become a leading brand in great health industry.

Tasly is active in integrating global resources, and to push forward the rapid development of great health industry. It strives to promote, push forward, and practice the construction of the 5 systems of great health: to build up great health ideological system; to promote great health education system; to innovate great health technological system; to develop great health industrial system; to complete great health service system. It is making effort in the ‘Six One’ brand project:one box of medicine, one bottle of water, one cup of tea, one glass of liquor, one health management program, one children education platform. Tasly is on its way of becoming the creator of great health product, the designer of great health management program, the practitioner of great health culture.

Tasly has undertaken hundreds of major national scientific research projects: 863 Project, 973 Project, 11th and 12th 5-year-plan for major new medicines research and innovation. The enterprise has received various titles, including: ‘High and New Technological Enterprise’, ‘Innovative Enterprise’, ‘National Employment Satisfaction Award’, ‘National Advanced Learning Organization’, ‘National Advanced Enterprise in Democratic Management and Factory Affair Openness’.

Tasly is delighted for your participation for a promising future. Let us build a healthy lifestyle together, to realize the China dream with the hope of health.

江苏恒瑞医药股份有限公司
Jiangsu Hengrui Medicine Co., Ltd.

江苏恒瑞医药股份有限公司始建于 1970 年，2000 年在上海证券交易所上市。公司以“科研为本，创造健康生活”为理念，坚持“质量第一，诚信经营”为原则，目前已发展成为国内最大的抗肿瘤药、手术药物的研究和生产基地，国家“重大新药创制”专项孵化器基地、国家抗肿瘤药技术创新产学研联盟牵头单位、国内最具创新能力的制药企业之一，同时也是国家重点高新技术企业、国家高技术研究发展计划（863 计划）成果产业化基地，建有国家靶向药物工程技术研究中心、国家博士后科研工作站。公司在美国、上海、成都和连云港建有四大研究中心和一个临床医学部，拥有各类高层次专业技术人员 1300 余名，并引进了 50 名海外高层次人才，有 5 名国家“千人计划人才”，每年科研经费占销售额的 10% 以上。近年来，公司先后承担了 4 项国家 863 计划重大科技专项项目、23 项国家“重大新药创制”专项，共申请了 200 项发明专利，其中 97 项全球专利（PCT 专利），有 2 个创新药艾瑞昔布和阿帕替尼已获批上市，2 个创新药已申报生产，另有 8 个创新药处于不同的临床阶段。近几年，公司注射剂和口服制剂先后通过美国 FDA 和欧盟认证，在海外主流市场销售，成为中国首家将国产注射剂打入欧美市场销售的民族制药企业。公司将继续致力于让中国老百姓以合理的价格用上国际先进品质的药品。

Jiangsu Hengrui Medicine Co., Ltd., established in 1970 and listed in Shanghai Stock Exchange in 2000, holding the idea of “create a healthy life based on science and research” and philosophy of “quality first, integrity management”, is the largest research and manufacturing base of antineoplastics and surgical medicine in China as well as the special incubator base for “New Drug Development”. Known as the lead of National Anti-tumor Medicine Production Technology Innovation Alliance, one of the most innovative pharmaceutical enterprises, Jiangsu Hengrui Medicine is also the National Key High-tech Enterprise and industrialization base of National Science and Technology Major Project (863 Project), which has a national engineering technology research center of targeted drugs and National Post-doctoral Scientific Research Workstation. Hengrui has established four R&D centers in US, Shanghai, Chengdu and Lianyungang, as well as a clinical medicine department. There are more than 1, 300 High-level professional and technical personnel, among which 50 overseas talent are introduced and five of them belongs to Recruitment Program of Global Experts. Scientific research funds occupy more than 10% of sales every year. In recent years, Hengrui undertakes four projects of National Science and Technology Major Project (863 Project) and 23 projects has been placed to “Major New Drug Development”. About 200 patents for invention have been applied, among which 97 are global patent (PCT). The innovative drug Imrecoxib and Apatinib have been approved for marketing; two innovative drugs have been submitted for manufacturing; another eight innovative drugs are in different stages of clinical research. Over the last three years, injection drug and oral preparation has been certified by U.S. FDA and EU, and sold in overseas market. Therefore, Hengrui becomes the first national pharmaceutical enterprise which penetrates into U.S. and European markets with domestic injection products. Jiangsu Hengrui Co., Ltd will continue to devote itself to making Chinese people be available of advanced international standard drugs with reasonable price.

贝达药业股份有限公司
Betta Pharmaceutical Co., Ltd.

贝达药业股份有限公司是一家由海归博士团队创办的、以自主知识产权创新药物研究和开发为核心，集研发、生产、营销于一体的国家级高新制药企业。成立于 2003 年，现有员工近 600 余人。总部设在杭州，建有生产基地 40 亩、厂房 8000m^2，占地 147 亩的新生产基地也在积极规划筹建中。在北京设有新药研发中心，拥有 100 余名研发人员，包括 9 位留学归国博士，其中 6 位已入选国家级“千人计划”。

公司致力于研发和生产拥有自主知识产权的国家一类新药。首个自主研发的 1.1 类抗癌新药——盐酸埃克替尼（商品名：凯美纳），历经十年，于 2011 年 7 月获国家药监局新药证书，8 月在北京人民大会堂上市。这是我国首个拥有自主知识产权的靶向抗癌药，打破了小分子靶向药物领域国外大型制药企业的垄断，标志着我国药物创新有了质的突破。该成果分别于 2012 年和 2014 年获得国家专利金奖，是国内唯一一个拥有两项专利金奖的新药产品。2013 年 8 月，凯美纳 III 期临床研究结果在世界顶尖医学杂志《柳叶刀》全文发表，编者按评价它“代表了肿瘤领域的一个里程碑”。公司在全国设有 11 个销售办事处，拥有 270 余人销售队伍，多次打造凯美纳销售传奇。截至 2014 年底，凯美纳实现销售逾 15 亿元。2013 年 5 月，公司与美国安进公司签署战略合作协议，成立贝达安进制药有限公司，将抗癌药物 Vectibix（帕妥木单抗）引进中国，让更多中国患者受益。2014 年 10 月，公司投资美国 Xcovery 公司，共同开发针对肺癌的新一代靶向药物 X-396，让其惠及美国、中国以及全世界的患者。公司成立 10 年来，共申报发明专利 100 余项，获国内、国外专利授权 23 项；获科技部创新基金 2 项、“863”高科技计划 1 项、火炬计划 1 项、国家重大新药创制专项立项 6 项。公司现有在研项目 22 个，包括 6 个国家一类新药、16 个国家三类新药及仿制药，主要针对恶性肿瘤、糖尿病、心脑血管等严重影响人们健康的疾病。

公司紧紧围绕创新为民、科技惠民，为中国百姓做更多吃得起的好药这一目标，以“三驾马车”---- 自主研发、市场销售、战略合作为龙头，带动贝达走上风光绮丽的山峰，努力为中国生物医药行业的创新发展作出新的更大贡献。

Betta Pharma is the leading innovative pharmaceutical company in China and has successfully launched Conmana (icotinib hydrochloride, a selective EGFR TK inhibitor) for the treatment of non-small cell lung cancer in 2011. Conmana is the 1st novel small molecule targeted cancer therapy developed in China. In 2012, Conmana was cited in the Annual Report of International New Drug Research and Development. In 2013, The Lancet Oncology published the Phase-III clinical study results of Conmana, while the editor's remark says, "Icotinib: Kick-Starting the Chinese Anticancer Drug Industry". More than 50,000 NSCLC patients have been treated with Conmana so far. Its sales have reached CNY700 million in 2014, a 50% increase from 2013.

Betta Pharma was founded in 2003 and headquartered in Hang-Zhou. We have established a fully integrated organization with more than 600 colleagues in R&D, GMP manufacture, as well as sales and marketing. In 2013, we established a joint venture with Amgen in order to bring Amgen's Vectibix® (panitumumab) to the Chinese market for the treatment of metastatic colorectal cancer patients. In 2014, we made a strategic investment of $20 million into Xcovery Holding, a Florida-based biotech company to develop X-396, a potential best-in-class ALK inhibitor for the treatment of non-small cell lung cancer patients.

We will continue to focus on developing innovative medicines to benefit more pastients.

天津中医药大学
Tianjin University of Traditional Chinese Medcine

天津中医药大学始建于 1958 年。学校建有中医学、中药学、中西医结合 3 个博士后科研流动站，中医学、中药学、中西医结合 3 个一级博士点，25 个二级博士点和 46 个二级硕士点，25 个本科专业。学校在校生达 12000 人，其中留学生达到 2000 人。学校拥有 6 所附属医院，共有 4000 张床位，年门诊量 400 余万人。

学校现拥有中医内科学和针灸推拿学国家级重点学科 2 个、28 个省部级重点学科，2 个国家级实验室，中意中医药联合实验室，23 个省部级重点实验室，3 个省部级工程中心。

学校以“进德修业，继承创新”为校训，以重点学科建设和中医药对外教育为特色，以科学研究为优势，以中医药学为主，医、理、文、管、工、教育等多学科协调发展。坚持“传承与创新协同，科研与服务并举，以质量求内涵，全面协调发展”方针，建设高层次、外向型、国内一流、国际知名的教学研究型中医药大学。

Tianjin University of Traditional Chinese Medicine was founded in 1958. The school has three post doctoral research stations, three primary doctoral disciplines (Chinese medicine, Chinese materia medica and integrative of Chinese and western medicine), 25 secondary doctoral disciplines, 46 secondary master disciplines and 25 undergraduate professionals. There are more than 12000 students, including about 2000 overseas students. The school also has 6 affiliated hospitals, which have 4000 beds and more than 4 million outpatient services.

The school has two national key discipline and specialties (internal medicine of TCM and acupuncture) and 28 provincial or ministerial level key discipline and specialties. There are also two national level laboratories, two Sino-Italian joint laboratories of TCM, 23 provincial or ministerial key laboratories and 3 provincial engineering centers.

The school motto is "improve the virtue and refine the achievements, inheritance and innovation". This school takes key disciplinary building-up and education for foreign students as its characteristic and has the advantage of scientific research on TCM, Besides TCM, other disciplines including medicine, science and engineering, literature, management and education develop in phase.

石药集团有限公司

China Shijiazhuang Pharmaceutical Group Co., Ltd.

石药集团有限公司始建于 1938 年 5 月，现有资产总额 200 亿元，员工 18000 人，拥有原料药、成品药和医药商业三大业务板块，其中设在香港的控股子公司(01093.HK)是中国医药行业首家境外上市公司，市值 400 亿元港币，是目前香港最大的制药上市公司之一，同时也是香港恒生红筹股指数成份股之一。

石药集团主要从事医药产品的开发、生产和销售。产品主要包括心脑血管、抗生素、维生素、解热镇痛、消化系统用药、抗肿瘤用药等七大系列近千个品种，有 30 个产品单品种销售过亿元，产品销售遍及全国和世界 60 多个国家和地区。

石药集团是 “国家级创新型企业”，新药研发实力位居全国药企最前列。目前在研的新药项目有 167 项，仅国家一类新药就有 25 个，涉及心脑血管、精神神经、内分泌、抗肿瘤等七大领域。集团已成功上市的具有自主知识产权的一类新药“恩必普”是脑卒中治疗领域的全球领先药物，在全球 86 个国家受到专利保护。2013 年该产品销售突破 10 亿元，成为首个销售过 10 亿元的国产原研药。创新药的研发和快速成长推动企业实现了转型升级，原料药、成药的销售比重从原来的 7:3 转变为 3:7，石药集团成为国内传统药企成功实现“主动转型”的典范。

为追求卓越，迈向高端，石药集团对标国际高端制药标准，持续提升产品质量的内涵。截至目前，集团旗下所有药品都通过了新版 GMP 认证，此外，共取得了 16 张 CEP 证书和 33 个 DMF 登记号，有 10 个产品顺利通过美国 FDA 现场检查，这标志着石药集团的产品已经可以拿到国外高端市场参与竞争，固体制剂可以直接摆上美国的药房和柜台，也标志着石药集团的药品质量已与国际先进水平实现对接。

CSPC group was founded from May, 1938 with total asset of 20 billion RMB, approximately 18,000 staff members. It owns mainly three business segments, API, Finished product and Pharmaceutical Business. CSPC, listed in Hong Kong(01093.HK) and market value over 40 billion HK dollars,.

CSPC is mainly engaged in the pharmaceutical product development, production and sale. Its key products include cardiovascular and cerebrovascular, antibiotic, vitamin, xanthine, digest system and anti-tumor drugs of nearly 1,000 varieties. Of which, 30 varieties achieve sales volumes over one hundred million RMB, and the products are sold throughout China and over 60 countries and regions in the world.

CSPC is a "National Innovative Enterprise". The new drug (R&D) capability is far ahead among the pharmaceutical companies in China. CSPC currently holds 167 new drug researching projects, including 25 National class 1 new drug, involving cardiovascular and cerebrovascular, nervous system, anti-tumor, internal system and other three fields. NBP, a national class 1 new drug successfully promoted in the market, is the third with owned intellectual property rights thereof are protected in 86 countries around the world. In 2013, NBP achieved sales revenue of 1 billion RMB, which becomes the first self innovative drug. The development and rapid growth of self innovative drug accelerate the upgrading pace of CSPC manufacturing. The proportion of API and Finished product changes from original 7:3 to 3:7 and CSPC becomes a model of domestic pharmaceutical enterprises that successfully realized “initiative transformation”.

In search of excellence and step forward to high-end, CSPC continuously conforms to the standards of international high-end and improves products quality. Up to now, every product of CSPC group has successfully passed the new GMP certification. Besides, CSPC has obtained 16 CEP certificates and 33 DMF registration numbers, and 10 products passed the site inspection of FDA. This symbolizes that product from CSPC is able to compete in the international high-end market and can be sold directly in US pharmacy, and also symbolizes the product quality of CSPC has reached at the international advanced level.

上海医药集团股份有限公司

Shanghai Pharmaceuticals Holding Co., Ltd.

上海医药集团股份有限公司是一家总部位于上海的全国性医药产业集团。公司主营业务覆盖医药研发与制造、分销与零售 2014 年营业收入 924 亿元，根据 2014 年中国企业 500 强排名，公司位居全国医药行业第二，入选上证 180 指数、沪深 300 指数样本股，H 股 8 入选恒生指数成分股、摩根斯坦利中国指数（MSCI）。

上海医药研发以创新为长期坚持的方向，致力于为重大疾病和慢性病提供安全有效的治疗药物，公司入选十余项“重大新药创制”国家科技重大专项，累计拥有发明专利 217 件。公司采用开放式研究模式，与各大科研院所等合作开展创新药物研发。

上海医药制造覆盖化学和生物药品、现代中药和保健品、医疗器械等领域，产品聚焦五大治疗领域，过亿产品 24 个。公司旗下拥有多个中国驰名商标。公司药品生产严格执行中国新版 GMP 要求，有多个原料药或制剂通过了 WHO、FDA、欧盟以及其他发达国家的质量认证。

上海医药的分销网络以华东、华北、华南三大重点区域为中心辐射全国各地，分销业务规模排名全国第三。公司的疫苗、高端耗材、DTP（高值药品直送）及 SPD（医药物流管理技术）等新业务发展在国内处于领先地位，并积极拓展电商新模式

上海医药药品零售销售规模居全国药品零售行业前五位，上海华氏大药房拥有药房的数量在华东地区位居前列。门店覆盖全国 12 个省、直辖市及自治区，门店总数近 1900 家。

公司倡导“创新、诚信、合作、包容、责任”的企业核心价值观，致力于持之以恒，提升民众的健康生活品质，努力打造受人尊敬、拥有行业美誉度的领先品牌药制造商和健康领域服务商。

Shanghai Pharmaceuticals Holding Co., Ltd. is a national pharmaceutical group headquartered in Shanghai, China. The Company's principal business covers pharmaceutical R&D, manufacturing, distribution and retailing. In 2014, the Company had reportedly the business revenues of RMB 92.4 billion, ranking No. 2 in the Chinese pharmaceutical industry in terms of the composite capabilities among the top 500 Chinese enterprises according to Chinese Enterprise Conferdation, The company is the one of the few listed pharmaceutical companies which holds a leading position in both pharmaceutical manufacturing and distribution in China. It is selected into the sample stocks of both the SSE 180 Index and CSI 300 Index, with its H shares selected into the Hang Seng Index Compositional Stocks and MSCI.

Adhering to innovation, Shanghai Pharma's Research and development is dedicated to providing safe and effective drugs against the grave and chronic diseases. Undertaking over 10 State-level scientific and technological R&D projects of “The development of Major New Drugs”. Shanghai Pharma has accumulated 217 invention patents in total. The Company adopts an open mode of R&D, carrying out R&d cooperation with uneversities and research institute in the R&D of innovative drugs.

Shanghai Pharma's manufacturing business provides products ranging from chemical and biopharms,modern Chinese medicine, healthcare products and medical devices etc., focusing on five major therapeutic areas. 24 products have sales revenue over RMB 100 million. The Company runs a number of brands, which are the renowned Chinese trademarks. The Company maintains its pharmaceutical production in strict conformity with the latest version of the Chinese GMP, having a number of APIs and preparations passed the quality authentication imposed by WHO, FDA, EU and other developed countries.

Shanghai Pharma's distribution networks focus on the Eastern China, Northern China and Southern part of China, and radiates out to other areas in the country. The Company is ranked No. 3 out of Top100 China's Pharmaceutical Wholesale Distributors. The Company boasts to hold a leading position in new business development in China in respect of vaccines, high-end consumables, DTP and SPD.The company is exploring the new pharmaceutical business mode of E-commerce. Shanghai Pharma's retail is ranked among the top 5 players in the nationwide drug-retailing industry in terms of sales revenues and the Huashi Pharmacy is one of the largest chain drugstores in East China area.,with a sales network comprising of about 1900 drugstores covering 12 provinces, autonomous regions and municipalities.

Adhering to the corporate's core conceptions that are described as “innovation, integrity, cooperation, inclusiveness and responsibility”, Shanghai Pharma is always dedicated to the enhancement of people's enjoyment of a healthier living condition, while endeavoring to be recognized as an esteemed manufacturer of the leading-brand pharmaceutical products and service provider in the healthcare industry with a sound reputation.

先声药业有限公司
Simcere Pharmaceutical Group

先声药业成立于 1995 年，当时是仅有几十名员工、注册资金 200 多万元的小型药品经销公司。经过十几年的发展，先声药业已发展成为年销售额 49.5 亿，年利税 6.1 亿元，净资产 37 亿元的创新型企业集团。

2007 年 4 月，公司成功登录纽约证券交易所，募集资金 2.62 亿美元，成为中国第一家在纽交所上市的化学生物药公司。公司上市以来的 5 年中，年研发投入占销售收入的占比均在 6% ～ 10%, 同时公司注重在海外和跨国公司引进研发和管理人才，这 2 年引进的人才总数超过过去 15 年的总和。

先声药业于 2003 年获准设立国家企业博士后工作站，2005 年批准为“国家认定企业技术中心”；2008 年批准设立“江苏省抗肿瘤分子靶向药物重点实验室”；2009 年被认定为“国家高新技术企业”；同时 2009 年获准设立“江苏省企业院士工作站”。

2010 年 11 月，跨国公司百时美施贵宝与先声药业同时宣布开展抗肿瘤药领域的国际合作研发；2011 年 7 月，全球第二大制药公司默克与先声药业在美国新泽西州签署协议，在中国成立二家合资企业，企资公司获得默克糖尿病新药西格列汀（该药品 2011 年全球销售额 40 亿美元）专利授权；2011 年 8 月，先声治疗类风湿关节炎一类创新药艾拉莫德在全球第一家获准上市，比日本卫材富山化学在日本获批提早了 10 个多月。2011 年先声的必奇原料和制剂产品通过欧盟 GMP 认证，标志着先声质量管理水平提升到了一个新的高度。

2010 ～ 2012 年间，先声药业共有 7 个一类创新药进入和即将进入临床研究阶段，这是中国 4000 多家制药公司中第一家取得如此进展的企业；2011 年，先声治疗脑卒中的创新药在澳大利亚完成一期临床，这也是第一个来自中国的创新药注射剂在澳大利亚开展临床研究。过去的 5 年，先声药业研究院共提交了 200 多项国内和 PCT 专利申请。先声药业近几年均被工信部和南方所评为“中国最具创新力的企业”。

Founded on 28th March 1995, Simcere swiftly evolved from being a pure distributor of pharmaceutical products to become a leading manufacturer and supplier of drugs in China's rapidly growing pharmaceutical market. Simcere currently operates five GMP-certified manufacturing facilities, two nationwide sales and marketing subsidiaries, a research and biological drug company to list on the New York Stock Exchange with IPO proceeds reaching US$ 261 million. Innovation is the key driver of our progress towards excellence. In recent years, we have refined our strategy to focus on the development of first-to-market generic and innovative pharmaceuticals. We currently manufacture and sell over 45 principal pharmaceutical products, which treat a range of medical conditions such as tumors and cardiocerebral vascular diseases and infections. scavenger available on the Chinese market. Endu, our innovative anti-angiogenic drug used in the treatment of Non-Small Cell Lung Cancer was the world's first listed recombinant human endostatin and has acquired patent protection in China and the United States. It is also gold medal winner of the '10th Outstanding Chinese Patent Invention Award' and second prize winner of the '2008 National Tech & Invention Award.' In recent years,Simcere has brought Anxin, China's first Biapenem Injection used in the In 2009, Simcere's acquisition of 35% equity stake in Shanghai Celgen Bio-Pharmaceutical Co., Ltd. marked our entry in to the field of antibody development. Following the acquisition, Qiangke, a Recombinant Human TNF Receptor-IgG Fusion Protein for Injection and manufactured by Shanghai Celgen, receive the State Food and Drug Administration ("SFDA") new drug registration approval and in October 2011 was successfully launched on the Chinese market. In 2011, we received a new drug approval from SFDA for Iremod, a new drug in the category of Disease Modifying Anti-rheumatic Drugs ("DMARDS"). It was independently developed by In July 2011, we reached a framework agreement with Merck to establish a pioneering joint venture, which will focus on serving China's rapidly expanding healthcare needs by providing Our brands are widely recognized throughout China and Simcere currently holds four Trademarks in China: Simcere, Zailin, Yingtaiqing and Bicun. Simcere's branded antidiarrheal drug Biqi smectite powder passed the Eu-GMP inspection Agency. To fuel our sustained growth and demonstrate our commitment to research and development, we established the Simcere Pharmaceutical Research Institute. In recent years, Simcere has averaged a6-8% reinvestment of the company's annual revenue in R&D activities. We also actively collaborate with domestic and international companies and research institutes to develop new chemical and biological drugs with strong market potential. We have a successful track record of agreements with international partners including OSI, Epitomic and BMS. Currently, we have over twenty candidate products in various stages of development. In 2010, is exciting progress and a tremendous step forwards. Simcere will continue on its path as a leading Chinese pharmaceutical company. Through the development of innovative medicines we will reshape the future of the pharmaceutical industry in China. We are working tirelessly to provide more effective medicines for our patients and to earn the respect from our clients and society.

中国医药集团总公司
China National Pharmaceutical Group Corporation

中国医药集团是由国务院国资委直接管理的中国规模最大的医药健康产业集团。以预防治疗和诊断护理等健康相关产品的分销、零售、研发及生产为主业。旗下拥有 11 家全资或控股子公司和国药控股、国药股份、国药一致、天坛生物、现代制药、盈天医药 6 家上市公司。2003 年至 2013 年，集团营业收入年平均增幅 31%，利润总额年平均增幅 42%，总资产年平均增幅 32%。2013 年营业收入超 2000 亿元，是中国唯一一家超千亿医药健康产业集团。

中国医药集团拥有覆盖全国 31 个省、自治区、直辖市的医药流通配送网络和与国际水平接轨的 30 个配送中心，是国内最大的生物医药研发、生产企业，承担了 80%以上的国家免疫规划用疫苗的生产任务。集团建立了生物制药、麻醉精神药品、抗感染药、抗肿瘤药、心脑血管用药、呼吸系统用药等生产基地和药材基地，拥有国内实力最强的应用性医药研究机构和工程设计院。2010 年，中国医药集团被评为国家创新型企业。

中国医药集团是我国医药行业与外资合作最早、最多和最成功的企业。从 1980 年开始先后与多个国际著名医药企业建立了中国大冢制药有限公司、华瑞制药有限公司、西安杨森制药有限公司、中美施贵宝制药有限公司、苏州胶囊有限公司等 20 家合资企业，与世界上 100 多个国家和地区建立了贸易合作关系，开展了多项国际技术合作，国际化步伐不断加快。

中国医药集团的发展目标是，“十二五”期间，建成涵盖医药行业全产业链的，具有行业带动力和国际竞争力的大型医药健康产业集团，成为进入世界 500 强的第一家中国医药健康企业。

China National Pharmaceutical Group Corporation, (Sinopharm) is the largest medical and healthcare group in China, with the core businesses of distribution, logistics, retail, scientific research and manufacture of healthcare related products. So far, Sinopharm owns 11 wholly owned or holding subsidiaries, and 6 listed companies including Sinopharm Group Co., Ltd. (01099.HK), China National Medicines Co., Ltd. (600511.SH), Beijing Tiantan Biological Products Co., Ltd. (600161.SH), Shyndec Pharmaceutical Co., Ltd. (600420.SH), Shenzhen Accord Pharmaceutical Co., Ltd. (200028.SZ)and China Traditional Chinese Medicine Co. Limited. (00570. HK) The sales revenue of Sinopharm exceeded over 200billion (RMB) in 2013. It is the only Chinese pharmaceutical company whose sales revenue exceeds RMB 100 billion.

With all-out efforts, Sinopharm is promoting the overall construction of five major platforms – the modern integrated distribution and logistics platform, the integrated manufacturing and R&D platform for scientific and technological innovation, the integrated globally operational platform, the health care industry platform and the highly efficient control and integration services platform, to comprehensively advance the joint development of the eleven core business sectors of modern pharmaceutical logistics and distribution; medicine retail; biological products; chemical pharmaceuticals; modern TCM; diagnosis reagents and chemical reagents; scientific instruments and medical equipments; medical scientific research and engineering design; pharmaceutical international trade and overseas industry, pharmaceutical exhibitions and media; health care industry. So far, Sinopharm has formed an immense and complete pharmaceutical and healthcare industrial platform, realized the scale effect and promote a high-speed growth. Besides the largest pharmaceutical and medical distribution network covering 31 provinces, autonomous regions and municipalities and 30 international standard distribution centers and production bases, Sinopharm also owns the first-class manufacturers for medicines, vaccines, blood products, high-level scientific and technological institutes, massive planting bases for medicinal herbs and most of domestic medicine and health care related professional exhibition brands in China. Since 1980s, Sinopharm has cooperated with renowned multinationals, established dozens of Sino-foreign pharmaceutical joint ventures, e.g. China Otsuka Pharmaceutical Co., Ltd. (COP) and Sino-Swed Pharmaceutical Co., Ltd. (SSPC), jointly conducted international technologic programs with companies from the U.S.A., Japan, France, UK., Germany, Italy and Korea, built up collaborative relationship with the clients from over 100 countries and regions. The broad international cooperation have energetically promoted the operation and management ability of the industry in China.

Sinopharm is aiming to be an international pharmaceutical and healthcare group which covering the whole industrial chain and can give strong impetus to the industry as well as the first Chinese pharmaceutical company of the Global Top 500 Corporations.

中国医学科学院药物研究所

Institute of Materia Medica, Chinese Academy of Medical Sciences

中国医学科学院药物研究所（以下简称“药物所”）成立于1958年，隶属于中国医学科学院北京协和医学院。

药物所始终以寻找和研究防治严重危害人民健康的常见病、多发病及疑难疾病的药物为主要方向，坚持以创制具有自主知识产权的新药为重点，是国家重点药物研究机构之一。采用现代药学理论和高新技术开展中草药和天然产物研究是药物所研究的特点之一，旨在走出有中国特色的新药创制之路。药物所主要研究方向包括抗肿瘤药物、防治心脑血管疾病药物、治疗神经精神类疾病药物、抗代谢紊乱药物、抗感染药物、抗炎免疫类药物、治疗老年退行性疾病药物等。

药物所现建有1个国家重点实验室，7个省部级重点实验室，和国家药物及代谢产物分析研究中心、国家新药开发工程技术研究中心、国家药物筛选中心、中国医学科学院北京协和医学院新药安全评价中心、药物所药物晶型研究中心。“十一五”期间国家“新药创制”重大专项在药物研究所建立了包括综合大平台在内的多个技术平台，有效地增进了研究所的研究能力。

药物所建所五十多年来，已研制上市新药百余种，获新药证书130项，其中以人工麝香、丁苯酞、双环醇、艾瑞昔布等为代表的一类创新药物20项。共获得各级科研成果奖272项，其中国家二等奖以上项目13项，共发表论文7350余篇，编写著作341本。已申请国内外专利1021项，获得授权的国内外专利240项。

药物所与国内及美国、法国、日本、德国、西班牙、加拿大等国家和地区的制药公司、大学、科研机构、全球非营利性组织建立了密切的协作关系，进行了广泛的科技合作和学术交流。自1989年开始，药物所还与新疆维吾尔自治区药物研究所（简称新疆药物所）建立了横向合作关系，新疆药物所挂牌为“中国医学科学院药物研究所新疆分所”，共同为推动新疆民族医药事业的发展而努力。

药物所还负责编辑出版《药学学报》、Chinese Chemical Letters（CCL, 中国化学快报）、Journal of Asian Natural Products Research（JANPR, 亚洲天然产物研究）及Acta Pharmaceutica Sinica B四种学术期刊；其中CCL和JANPR为SCI收录杂志。

药物所人始终以“献身、创新、求实、协作”的精神为指引，勤奋钻研、刻苦攻关、与时俱进、继往开来，努力为我国医药卫生事业的可持续发展，为创造社会效益和增强人类健康贡献力量。

Institute of Materia Medica (IMM) was founded in 1958, and now it is part of the Chinese Academy of Medical Science (CAMS) and Peking Union Medical College (PUMC).

The fundamental task of IMM focuses on research and discovery of innovative drugs for treating or preventing human diseases. To fulfill this goal, innovative multidiscipline research based on natural medicine in combination with modern theories and technologies in medicine and biology, is part of the most important field in IMM. We adhere to the creation of new drugs with independent intellectual property rights. The main research areas cover drugs against cancer, cardiovascular diseases, neuropsychiatric diseases, metabolic disorders, infectious diseases, inflammation and degenerative diseases.

The institute hosts a State Key Laboratory and 7 Ministry-level key laboratories. In addition, IMM has several government-sponsored special research centers, including the National Research Center for Analysis of Drugs and Metabolites, the National Engineering Research Center for Development of New Drugs, the National Center for Pharmaceutical Screening, the New Drug Safety Evaluation Center and the Research Center of Polymorphic Drugs. The Comprehensive Drug Platform funded by the National Science and Technology Major Project for “Major New Drugs Innovation and Development” is one of the very few state drug platforms established by central government in China. Establishment of such platforms has significantly enhanced our research capabilities.

Since the time of its establishment, scientists in this institute have acquired 130 new drug certificates from CFDA, including 20 Class I drugs (innovative drugs), such as Muoschus Artifactus, Butylphthalide, Bicyclol and Imrecoxib et al. IMM has published 7350 academic papers, 341 monographs and obtained 272 scientific rewards. IMM has applied for more than 1000 patents in and outside China, of which 240 patents have been issued. Two hundred and seventy two governmental and society awards or prizes were granted to IMM’s contributors for their research efforts in drug R&D.

IMM has established extensive partnerships and collaboration with pharmaceutical companies, universities and research institutes in different countries and regions of the world, including the United States, France, Japan, Germany, Spain and Canada. Since 1989, IMM has established collaboration with the Xinjiang Institute of Materia Medic, launching a new research facility called Xinjiang Branch of Institute of Materia Medica, Chinese Academy of Medical Sciences. The goal of this action is to cooperatively promote the drug R&D of the minority medicine in Xinjiang.

IMM also hosts a general editorial office for four scientific journals which are Acta Pharmaceutica Sinica, Chinese Chemical Letters (CCL), Journal of Asian Natural Products Research (JANPR) and Acta Pharmaceutica Sinica B. The latest impact factors of SCI-indexed journals CCL and JANPR are about 1.0.

Bearing the spirit of "Devotion, Innovation, Reality and Cooperation", staffs and faculties in IMM are doing their best to make contribution for human health.

成都康弘药业集团股份有限公司

Chengdu Kanghong Pharmaceutical Group Co., Ltd.

成都康弘药业集团股份有限公司（以下简称康弘药业）是一家致力于中成药、化学药及生物制品的研发、生产、销售及传播服务的医药集团，总部位于四川省成都市，销售网络遍布全国。

康弘药业坚持以专业、创新、国际化为核心发展战略，开创了“聚焦领域－需求导向－深入研究－专利新药－规范生产－专业营销”六位一体的独特经营模式，完成了在中枢神经系统、消化系统、眼科及其他等重点临床领域具有“康弘特色”的产品布局。

康弘药业的核心竞争力来源于长远战略布局和持续专业创新能力，研发投入远高于行业平均水平，且正向国际平均水平靠拢。依托国家认定企业技术中心、国家级博士后科研工作站以及四川省重点实验室，康弘药业建立了多个创新平台，承担了11项国家级课题；现已获授权专利100余项，其中30余项为国际专利。

2009年，商标被国家工商总局认定为“中国驰名商标”。2010年，康弘药业被国家知识产权局列入“全国企事业知识产权试点单位”；2011年，被中国化学工业协会评为“中国化学制药行业创新型企业品牌十强”；2012年，被国家科技部、国务院国资委、中华全国总工会列入国家第五批“创新型试点企业”。

康弘药业将不断努力研制专业创新的医药产品，促进人类健康事业的进步，努力成为中国最杰出的药业集团之一。

Chengdu Kanghong Pharmaceutical Group Co., Ltd. is a modern medicinal enterprise located in Chengdu, China. Kanghong’s core business is to develop, manufacture, market and promote innovative medicine including Traditional Chinese Medicine, small molecule and biologic drugs.

Kanghong, always maintaining development strategy as profession, innovation and internationalization, created a distinctive business model as core therapy areas focused, demand oriented, research in-depth, patent drug, manufacture standardized and professional marketing. Kanghong has set up a product layout of Kanghong’s own characteristics in C.N.S, digestive system, ophthalmology and others.

The core competitiveness of Kanghong is the ability of long term strategic layout and sustained professional innovation. Kanghong has established several innovative platform including the National-level Enterprise Technology Center, the National Post-doctoral Scientific Research Workstation, Key Laboratory of Sichuan Province and so on. Until now, Kanghong has authorized more than 100 patents, among which there are more than 30 foreign patents.

Since the establishment of the Kanghong, it has received wide-spread identity from various levels of government, clients and consumers from all walks of life. We are the only corporation in Sichuan province that has been awarded“National Pilot Innovative Corporation”in 2012. We are National Experimental Enterprise for Intellectual Property. The Kanghong trade mark is awarded“Famous Trade Mark of China”.

Kanghong will always focused on developing and researching innovative medicine to promote human health and to becoming one of the most outstanding Chinese pharmaceutical enterprise.

扬子江药业集团
Yangtze River Pharmaceutical Group

扬子江药业集团创建于 1971 年，是一家跨地区、产学研相结合、科工贸一体化的国家大型医药企业集团，也是科技部命名的全国首批创新型企业。集团总部位于江苏省泰州市，旗下 20 多家成员公司分布北京、上海、南京、广州、成都、苏州、常州等地；营销网络覆盖全国各省、市、自治区。

多年来，集团始终秉承“求索进取，护佑众生”的理念，践行“高质惠民，创新为民”发展宗旨。企业综合经济效益自 1996 年起，连续十多年排名江苏省和全国医药行业前列，并跻身“中国企业 500 强”、“中国民营企业 500 强”、“全国纳税 500 强”。据国家工信部公布的数据，2009 年以来，扬子江药业集团有限公司主营业务收入连续 5 年名列全国医药工业企业百强榜前三甲。

集团坚持以创新引领发展，加快实施“三药并举”研发创新战略。依托产学研联合建成设施一流的江苏省（扬子江）新药研究院，拥有国家级企业技术中心、药物制剂新技术国家重点实验室、中药国家工程研究中心等创新研发平台。经过多年的持续积累和创新，产品体系中西药并举，覆盖 10 多个领域、20 多种剂型、200 多个品规。

集团视质量为企业的生命。现有 20 多个产品被评为“江苏省名牌产品”，11 个产品获“中国名优产品”称号，9 个产品被列入“国家中药保护品种”，2 个产品获“国家科技进步二等奖”；另有 20 多个产品质量达到欧美药典标准，3 个车间已通过欧盟 GMP 认证。集团自 2005 年以来蝉联全国医药行业 QC 成果评比一等奖总数“十连冠”，并被中国食品药品检定研究院、江苏省食品药品监督管理局指定为“实训基地”。

面向未来，奋进中的扬子江药业集团以振兴民族医药为己任，怀着科学、严谨、负责的态度，竭诚为全人类的健康服务，努力向世界一流制药企业的目标迈进。

Established in 1971, YRPG is a large cross-regional pharmaceutical group that features industry-university-institute cooperation and integrates scientific research, industrial production and sale. It is among the first group of Innovative Enterprises named by the Ministry of Science and Technology. Headquartered in Taizhou (Jiangsu Province), The sales network spans all of China. YRPG has over 20 subsidiary companies.

Since its inception, YRPG follows its philosophy of "seeking progress at all times and safeguarding all human beings" and principle of "benefiting the general public through quality products and innovation". Since 1996, the group's overall economic strength has topped the list of pharmaceutical industry in Jiangsu as well as in China. According to figures from the Ministry of Industry and Information, YRPG's prime operating income was among the top three of the Chinese pharmaceutical companies since 2009.

YRGP upholds the principle of developing through innovation,. It is now stepping up the R&D strategy of "three medicines in one go". it has built the Jiangsu (YRPG) New Medicine Institute through industry-university-institution cooperation.Its R&D platforms include a nation-level class enterprise technological center, a key state-level laboratory of pharmaceutical preparation,and an engineering R&D center for traditional Chinese medicine.With these platforms .Through years of work, its products include both Chinese and Western medicines, encompassing over 10 fields, 20 preparations and 200 sizes for medicine.

YRPG sees quality as the life of our company. It now has over 20 products awarded "Jiangsu Well-known Brands", 11 "Chinese Excellent Products" and 9 "National Protected TCM Medicine". Two of YRPG's products won Second Prize for National Science and Technology Progress.More than 20 products meet the pharmacopeia standards in the U.S.A and EU.,and three facilities have gained EU GMP qualification. Since 2005, it has consecutively won first-place prizes year after year from the National Pharmaceutical Industry QC. It was also designated a training center by the Chinese Food and Drug Administration and Jiangsu Food and Drug Agency.

Looking forward, YRPG will continue working to help build up the Chinese pharmaceutical industry, and serve all human beings scientifically, rigorously and responsibly.

太极集团有限公司
Taiji Group Co., Ltd.

太极集团有限公司（简称太极集团）是中国企业 500 强之一，资产 200 亿元，拥有“太极集团”（重庆太极实业（集团）股份有限公司）一家上市公司。“太极”（TAIJI）为中国首批驰名商标，OTC 品牌药企第一名，2014 年集团销售总额达 230 亿元，2021 年将跨越千亿大关。

太极集团拥有 10000 家药房、13000 名员工、20 多家医药商业公司、13 家制药厂及太极医药研究院、重庆中药研究院两大研发机构。1998 年，太极集团与国内外 15 所院校合作建立博士后工作站；1999 年，太极集团技术中心被认定为国家级企业技术中心；2013 年，获国家批准建立太极院士专家工作站，中国工程院近 20 位院士成为太极研发顾问。

太极集团现有中西药品种 1500 多个、全国独家生产品种 50 多个、获得国家中药保护品种 50 多个、国家基药品种 165 个，获国家专利 120 项、年销售额逾亿元的品种 15 个。

太极集团的快速发展主要得益于日益增强的科研开发能力，日益完善的国内市场网络，日益成熟的信息化管理，先进的生产装备，畅销的外贸营销渠道，一流的员工队伍和管理团队，颇具中国特色的管理经验。更为重要的是，太极员工多年受“忠诚、责任、团结、努力”的太极精神熏陶，充满了 “光大太极、振兴中华”的必胜信念。

习近平、张德江、江泽民、李鹏、温家宝、吴邦国、曾庆红、邹家华等党和国家领导人多次亲临太极集团视察工作，充分肯定太极集团的发展壮大之路，江泽民同志亲笔书写“太极集团”四个金光闪闪的大字予以鼓励。阴阳互根方能相长，阴阳平衡万事万物方能和谐发展。太极集团渴望交流，期待合作，愿和您为中国医药事业走向世界而共同努力！

Taiji Group Co., Ltd. (short for Tai Chi Group) is one of the top 500 Chinese enterprises, having 20 billion yuan assets, with three listed companies.-------Taiji Group (Chongqing Taiji Industry (Group) Co., Ltd.), "Tai Ji" (TAIJI) have been a well-known brand in China, In 2014,the gross sales was23.0 billion yuan, In 2021,Taiji Group plans to reach one billion yuan in the next decade.

Taiji Group owns more than 1,500 drugs varieties, of which 50 exclusive products, 165 national base products.The enterprise has achieved more than 120 patens and 15 of single product sales reach one billion per year.

The great achievements we made is mainly due to the growing research and development capabilities, increasing domestic market, advanced equipment ,outstanding workforce and specialized management.

More importantly, Taiji staff observe the spirit of "loyalty, responsibility, unity, and hardwork " for many years, having the notion of contributing to long-term development of the company.

Xi Jinping,Zhang Dejiang,Jiang Zeming, Li Peng,Wen Jiabao and other state leaders have been visited Taiji and totally gave affirmation to our company. Moreover, Jiang Zeming handwritten “tai ji ji tuan” four glittering characters to encourage Taiji Group.

Taiji Group longs for communication and desperately waiting for cooperation with all the excellent companies. Let's make efforts to push traditional Chinese medicine into the international market. We are always dedicated to the health of people around the world!

浙江康恩贝制药股份有限公司

Zhejiang Conba Pharmaceutical Co., Ltd.

浙江康恩贝制药股份有限公司是一家集药品研发、生产、销售及药材种植为一体的医药上市企业。

公司前身为创建于 1969 年的“兰溪云山制药厂”，目前管理总部设在浙江省杭州市，公司在杭州、兰溪、金华，以及 江西、云南、内蒙古、四川等地拥有先进规范的药品生产基地，并在兰溪建有国内最大的现代植物药制造基地——康恩贝植物药产业园。公司旗下拥有浙江康恩贝中药有限公司、浙江金华康恩贝生物制药有限公司、云南希陶绿色药业股份有限公司、杭州康恩贝制药有限公司、江西天施康中药股份有限公司、上海康恩贝医药有限公司、云南康恩贝植物药有限公司、内蒙古康恩贝药业有限公司等多个颇具规模和实力的全资及控股子公司。

公司为国家高新技术企业、国家创新型企业、国家知识产权试点企业，建有国家认定企业技术中心、国家博士后科研工作站、院士工作站，并拥有一支由博士、硕士和高中级技术人员组成的实力雄厚、专注于现代植物药和特色化学药研发的团队，已建立新药研发的多个技术平台，在心脑血管系统用药、泌尿系统用药、抗糖尿病用药、呼吸道系统用药、消化系统用药和抗感染药等药物的研发，以及植物提取分离和结构改造、新型药物释放系统应用等诸多方面，研发具有自主知识产权的新药，在药材种植、植物提取、制剂生产、市场营销等各环节，已建立起规范高效的产业体系。

公司历来十分重视产品品牌和企业品牌的培育和保护，在药品多个领域建立了消费者熟知与认可的品牌，“康恩贝”、“前列康”是中国驰名商标，“天保宁”、“阿乐欣”、“金康”、“金奥康”、“希陶”、“天保康”、“天狮”等均在各自领域拥有较高的品牌知名度，在同类竞争产品中已树立起了较突出的品牌优势。

Zhejiang Conba Pharmaceutical Co., Ltd. (founded in 1969, listed in 2004, stock code 600572) is a holding subsidiary and main member enterprise of Conba Group Co. Ltd. It is a listed pharmaceutical enterprise integrating herbs planting and pharmaceutical R&D, production and sales. The company was previously known as “Lanxi Yunshan Pharmaceutical Factory” founded in 1969 and was renamed “Zhejiang Conba Pharmaceutical Co., Ltd.” in October 1999. The company was registered in Lanxi , Zhejiang Province, with head office set in Hangzhou, Zhejiang. It owns advanced and standard pharmaceutical production bases in Hangzhou, Lanxi, Jinhua as well as Jiangxi, Yunnan, Inner Mongolia and Sichuan, etc., and has built domestic largest modern herbal medicine manufacturing base, Conba Herbal Medicine Industrial Park in Lanxi. The company owns a dozen of wholly owned and holding subsidiaries of considerable size and strength including Zhejiang Conba Chinese Medicine Co., Ltd.,Zhejiang Jinhua Conba Bio-Pharm. Co., Ltd., Yunnan Xitao Green Pharmaceutical Co., Ltd., Hangzhou Conba Pharmaceutical Co., Ltd., Jiangxi Herbi-sky Co., Ltd., Zhejiang Conba Pharmaceutical R&D Co., Ltd., Zhejiang Conba Pharmaceutical Sales Co., Ltd., Shanghai Conba Pharmaceutical Sales Co., Ltd., Yunnan Conba Herbal Medicine Co., Ltd. and Inner Mongolia Conba Pharmaceutical Sales Co., Ltd., etc.

Zhejiang Conba Pharmaceutical Co., Ltd. always adheres to building its own core competitiveness. R&D and brand have always been two advantages of company.

First of all, Company has multiple new drug R&D technology platforms and an elite technical team. It has established long-term strategic partnership and strategic alliance relationship with domestic and foreign well-known research institutions, colleges and universities. In the fields of drug R&D as well as plant extraction and separation, structure modification and new drug release system application, etc., it develops new drugs with independent intellectual property right, and in the links of herbs planting, active pharmaceutical ingredients and plant extraction, new drug R&D, preparation production and marketing, etc., it has built a standard and efficient industrial system and become the only enterprise integrating national technology center, national post-doctoral research workstation, academicians workstation, national innovative enterprise and Zhejiang key enterprise research institute in traditional Chinese medicine industry in Zhejiang.

Secondly, company attaches particular importance to product brand and enterprise brand cultivation and protection, so it has built brands familiar to and recognized by consumers in several fields including urinary system and cardiovascular system, etc. Now, the company has become one of the enterprises owning the most famous trademarks and brand products, among which “Conba”, “Prostate Plus”, “Zhenshiming" are identified as famous trademark of China, while “Prostate Plus”, as the company’s leading herbal medicinal product, has become the first brand in domestic Chinese herbal medicines treating BPH; “Tianbaoning” is China’s first modern herbal medicine preparation meeting international quality standards. In addition, “Alocin”, “Xitao”, “Yuanbang”, “Baby” and “Omeprazole”, etc., have considerable brand awareness in their respective fields and set up considerable brand advantages in similar competitive products.

神威药业集团

Shineway Pharmaceutical Group

神威药业集团是集研发、生产、销售于一体的大型现代医药企业集团，中国中药行业前五强，香港联合交易所主板市值最大的现代中药企业，国家重点高新技术企业，拥有“神威”、“五福”、“神苗”三个中国驰名商标，是全国规模最大、技术水平最高、质量控制能力最强的现代中药注射剂、软胶囊、颗粒剂专业制造商，成为全国唯一的中药制剂高技术产业化示范基地，被国家科技部等五部委联合授予国家认定企业技术中心、国家技术创新示范企业、国家级知识产权优势企业。

神威拥有全国唯一的“中药注射剂新药开发技术国家地方联合工程实验室”，每年有数个国家级新药投入市场，多项科研成果获得国家、省级科学技术进步奖和国家发明专利。神威清开灵注射液、参麦注射液、舒血宁注射液为“全国百姓放心药”，占据了国内同品种 70% 以上市场份额，降脂通络软胶囊、舒筋通络颗粒等多个品种被列为国家中药保护品种，五福心脑清软胶囊、小儿清肺化痰颗粒、滑膜炎颗粒等知名产品畅销全国。神威主导完成的“中药注射剂全面质量控制及在清开灵、舒血宁、参麦注射液中的应用”技术获国家科技进步奖二等奖。神威与中国中医科学院、澳大利亚知名科研单位联合开发组分中药 SLT 胶囊，治疗老年性痴呆，首开中药国际产学研合作模式先河。

Shineway Pharmaceutical Group is a large modern pharmaceutical enterprise in herb planting, research and development, manufacture and distribution in China, recognized as one of the top 5 enterprises in the Chinese medicine industry, the Group is the largest modern Chinese medicine enterprise listed on the Main Board of Hong Kong Stock Exchange by market value. Shineway is named as one of the “Key State-level High-tech and Innovative Enterprise”, holding 3 “China Famous Br and”,“Shineway”,”Wufu”,”Shenmiao”, it is the professional manufacturer of modern Chinese medicine injections, soft capsules, granules with the largest scale, the highest technology and the strongest quality control, and became the only modern Chinese medicine formulation high-tech industrialization demonstration base, authorized by five national ministries including the Ministry of Science and Technology as National Enterprise Technology Center, National Technology Innovation Demonstration Enterprise, and National IPR Advantageous Enterprise.

Only Shineway has the "Chinese medicine injection new drug development technology national local joint engineering laboratory", in each year several national new drugs will be released into the market, a lot of scientific research achievements are honored with the National or Provincial Science and Technology Progress Award and the National Invention Patents. Shineway's Qingkailing injection, Shenmai injection, Shuxuening injection are regarded as " Assured Drug", which occupy more than 70% domestic market share in similar varieties, Jiangzhi Tongluo soft capsules, Shujin Tongluo granules and other species are listed as a national Chinese medicine protection species, Wufu Xinnaoqing soft capsules, Xiaoer Qingfei Huatan granules, Huamoyan granules are well known and sold nationwide. Shineway leads to complete the "traditional Chinese medicine injections comprehensive quality control and the application in Qingkailing Shuxuening Shenmai Injection" obtain the National Science and Technology Progress Award. Shineway combine with China Academy of Chinese Medical Sciences, Australia renowned research institutions to jointly develop components of traditional Chinese medicine SLT capsules, aiming at the treatment of senile dementia, it is a precedent to open traditional Chinese medicine international cooperative mode on industry-study-research.

浙江医药股份有限公司

Zhejiang Medicine Co., Ltd.

浙江医药股份有限公司是于 1997 年 5 月组建的大型股份制综合制药企业。1999 年 8 月经中国证监会核准，公司向社会公开发行了人民币 A 股 5800 万股，同年 10 月公司股票在上海证券交易所挂牌上市。截至 2013 年末，注册资本 9.3 亿元，总资产 76 亿元。

浙江医药现拥有新昌制药厂、维生素厂、浙江昌海生物有限公司、浙江来益生物技术有限公司、浙江来益医药有限公司等五家主要分公司（子公司）和医药工业研究院、上海来益生物药物研究开发中心两家研发单位，为国家高新技术企业，国家创新型企业，拥有国家级企业技术中心，设有国家级博士后科研工作站。现有员工 5000 余名，其中各类专业技术人员 2000 余名，占员工总数的 40%以上。

目前，浙江医药已经形成了脂溶性维生素，类维生素，喹诺酮类抗生素，抗耐药抗生素等系列产品的专业化，规模化生产。维生素 E 产量国内最大，为全球第二大生产商；盐酸万古霉素占全球产量的 40% 以上；β- 胡萝卜素和斑蝥黄素是全国最大、全球第三大供应商；辅酶 Q10 占全球产量的 20%。

浙江医药通过认真实施“创新创业、竞争发展、科技兴企、人才强企”的发展战略，紧紧抓住产品开发这条主线，突出结构调整，整合各种资源，加强原始技术创新和优势产品技术创新，做好优势品种的 DMF 文件注册和 FDA 认证工作，大力推行清洁生产、循环经济，以全球化为立足点，构建完善的市场网络，树立良好的品牌形象，创建先进的企业文化，大力提升了企业的核心竞争力，目前，浙江医药已发展成为一家技术先进、规模庞大、实力雄厚、对全球市场具有影响力的医药企业。

Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Exchange. Up to the third quarter of 2013, the registered capital has reached CNY 930,000,000, and the total assets have reached CNY 7,600,000,000.

Zhejiang Medicine Co. Ltd. owns five subsidiaries including Xinchang Pharmaceutical Factory, Vitamin Factory, Zhejiang Changhai Biological Co. Ltd., Zhejiang Health Creation Bio-technology Co. Ltd., and Zhejiang Health Creation Pharmaceutical Co. Ltd., and two R&D units including Research Institute of Pharmaceutical Industry and Shanghai Health Creation Bio-Pharmaceutical R&D Center. The company has been rated as "National High-tech Enterprise" and "National Innovative Enterprise", which owns state-level enterprise technology center and also has established a postdoctoral research station. There are more than 5000 employees, more than 2000 of which are professional technicians accounting for more than 40%.

At present, Zhejiang Medicine Co. Ltd. is specialized in the large-scale production of fat-soluble vitamins, quasi-vitamins, quinolone antibiotics, anti-drug-resistant antibiotics and other products. Its output of vitamin E is the largest domestically, and the 2nd largest globally;the output of Vancomycin hydrochloride accounts for more than 40% of the global production; it is the largest vendor of β -carotene and canthaxanthin domestically, and the 3rd globally; the output of Coenzyme Q10 accounts for 20% of the global production.

Through earnestly implementing the development strategy of " innovation, competition, science and technology as well as talent thriving are all critical in the development of the company", Zhejiang Medicine Co., Ltd. tightly holds the main line of product development, highlights the structure adjustment and integration of various resources, strengthens the original technological innovation and competitive product technology innovation, does well on DMF file registration and FDA certification for some competitive varieties, actively promotes clean production and circular economy, builds perfect market network by taking globalization as standpoint, establishes good brand image , building up advanced enterprise culture, and strongly promotes the core competitiveness. Currently, Zhejiang Medicine Co., Ltd. has become a large-scale pharmaceutical company with advanced technology,strong capital and technical strength which has an influence in the global market.

浙江海正药业股份有限公司

Zhejiang Hisun Pharmaceutical Co., Ltd.

浙江海正药业股份有限公司（简称“海正药业”）创始于 1956 年，为国有控股公司，现有员工 8300 多人，在浙江台州、杭州以及江苏如东等地区建有一体化制药基地，主营抗肿瘤、抗感染、心血管、内分泌、免疫抑制、抗抑郁、骨科等领域的原料药、制剂的研产销业务。海正药业是国家首批“创新型企业”、“技术示范企业”和“国家知识产权试点企业”，2013 年入选“最具投资价值医药上市公司十强”，并进入“全国制造业 500 强”。

海正药业建有国家级企业技术中心、博士后科研工作站、院士工作站，拥有制剂、生物、微生物、合成、酶工程、药物器械等六个研究所和上海、北京两个创新基地；每年研发投入占工业销售收入 10% 以上，专职研发人员 869 人，其中国家“千人计划”特聘专家 6 人；围绕“生物药、化学药”两大领域开展自主品牌新药创制，与国内 30 所大学、研究院所产学研结合，联盟化发展；在特色原料药产业化和高端制剂产业化等形成了特色和优势。

海正药业积极推进民族医药创新和国际化进程，不断推进原料制剂一体化、制剂品牌化和生物产业化。已有 50 多个药品通过了美国 FDA、欧盟 EDQM、澳大利亚 TGA 等国家的认证，是通过欧美国家产品认证最多的中国企业，产品销往全球 70 多个国家和地区。2012 年，和全球领先的辉瑞公司成立合资企业，被国内资本市场广泛誉为“海正模式”。

海正药业于 2006 年发布首份社会责任报告，通过 ISO9002 质量管理体系、ISO14001 等体系认证，在国内医药行业内率先导入欧美 GMP 管理体系和建立 EHS 管理体系，是国家医药行业 EHS 体系标准的起草企业。

秉持“执著药物创新，成就健康梦想”的使命，承载“成为广受尊重的全球化专业制药企业”的愿景，海正药业将不断整合药物研发与生产资源，为全球客户提供更好的产品和服务，努力实现海正全球化、可持续发展的医药中国梦。

Hisun Pharmaceutical Co., Ltd(abbrev.as “Hisun Pharm”) was founded in 1956, as a state-owned holding corporation, Hisun employs more than 8300 personnel and has developed multiple integrated pharmaceutical bases in regions such as Taizhou, Hangzhou in Zhejiang province and Rudong in Jiangsu province, Hisun’s primary research-production -marketing business of APIs and formulations cover areas in anti-tumor, anti-infection, cardiovascular, endocrine, immune suppression, anti-depression, orthopaedics, etc. Hisun Pharmaceutical Co., Ltd is among the first “Innovative Enterprises”,“Technical Demonstration Enterprises”and “National Intellectual Property Right Pioneer Enterprises”, in 2013 Hisun has been selected as“Top Ten Most Investment- Valuable Listed Pharmaceutical Companies”and also enter into“Fortune 500 enterprises in national manufacturing industry”

Hisun Pharmaceutical established a nation-certificated enterprise R&D center, a post-doctoral scientific research workstation and an academician workstation, Hisun boasts six research stations covering preparations, biology, microbe, synthesis, enzyme engineering and medical equipment and two innovation bases in Shanghai and Beijing; Hisun’s annual R&D investment input occupies more than 10% of its industrial sales income, Hisun employs 869 full-time research personnel and 6 distinguished experts from national“one-thousand-talent”plan; carrying out proprietary brand new medicine development enclosing “biological and chemical drugs ”, developing mechanism of production-teaching-research combination and federalization with 30 national universities and research institutions; forming features and characteristics in the industrialization of distinctive APIs and high end preparations.

Hisun Pharmaceutical has actively pushed forward the innovation of national medicine and the process of internationalization, constantly propelling the integration of APIs and formulations, the brand marketing of formulations and the industrialization of biological drugs. More than 50 drugs have passed through certifications by US FDA, EDQM and TGA, etc, and Hisun becomes the national enterprise with the most product certifications approved by European and North American countries, with its products sold to more than 70 countries and regions worldwide. In 2012, Hisun has established a joint-venture enterprise with global leading company-Pfizer, which has been broadly praised as“Hisun Model”in the national capital market.

Hisun Pharmaceutical released the first social responsibility report in 2006, passing through ISO9002 quality management system and ISO14001 system certification, taking an initiative to guide into European and American GMP management system and established EHS management system in domestic pharmaceutical industry, and become one of the companies who drafts the EHS system standard in national pharmaceutical industry.

Adhering to the vision of“becoming a widely respected international pharmaceutical company”by“persisting in pharmaceutical innovation for the benefit of human being”, Hisun will continually integrate the resources for the R&D and production of drugs, providing better products and services for global customers, dedicating effort to realize Hisun’s China Dream of globalization and sustainable development in pharmaceutical area.

华北制药集团有限责任公司

North China Pharmaceutical Group Corporation

华北制药集团公司是中国最大的化学制药企业之一。1953年建厂，开创了中国大规模生产抗生素的历史。经过50多年的发展，现拥有27家子公司，5大生产基地，新头孢药物生产基地，新制剂药物生产基地，抗肿瘤药物生产基地，青霉素类药物生产基地，生物技术药物生产基地，产品涵盖了抗生素与半合成抗生素，生物技术药物，抗肿瘤药物，维生素，农兽药等600多个品种的原料和制剂。2014年华北制药实现销售收入166.5亿元。

华北制药新制剂分厂是华药非青霉素非头孢菌素类制剂生产基地，占地面积388亩，总投资26亿元。厂房及布局设计完全按照cGMP规范要求进行设计、施工。现有生产线25条，年生产能力粉针制剂5亿支、口服制剂159.3亿片（粒、袋）、小容量注射剂3亿支、滴眼剂4300万支。有无菌粉针制剂、小容量注射剂、滴眼剂、胶囊剂、片剂、颗粒剂等主流剂型。产品涵盖心脑血管类、免疫抑制剂类、新抗生素类、保健品类等。

华北制药生物技术分公司是华药生物技术药物生产基地，是国内规模最大、技术水平最高、工艺设备先进的中国第一家重组人血白蛋白产业化基地。厂房及布局设计完全按照国际GMP标准建造，年产吨级以上产品，质量达到国际先进水平。基因重组人血白蛋白项目是国家重大新药创制重点课题，拥有自主知识产权，截止到2014年底，重组人血白蛋白技术已获得专利20余项，比传统血源人血白蛋白具有纯度更高、无动物组分、不含病毒残留的优势，产品更安全、更可靠。

华北制药华民药业有限责任公司成立于2010年，是华药头孢抗生素生产基地，也是目前中国最大的头孢产品生产基地。占地面积300亩，总投资12亿元。厂房及布局设计完全按照cGMP规范要求进行设计、施工，生产过程闭环管理、生产环节自动监控、产品质量全程跟踪，立体仓库实现了自动化物流信息管理。目前有9个模块18条生产线，产品涵盖四代头孢所有主导产品，年生产能力粉针9亿支，片剂7亿片，胶囊25亿粒，颗粒剂1亿袋。形成了从药用中间体原料至制剂的完整的头孢产业链及丰富的头孢产品群。

NCPC is one of the largest pharmaceutical enterprises in China. Established in 1953, NCPC created a history of large-scale production of antibiotics. During more than 50 years' development, NCPC owns 27 subsidiaries, 5 major production bases, including new cephalosporins production base, new formulation production base, antineoplastic production base, penicillins production base and biotechnology drugs production base, covering more than 600 kinds of APIs and preparations, such as antibiotics, semisynthetic antibiotics, biologicals, antineoplastic, vitamins, pesticides and veterinary etc. NCPC brand obtains the comprehensive awareness in domestic and abroad market, renowned both inside and outside the country. NCPC achieved the sales revenue of NCPC achieved the sales revenue of RMB 16.65 billion in 2014.

NCPC New Formulation Branch Factory is the production base for formulation of non-penicillin and non-cephalosporin, covers an area of 388 acres, total investment is RMB 2.6 billion. The plant and layout design are designed and constructed according to the requirements of cGMP. There are 25 production lines, the annual production capacity of 500 million vials powder for injections, 15.93 billion tablets (capsules, sachets) oral preparation, 300 million ampoules small volume injections and 43 million eye drops. Covering the main dosages of sterile powder for injection, small-volume injection, eye drops, capsules, tablets and granules etc. The products cover the therapeutic drugs of cardiovascular and cerebrovascular, immunosuppressant, new antibiotics and healthcare products etc.

NCPC Biotechnology Branch Company is a production base for biotechnology drug in NCPC, is the first industrialization base for rHSA in China, has the Largest scale, highest technology and advanced process equipments. The plant and layout design are built according to cGMP standard, the annual capacity is more than tons of products, and the quality reaches advanced international level. rHSA project is a National innovative key project for important new drug, holds proprietary intellectual property rights, up to the end of 2014, the project has obtained over 20 related patents, compared with the traditional natural human serum albumin, rHSA has the advantages of higher purity, no animal components or virus residues, the product is much more safe and reliable.

NCPC HebeiHuamin Pharmaceutical Co., Ltd. was established in 2010, is the production base for cephalosporins in NCPC and the largest production base for cephalosporins in China. Covering an area of 388 acres,and the total investment is RMB 1.2 billion. The plant and layout design are designed and constructed according to the requirements of cGMP, the closed-loop management in the production process, the automatic monitoring at the production steps and the whole-process tracking on the product quality, and the automatic logistics information management in the stereoscopic warehouse. At present, there are 9 modules and 18 production lines, covering all of the leading products in the 4th generation cephalosporins, the annual production capacity of 900 million vials powder for injection, 700 million tablets, 2.5 billion capsules and 100 million sachets granules. The complete cephalosporin industry chain and the abundant cephalosporin products group covering from the intermediate material to formulation products have been established.

东北制药集团股份有限公司

Northeast Pharmaceutical Group Co., Ltd.

东北制药集团股份有限公司（简称“东北制药”）1946年始建于佳木斯，1949年迁至沈阳，1993年6月成立东北制药集团股份有限公司，并于1996年在深交所上市。截至2014年底，公司总资产86亿元，从业人员10500人，年销售收入43亿元，年出口创汇近1亿美元。

东北制药拥有医药中间体，化学原料药，制剂，医药商业，医药工程这一横跨药品生产流通领域的产业链条，是国内知名的综合性医药企业。公司主要生产抗生素类，维生素类，心脑血管类，消化系统类，麻醉药品类，计生药品类，生物诊断试剂类等12大系列产品，400多种医药中间体，化学原料药和制剂产品。主导产品远销100多个国家和地区。目前，企业拥有制剂产品国家批准文号351个，现有244个品规药品进入“国家基本医疗保险，工伤保险和生育保险药品目录”甲乙类药品目录，其中基本药物产品批准文号123个。

东北制药具备完善的质量管理体系，产品质量符合EP8.0,USP37,JP16,BP2014,CP2010等最新质量标准。公司多个产品先后通过了EDQM,FDA.日本厚生省，BRC,HALAL,KOSHER等国际高端认证，目前公司全部34条制剂生产线均通过了新版GMP认证。主要产品通过了美国，欧洲，日本，巴西，俄罗斯等多个国家和地区的注册和质量审计。

面向未来发展，东北制药以“一切为了健康，向未知与不可能挑战”为核心价值观，瞄准国际国内先进标杆企业，致力于在化学制药，生物医药，医药商业，医药工程，医疗服务五大板块实现跨越式发展，充分展示“把健康送给您”的企业愿景，着力打造国内一流，国际之知名的大型医药企业集团。

Northeast Pharmaceutical Group Co., Ltd. (referred to as “NORTHEAST PHARM” was founded in Jiamusi in 1946, moved to Shenyang in 1949 and established on June，1993.It is launched in Shenzhen Exchange Stock in 1996. By the end of 2014,total company assets were 8.6billion RMB and employed 10500 people. The annual sales was 4.3billion RMB.The annual exchange was nearly $ 100 million.

NORTHEAST PHARM covers the whole industrial chain from medicine production to circulation field, which includes pharmaceutical intermediates, chemical active pharmaceutical ingredients, finished dosage forms, pharmaceutical business, and pharmaceuticals engineering. It is one of the famous comprehensive pharmaceutical companies in our country. It produces 12 major series, mainly covering antibiotics, vitamin series, cardiovascular, digestives, narcotic medicines, birth control drugs, biological diagnostic reagents; more than 400 kinds of pharmaceutical intermediates, chemical active pharmaceutical ingredients and finished products. The leading products are exported to over 100 countries and regions. Currently, the company has been approved with 351 finished products in China. There are 244 products listed in “national basic medical insurance, injury insurance and maternity insurance drug index“ CATAGORY A, B, including 123 basic pharmaceutical products.

NORTHEAST PHARM has a sound quality management system. And products comply with EP8.0, USP37, JP16, BP2014, CP2010 and other latest quality standards. A number of products have passed the inspection by EDQM, FDA, Ministry of Health, Labour and Welfare, BRC, HALAL, KOSHER and other international certification. At present, 34 finished product lines have passed new GMP inspection. And the main products have been registered and audited by the United States, Europe, Japan, Brazil, Russia and other countries and regions.

NORTHEAST PHARM takes “All for health, we will challenge the unknown and the impossible” as core values, aiming at the international and domestic advanced business models. It devotes to chemical pharmaceuticals, biomedical, pharmaceutical business, pharmaceutical engineering, medical services for Great-Leap-Forwards development.

“Everything for your health” is our business vision, to create a world-class large pharmaceutical enterprise domestic and internationally.

四川科伦药业股份有限公司

Sichuan Kelun Pharmaceutical Co., Ltd.

科伦集团创立于 1996 年，历经 18 年发展，现已成为拥有海内外 87 家子（分）公司的现代化药业集团。集团的产业板块，科伦药业于 2010 年 6 月 3 日在深圳证券交易所成功上市，成为全球最大的大输液专业制造商和运营商。

2014 年科伦集团营业收入超过 350 亿元、利税超过 20 亿元人民币。根据商务部发布的 2012 年中国药品流通行业销售排序和工信部医药统计年报，科伦集团旗下的商业和产业双双进入全国前十强。

作为科伦集团旗下的产业板块，科伦药业生产和销售包括输液、粉针、冻干粉针、小水针、片剂、胶囊剂、颗粒剂、口服液、透析液以及原料药、医药包材、医疗器械等共计 562 个品种 932 种规格的产品。其中，拥有 107 个品种共 257 种规格的大容量注射剂产品、377 个品种共 591 种规格的非大容量注射剂产品、还拥有 45 个品种共 47 种规格的原料药、2 种抗生素中间体、27 个品种的医药包材、4 个品种共 8 种规格的医疗器械产品，是中国输液行业中品种最为齐全、包装形式最为完备的医药制造企业之一。以具体产品计，公司有 117 个品种纳入《国家基本药物目录》，是目前国内产业链最为完善的大型医药集团。

2009 年 10 月 30 日，科学技术部批准公司组建“国家大容量注射剂工程技术研究中心”，并被列入 2009 年国家工程技术研究中心首批组建项目计划；多年来，公司先后被国家发展与改革委员会、科学技术部、财政部、海关总署、国家税务总局、国资委、工信部、中华全国总工会授予“国家创新型企业”、“国家技术创新示范企业”、“工业品牌培育示范企业”、“国家级信息化和工业化深度融合示范企业”、“守合同重信用企业”等多种荣誉称号。

Founded in 1996, Kelun Group has developed into a modern pharmaceutical group, with 87 subsidiaries (branches) both at home and abroad, all this rapid development took place within just 18 years. On June 3, 2010, the bell at Shenzhen Stock Exchange rang to declare the listing of Kelun Pharmaceutical, the industrial segment of the Kelun Group. That memorable day marked the entrance of the biggest manufacturer and distributor of IV Solutions into the capital market.

Kelun Group´s sales revenues in 2014 exceeded RMB 35 billion, and profit tax was over RMB 2 billion. According to the 2012 Sales Ranking of China Drug Circulation Industry released by the Ministry of Commerce and the Pharmaceutical Statistic Annals of the Ministry of Industry and Information Technology (MIIT), the business and industrial segments of the Kelun Group ranked within the Top 10.

As the industrial segment of the Kelun Group, Kelun Pharmaceutical is specialized in manufacture and sale of 562 different products in 932 specifications, including IV solutions, lyophilized, sterile powders for injections, small volume parenterals, tablets, capsules, granules, oral solutions, dialysis solutions, APIs, pharmaceutical packaging materials, and medical devices, among which 257 specifications in 107 varieties belong to IV solutions; 591 specifications in 377 varieties belong to non-IV solutions; 47 specifications in 45 varieties belong to APIs; 2 varieties belong to antibiotic intermediates; 27 varieties belong to pharmaceutical packaging materials; 8 specifications in 4 varieties belong to medical devices. Kelun is the pharmaceutical manufacturing enterprise with the largest number of different products and packaging forms in the IV solution industry of China. In terms of specific products, 117 varieties of Kelun products have been included in the National Essential Drugs List. At present, the company is one of the largest pharmaceutical groups with the most complete industrial installations in China.

On October 30, 2009, Kelun Pharmaceutical was approved by the Ministry of Science and Technology to set up the “National Engineering Research Center of Large Volume Parenteral Preparations” and listed for the first group of building programs for the National Engineering Technology Research Center in 2009. Thoss years, Kelun Pharmaceutical was honored by National Development and Reform Commission (NDRC), Ministry of Science and Technology (MOST), Ministry of Finance, National General Customs Administration, State Administration of Taxation, State-Owned Assets Supervision and Administration Commission of the State Council, Ministry of Industry and Information Technology and All China Federation of Trade Unions as the “National Recognized Enterprise Technology Center”,“State Exemplary Enterprise of Technology Innovation”,“Model Enterprises of Industrial Brand Cultivation”,“National Model Enterprises of Good Combination of Informatization and Industrialization” as well as “Contract-Honoring and Credit-Valuing Enterprise”.

通化东宝药业股份有限公司

Tonghua Dongbao Pharmaceutical Co., Ltd.

通化东宝药业股份有限公司始建于 1985 年 12 月 1 日，1992 年 11 月改制为股份制有限公司，1994 年在上海证券交易所挂牌上市。公司最早以发展中药产业为主，研制推出的“镇脑宁胶囊”，成为中药治疗头痛的经典产品。公司从 1998 年开始发展生物制药，于 1998 年成功研制出具有中国独立知识产权的重组人胰岛素“甘舒霖”，填补了国内空白，使中国继美国、丹麦之后成为世界上第三个能生产重组人胰岛素的国家，项目获国家科技进步二等奖。人胰岛素的生产打破跨国企业对中国人胰岛素市场的垄断，经过十余年专业化的市场营销，目前东宝人胰岛素市场占有率已经超越部分跨国企业排第二位。公司秉承 " 坚持自主创新、创造世界品牌 " 的发展理念，加快胰岛素类似物产品开发，目前市场上在售的所有类似物通化东宝均已申报注册，未来通化东宝将成为胰岛素制剂最全的公司。为东宝立足于糖尿病领域的发展打下坚实基础。

通化东宝在加大产品研发同时，不断加大产能建设，到今年 9 月通化东宝的胰岛素生产能力从原料到制剂都能独自承担上亿中国糖尿病人的胰岛素治疗需求，成为中国糖尿病人的坚强依靠。2013 年 4 月通化东宝年产 3 吨的人胰岛素原料生产线通过欧盟 GMP 认证，标志通化东宝成为世界一流重组人胰岛素生产企业，也是世界三大重组人胰岛素生产基地之一。通化东宝正一步一个脚印朝着一流的生物制药企业前进。

Tonghua Dongbao Pharmaceutical Co., Ltd. was founded on December 1, 1985, restructured into joint-stock Co., in November, 1992, and listed on the stock exchange of Shanghai in 1994. Initially, Tonghua Dongbao mainly focused on traditional Chinese medicine industry and produced “Zhennaoning Capsule”, which is the classic treatment to headache. The company began to develop biopharmaceuticals in 1998, and successfully produced the recombinant human insulin “Ganshulin” with Chinese independent intellectual property rights in that year, filling the blank of human insulin field in China. This breakthrough made China become the first three countries in the world that are able to produce the recombinant human insulin, ranking after the United States and Denmark. The project won the second class prize of the National Scientific and Technological Progress. Production of human insulin broke the monopoly of the multinational enterprises in Chinese market. After more than ten years of professional marketing, the market share of Dongbao human insulin has bypassed some multinational enterprises, ranking the second. The company adheres to the concept of development, “to independent innovation, create a world brand”, to accelerate the development of insulin analogue products. Currently, Tonghua Dongbao has declared to be registered on the market for sales of all analogues. In the future, Tonghua Dongbao will become the most comprehensive insulin preparations company, which will lay a solid foundation in the field of diabetes for the future development of Dongbao.

When Tonghua Dongbao increases the product research and development, we also increase the capacity of production. By September of this year, Tonghua Dongbao’s production capacity of insulin from the raw material to the preparation alone will meet the demand of hundreds of millions of diabetes insulin treatment, becoming a strong support for Chinese diabetes patients. In April 2013, Tonghua Dongbao’s production line that produces 3 tons of insulin raw materials has attained the EudraGMP approval, which made it become the world first class human recombinant insulin production enterprise. It is also one of the world’s three largest production base for recombinant human insulin. Tonghua Dongbao is walking towards the first class biological pharmaceutical enterprise by one step at a time.

山西振东制药股份有限公司

Shanxi Zhendong Pharmaceutical Co., Ltd.

振东制药股份有限公司是山西省首家登陆创业板的上市企业，为高新技术企业，拥有中药材开发公司、北京研究院、生物健康科技公司、医药物流公司和振东、泰盛、安特、开元四个药品和两个饮片六大生产基地。主要生产抗肿瘤、心脑血管等八大系列 615 个品种，现已形成中药材种植、研发、生产、销售为一体的完整产业链。

振东制药长期与国内外多家科研院所进行合作。国内与中国医学科学院、中国军事医学科学院、中国中医科学院、中国药科大学等合作，进行新产品的研制开发，并承担了国家重大专项科技项目；国外与澳大利亚阿德莱德大学、美国国立卫生研究院及沃特世公司、荷兰 SU 生物医药公司等进行国际合作，旨在推动中医药走出国门，造福全球人类。

振东制药营销网络覆盖全国 400 余个城市，与全国数千家医疗单位建立了业务关系，形成了“多渠道，多模式”的销售体系，有完善的学术支持、售后服务与信息反馈渠道。

面向未来，振东制药将以“百年企业，百亿振东”为目标，以“好人好药，好药好人”为理念，全力打造“振东制药”全国知名品牌，为人类的健康事业贡献力量。

The Zhendong Pharmaceutical Co., Ltd., located in Shanxi Province, is the first listed high-tech company on the Growth Enterprise Market, which comprises Chinese Herbal Medicine Development Company, Beijing Pharmaceutical Research Institute, the Bio-health Technology Company, the Pharmaceutical Logistics Company, and also has four drugs and two Chinese herbal pieces of production basis (the Zhendong Pharmaceutical, the Taisheng Pharmaceutical, the Ante Pharmaceutical, the Kaiyuan Pharmaceutical). It has 615 kinds of products in eight medicine series for antitumor, cardiovascular and etc. A health industrial chain with the integration of Chinese herbal materials planting, researching, manufacturing and marketing has been formed completely.

The Zhendong Pharmaceutical Co., Ltd. has established a long term cooperation relations with home and abroad institutes and universities. Seeking national cooperation with institutions and university like the Chinese Academy of Medical Sciences, the Academy of Military Medical Sciences, the China Academy of Chinese Medical Sciences and the China Pharmaceutical University is dedicated to the research and development of new medical products as well as some of the national key Science and Technology Special Projects. Purpose of international cooperation with the United States National Cancer Research Center, Australia Adelaide University, the Waters Company and SU BioMedicine B.V. of the Netherlands is to promote Chinese herbal medicine abroad and benefit the global human beings.

Zhendong Pharmaceutical Co., Ltd, whose marketing network has covered more than 400 Chinese cities, has established business relations with thousands of medical institutions nationwide, and formed a marketing system of “multiple channels, and multiple modes” with its well-developed academic mechanism, after-sale service and information feedback channels.

Looking forward to the future, Zhendong Pharmaceutical Co., Ltd will take “century-old enterprise and 10 billion yuan Zhendong” as target, establish the philosophy of “being good person for high quality drug, high quality drug from good person”, make great efforts to create the national well-known brand “Zhendong Pharmaceutical” and contribute to human’s health industry.

绿叶制药集团

LUYE Pharma Group

绿叶制药集团是一家以研发为基础的专业制药企业，专注于肿瘤、心血管、消化及代谢以及中枢神经系统等领域。公司成立于 1994 年，2014 年在香港主板上市（股票代码：02186），在烟台、南京、北京、泸州等地设有生产和研发基地，现有员工近 4000 人，其中专业研发人员近 300 人。绿叶致力于为客户提供高品质的医药产品和专业化的服务，目前集团约有 30 个上市产品，覆盖抗肿瘤、心血管、消化及代谢等领域，其中有专利保护的产品占总收入的 80% 以上，公司业务遍及国内绝大部分省、自治区、直辖市，产品进入 8500 多家医院，并出口多个国家和地区。

目前，绿叶制药已成为中国健康领域的知名企业，并进入中国医药行业创新力 20 强。集团将以创新和国际化为目标，力争 2020 年成为世界 100 强的国际性专业制药企业。

As a leading innovative pharmaceutical Company in China, Luye focuses on developing, producing, marketing and selling innovative pharmaceutical products in three of the largest and fastest growing therapeutic areas in the PRC—oncology, cardiovascular system and alimentary tract and metabolism. Luye was successfully listed on the main board of Hong Kong Stock Exchange on 9 July, 2014.

Luye’s product portfolio consists of 30 products, of which the products with patent protection account for over 80% of the total revenue. Luye has a well-established nationwide sales and distribution network across 30 provinces, municipalities and autonomous regions in China and sells its products to over 8,500 hospitals. The production lines of 5 advanced manufacturing bases located in Yantai, Nanjing, Beijing and Luzhou, all have passed the latest GMP certification in China.

Luye owns a rich pipeline of product candidates, comprising 21 product candidates. Luye is also actively expanding overseas market, with 7 product candidates pending patent applications overseas, of which 4 have entered into clinical trials of the United States FDA.

美罗药业股份有限公司

Merro Pharmaceutical Co., Ltd.

美罗药业是以药品研发、制造和销售为核心业务的专业化上市公司，注册资本3.5亿元，是国家级高新技术企业，拥有“国家级博士后工作站”，现已通过美国 FDA 认证、澳大利亚 TGA 认证等。

美罗拥有占地面积 15.5 万平方米、建筑面积 13 万平方米的现代化医药产业基地，包括美罗大药厂、美罗中药厂以及美罗国际药物研发中心等，一直致力于化学药制剂、生物医药、中药、植物药的研究、生产和销售，在行业内具有突出地位。美罗产品的三个方向是：国家基本药物、国际仿制药和生物医药的研发、制造，并在现有 200 多个产品的基础上重点发展缓控释制剂和生物制剂，还相继承担了数个国家级重点课题研究项目及重大高新技术产业化工程项目、国家十二五重大新药创制项目，在中成药开发、现代剂型创新、原生药资源利用、天然植物保健品、生物药品和生物医用材料的开发与应用等诸多研究项目中均取得重大突破。

美罗积极与国际制药公司合作，不断研发、引进新品种，全力推进国际医药市场产品、技术的广泛合作，不断提升公司创新能力，向专业化、规范化、国际化迈进，把美罗建设成为一个运用科技、服务卓越、精于变化的国际制药公司。

Merro Pharmaceutical Co., Ltd. is a public listed pharmaceutical company specializing in R&D,manufacturing and marketing of pharmaceutical products, with registered capital of 350 million yuan. Merro is a national high-tech enterprise, has a state-level post-doctoral working station. Now it had been approved by US FDA and Australia TGA Regulatory.

Merro is a modern medicine industry base which covers a land of 155,000 square meters and the build-up area is 130,000 square meters, contains Dalian Merro Pharmaceutical Factory, Dalian Merro Traditional Chinese Medicine Factory and Merro Drug Research and Development Center etc. Merro has been devoting to the development, manufacture and sales of chemical medicine, biological medicine, Chinese traditional medicine and herbal medicine, Merro is a leading company in the pharmaceutical field. Merro’s core strategies are: developing and manufacturing of National Essential Drugs, Generic drugs and Biomedicines; focusing on ER preparation and biologicals based on more than 200 products; Merro also undertakes a number of National important research projects, vital High-tech Industry demonstration projects and National twelfth five-year major new drug innovation projects, it gains a lot of major breakthrough in Chinese medicine development, modern dosage form innovation, original resource utilization and development and application of natural plant health products and biological drugs and biomedical materials.

Merro collaborates widely with international pharmaceutical companies, improving the company’s innovation capability and becoming an international pharmaceutical company with high technology, superior service and adaptability to changes.

上海信谊药厂有限公司

Shanghai SINE Pharmaceutical Co., Ltd.

上海信谊药厂有限公司是上海医药直属企业。信谊品牌始创于 1916，是近代中国最早的民族化学制药企业之一。历经百年传承，不断发展壮大，成为集制造、销售、研发为一体的大型民族制药企业。旗下拥有九大工业生产基地，四大商业公司、一家市级研发中心。信谊具有强大的渠道和终端覆盖能力，营销网络辐射全国 30 多个省、市、自治区，覆盖了全国近 10000 家医院终端、800 余家主要经销商、150 多个地级市，拥有一支 1200 多人的高素质、专业化的终端销售队伍。

信谊是中国化学制药企业产品最多、剂型最全的产业实体之一，拥有产品批文 1114 个，涉及 14 个治疗领域，覆盖 16 种剂型，有 3 个国家一类新药品种，其中“培菲康”是国家一类生物制品，已获得中国、美国、英国、加拿大、澳大利亚等多国专利。2012 年，“培菲康”被选为益生菌制剂“国家标准菌种”，目前正作为自主知识产权产品在申报美国 FDA 注册。公司在保持处方药领先的基础上，以“培菲康”为主要产品进入 OTC 业态，将通过未来几年的不懈努力，使之成为中国制药行业最具规模的企业之一，并始终成为引领微生态领域发展的先行者。

信谊品牌已获得“中国驰名商标”、“中国最具历史文化价值品牌”、“上海市著名商标”等多项殊荣，作为上海医药产业的重要组成部分，信谊人将秉承 “以信治厂，以谊为人”的经营理念，立足于品类发展、产业整合、品质提升、职能管控四大创新，提高企业的核心竞争力。

SINE is an affiliate of Shanghai Pharmaceuticals Holding Co., Ltd. Established in 1916, this brand is one of the first national chemical and pharmaceutical companies in modern China. With over one century of experience, we have become a large national pharmaceutical company with manufacturing, sales, and R&D capabilities.We have nine industrial production bases, four business companies, and one R&D center at municipal-level. SINE has our powerful channels and a marketing network of more than 30 provinces, cities, autonomous regions in the nation, covering nearly 10,000 hospitals, more than 800 major dealers, and more than 150 prefecture-level cities. We have a high-quality and professional sales team consisting of 1,200 employees.

SINE is one of the Chinese pharmaceutical enterprises with the largest and most comprehensive product portfolioand formulations. We have gained official approval for 1,114 products involving 14 treatment fields and covering 16 formulations, and 3 State Type I new drugs where “Bifico” is a State Type I biologicalproduct and patented in China, U.S., UK, Canada, and Australia.

SINE has been granted a “Chinese national well-known trademark,” a “Chinese brand with the greatest historical and cultural value,” and “well-known trademark of Shanghai.”Jinqiao Development ZoneCMC’s good Service philosophies and practical service initiatives provide much assistance and support for us. As an important component of the Shanghai pharmaceutical industry, SINE employees adhere to the business philosophy “Govern Factory By Trust, Be Friendly”,and practice four innovations “Category Development, Industry Consolidation, Quality Improvement, and Competency Control &Management” to improve our core competitiveness.

SINE R&D center focuses on independent research and development while fully utilizing the social resources and insisting on the collaborative R&D thinking. To master core technologies, we work with the domestic and overseasscientific research institutions in various professional fields to build a R&D platform for probiotics products. SINE Institute has established a good relation with Shanghai Institute of MateriaMedica, China Academy of Science, Institute of MateriaMedica, Chinese Academy of Medical Science & Peking Union Medical College, and Institute of Pharmacology and Toxicology,Academy of Military Medical Sciences. It has also worked with East China University of Science and Technology, National Institutes for Food and Drug Control, Tongji University, Shanghai Sixth People’s Hospital Affiliated Shanghai Jiao Tong University School of Medicine, and Nanjing Drum Tomer Hospital, the Affiliated Hospital of Nanjing University Medical School to build a probiotics R&D platform. It has built a branded generics R&D platform in cooperation with Chinese Academy of Medical Science & Peking Union Medical College, National Pharmaceutical Engineering Research Center, Shanghai Institute of Pharmaceutical Industry, Second Military Medical University, and Fudan University.

华润双鹤药业股份有限公司

China Resources Double-Crane Pharmaceutical Co., Ltd.

华润双鹤药业股份有限公司拥有 70 余年制药历史，1997 年挂牌上市【股票代码 600062】，2010 年进入位列世界 500 强企业的华润（集团）有限公司旗下，成为其医药板块化学药平台的支柱企业。目前拥有 13 家子公司，万余名员工，年工业收入 42.32 亿元，净利润 5.42 亿元，是“中国驰名商标”企业和“国家高新技术企业”。经济实力、竞争活力和可持续发展能力位居国内制药公司前列。

公司主要产品聚焦大输液、心脑血管、内分泌和儿科等领域；拥有盈源、一君、O号、冠爽、糖适平、儿泻康、珂立苏等多个知名产品；销售网络深入医院、社区医疗卫生服务站、地县卫生院及药店等终端。

公司坚守“关心大众，健康民生”的企业宗旨，秉承华润集团“诚实守信、业绩导向、客户至上、感恩回报”的价值观，正向着“百亿工业”发展战略目标稳步迈进。

China Resources Double-Crane Pharmaceutical Co., Ltd. has over 70 years of history in pharmaceutical industry. The company was listed in 1997 (Share Code: 60006), acquired by China Resources (Holding)Co., Ltd. (Global 500) in 2010 and becoming one of its pillar enterprises in Chemical Pharmaceuticals. Currently, the company has 13 subsidiaries, over 10 thousand employees, Industrial annual revenue of 4.2 billion RMB, and net profit of 542 million RMB. The company is recognized as “China Top Brand” and “National High-tech Enterprise” and its economic strength, competition vitality, and development sustainability are ranked among the highest in the nation.

The company’s main product focuses on four therapeutic areas: IV solution, cardiovascular and cerebrovascular diseases, endocrine diseases, and pediatric pharmaceuticals. The company has developed a wide range of well-known products including Yingyuan, Hypertensive No.0, GuanShuang, Tangshiping, Erxiekang, and Kelisu. Sales network covers hospitals, community health service stations, county hospitals, and pharmacies.

China Resources Double-Crane Pharmaceutical Co., Ltd. has been advocating tenet of the company:“Care for People and Promote Health” and adhering to the enterprise value of China Resources: “Integrity, Pursuing Excellence, Customer Come First, and Return to Community.” China Resources DoubleCrane Pharmaceutical Co., Ltd. has been moving forward steadily to achieving 10 billion-industry strategic objective.

丽珠医药集团股份有限公司

Livzon Pharmaceutical Group Inc.

丽珠医药集团股份有限公司是集医药研发、开发、生产、销售为一体的综合性医药企业集团，创建于 1985 年 1 月，注册资本约为 3 亿元。丽珠集团毗邻港澳，借力广深，区位优势明显。丽珠医药集团已经建立了覆盖国内市场的营销网络；随着质量体系的持续提高，随着销售的快速增长，随着产能的不断扩大，随着新厂建设步伐的加快，丽珠即将整体搬迁新厂，新厂占地 42.7 万平方米，建造国际一流的现代化制药生产基地，这标志着丽珠集团从此进入了一个全新的发展阶段，丽珠集团将成为国内领先、国际一流的现代化制药龙头企业。

丽珠集团已经跻身中国上市企业投资 10 强，最佳上市企业治理 10 强、广东省高新技术企业、广东省医药行业杰出贡献企业、中国制药工业（销售）百强企业第 46 名、广东省医药工业综合实力 50 强。

目前，丽珠集团正在进行战略转型，一方面继续保持既有的优势领域并做大增量，另一方面快速进入代表当今和未来国际医药发展方向的单抗和疫苗的前沿阵地，实现战略转型，朝着中国民族制药工业最卓越的目标前进，全力建设致力于人类生命常青事业的伟大公司。

Livzon Pharmaceutical Group Inc., founded in 1985, is a comprehensive pharmaceutical enterprise integrating development & research, production and sales of pharmaceutical products. Livzon has 9 GMP production plants located in Guangdong, Shanghai, Sichuan, Fujian, 3 plantation bases for Chinese drug preparation production located in Shanxi, Gansu, Yunan of China, with more than 5,700 employees.

Livzon has modern industrial chain and product group, operates to manufacture drug preparation, bulk medicines and intermediates, as well as diagnostic reagents and equipment, with approximate 280 products therapeutically grouped as gastrointestinal, cardio-cerebral-vascular, anti-biotic, gonadotropic hormone etc. Meanwhile, Livzon possesses production bases as leading manufacturer of Chinese drug preparation injection, and specialist bulk medicines and intermediates such as fermented antibiotics, sterile cephalosporins, and hypolipidemic “statins”.

All production lines are compliant with GMP requirements, including some DMFs, USA FDA inspection and COS approvals etc. Benefited from the regulatory compliance, an extensive overseas market is under robust development, including India, Japan, Eastern Europe for bulk medicines and intermediates, and the Philippines, Kyrgyzstan, Uzbekistan, Tajikistan, Hong Kong and Pakistan for drug preparation.

In recent years, Livzon implement the strategic transformation of R&D, focusing to antibody medicines and vaccines, and it has already established laboratories of antibody medicines and vaccine development. At the meanwhile, Livzon adjusts R&D direction of chemical pharmaceutical for carrying out transformation and upgrade. Livzon forms a complete research system. In addition, Livzon has established long-term cooperative relationship with more than 30 domestic and overseas scientific research institutes.

杭州民生药业有限公司

Hangzhou Minsheng Pharmaceutical Co., Ltd.

杭州民生药业有限公司（杭州民生药厂）创建于 1926 年，是中国最早的四大西药厂之一。90 余年来，民生药业一直专注于西药制药产业，见证了中国整个西药制药的历史。2006 年被商务部评为第一批“中华老字号”企业。经过多年的积累和发展，民生药业成为了一家专业化、负责任的现代化制药公司。公司在 2002 年至 2006 年间成功实施了跳跃式发展战略，从 2007 年开始全面实施的国际化发展战略将引领企业走向新的辉煌。

民生药业的第一只处方药已于 2011 年通过美国 FDA 的认证，产品在美国成功销售，标志着药业制剂产品已取得出口美国的通行证，迈进了制剂产品国际化的门槛，这具有里程碑式的意义。2010 年民生药业与法国拉曼公司合作，微生态制剂“普瑞宝”保健产品上市，将打造成为民生继 21 金维他以后第二个大品牌产品。公司在抗肿瘤及大输液等领域均享有较高的市场声誉。民生药业以传播科学健康观为己任，不断追求卓越，致力于打造充满活力的百年企业。

Hangzhou Minsheng Pharmaceutical Co., Ltd. was established in 1926. It is one of the earliest four chemical pharmaceutical factories in China,and was appraised one of the first approved "China's Time-honored Brand" Enterprises in 2006. The company has been specializing in the pharmaceutical industry for over ninty years, witnessed the entire history of western medicine in China. After years of development, the company has grown as an extremely professional and responsible modernized pharmaceutical company. Between 2002 to 2006, the company had implemented the leap-forward development strategy successfully. From the year of 2007, the company has put the international development strategy in practice. Since then, Minsheng has entered a new period of development.

Minsheng have got the first generic drug approval from FDA in 2011, and the product has been sold in USA, which means Minsheng have obtained permits to enter the international market. And it is a milestone to the development of Minsheng. In 2010 Minsheng launched a new product - " Probio'stick ", cooperated with Lallemand. This micro-ecological product will be created as another star brand besides 21 Super-Vita.

In addition, the company has high prestige in anti-oncology drugs and large volume parenterals. The vision of Minsheng is to build an unfailing, dynamic company.

浙江佐力药业股份有限公司

Zhejiang Jolly Pharmaceutical Co., Ltd.

浙江佐力药业股份有限公司发起设立于 2000 年 1 月，是一家集科研、生产、销售于一体的国家高新技术制药企业。2011 年 2 月 22 日，公司成功登陆创业板（股票代码 300181），成为湖州市第一家创业板上市公司。目前，公司拥有浙江佐力健康产业投资管理有限公司一家全资子公司，青海珠峰冬虫夏草药业有限公司、浙江凯欣医药有限公司两家控股子公司，投资并参与德清县第三人民医院合作办医。

公司位于风景秀丽的莫干山脚下，占地 200 余亩，建筑面积 10 万多平方米，拥有现代化的原料药、片剂、胶囊、颗粒和冻干粉针等生产流水线。公司研发中心是省级高新技术研究开发中心、浙江省企业技术中心、药用真菌制药技术国家地方联建工程实验室。

公司立足于药用真菌生物发酵技术生产中药产品，通过多年的研发、改进，实现了珍稀中药材——乌灵参的产业化生产，实现了传统中药材和现代生物技术的结合。公司利用从天然乌灵参中分离获得的菌种，运用现代生物发酵技术，实现了乌灵参发酵菌粉（乌灵菌粉）的工厂化、规模化生产。公司以市场为导向，不断加强对乌灵菌粉的深度研究，成功开发了国家一类新药乌灵胶囊，以及用于治疗更年期综合症的灵莲花颗粒和用于治疗前列腺增生的灵泽片等乌灵系列产品。通过收购控股青海珠峰冬虫夏草药业有限公司，公司在药用真菌领域又收获重磅产品－冬虫夏草发酵制剂产品百令片。

多年来，公司坚持产品创新、市场创新和管理创新，积极开拓市场，连续实现销售、利税的大幅增长，取得了快速发展。与此同时，公司也获得了诸多荣誉：“国家级火炬高新技术企业”、“国家高新技术企业”、“全国模范劳动关系和谐企业”、“全国五一劳动奖章”、“浙江省绿色企业”、“浙江省诚信守法企业”、“浙江省文明单位”、“浙江省创新型试点企业”、“浙江省优秀民营企业”、“中国驰名商标”、“浙江省著名商标”、“浙江省知名商号”、“浙江名牌产品”等。

公司将始终秉承“辅佐人类身体健康，致力祖国医药发展”的使命，倡导“创新、奉献、卓越、合作、共赢”的核心理念，坚持以乌灵系列产品为起点，以药用真菌的产业化为己任，依托“医药制造、医药流通、医药服务”三大平台，构建慢病及健康管理生态系统。

Zhejiang Jolly Pharmaceutical Co., Ltd is a national high-tech enterprise with an integration of scientific research, production and marketing which was founded in Jan, 2000. On Feb. 22nd, 2011, it successfully became a public company in the Growth Enterprises Market in Shenzhen Stock Exchange(Stoke Code:300181), which is also the first public enterprise in the Growth Enterprises Market of Huzhou. At present, the company has a wholly-owned subsidiary, Zhejiang Jolly Health Industry Investment Management Co., Ltd., two subsidiaries, Qinghai Everest Cordyceps Sinensis Pharmaceutical., Ltd and Zhejiang Kaixin Medicine., Ltd. Moreover, the company also invests and participates in Deqing No.3 People's Hospital's cooperating medical service.

Our company is located at the foot of the scenic Mount Mogan, covering an area of over 200 mu, and reaching an construction area of 100 thousands square meters. We have modern production lines, including raw materials, tablets, capsules, particles, frozen dry powder injection. Our R & D center is titled as “Provincial High-Tech Research and Development Center”, “Zhejiang Enterprise Technology Center” and “National & Local Co-operational Engineering Lab for Medicinal Fungi Pharmaceutical Technology”.

Based on bio-fermentation technology, our company uses medicinal fungi to produce traditional Chinese medicinal products, and with years of research and improvement, we have developed an industrialized production pattern for Wulingshen, a rare Chinese herbal medicine, which successfully combines the traditional Chinese herbal medicine and the modern biotechnology together. Applying modern bio-fermentation technology, we use Wuling strains, which come from natural Wulingshen, to develop an industrialized production pattern for Wulingshen fermentation power (Wuling Powder). By taking the market-oriented approach, our company keeps an intensive research in Wuling Powder, and has successfully developed Wuling series products, Wuling Capsule, a kind of national first class new medicine, Linglianhua Particle for menopausal syndrome treatment, Lingze Tablet for BPH treatment. With the acquisition of Qinghai Everest Cordyceps Sinensis Pharmaceutical., Ltd, we successfully own a blockbuster, the “Bailing Tablet”, a cordyceps sinensis fermented preparation which belongs to the medicinal fungi field

For years, our company keeps on product innovation, market innovation and management innovation. Thanks to the actively development of the market, we have achieved growth in sales, profits and tax payment in succession, and consequently our company is developing at an incredible speed. Meanwhile, we have also received many honors like “National Torch High-tech Enterprise”, “State High-tech Enterprise ”, “National Model Harmonious Enterprise”, “National Labor Medal ”, “Zhejiang Green Enterprise”, “Zhejiang Honest and Faithful Enterprise”, “Zhejiang Model Unit”, “Zhejiang Innovation-based Pilot Enterprise ”, “Zhejiang Excellent Private Enterprise”, “Chinese Famous Trademark”, “Zhejiang Famous Brand”, “Zhejiang Well-known Enterprise” and “Zhejiang Famous Brand product”.

We will stick to our enterprise spirit: “assist human health and attribute to the pharmaceutical development of China”, take “innovation, dedication, excellence, cooperation and win-win” as our core concepts, stick with the Wuling-series products and take the industrialization of medicinal fungi as our responsibility, and rely on "pharmaceutical manufacturing, pharmaceutical distribution, medical services" the three major platforms to construct chronic disease and health management ecosystems.

广西梧州中恒集团股份有限公司

Guangxi Wuzhou Zhongheng Group Co., Ltd.

中恒集团是一家拥有制药、保健食品等多元产业、现代化、跨行业、集团化经营的民营控股上市公司（股票代码：600252），是国家高新技术企业、中国制药工业百强企业、全国百强金牛上市公司、中国最具竞争力医药上市公司 20 强企业、全国就业先进企业，连续 3 年获得“AAA ＋级中国质量信用企业”和“全国实施卓越绩效模式先进企业”，得到了社会各界的广泛赞誉认可。

中恒集团属下子公司梧州制药是一家具有 80 多年发展历程，集生产、销售、研发、种植于一体的现代化综合型高新技术制药企业，拥有全国最大的中药现代科技生产基地，具有丰富的产品资源优势，药品生产文号 310 个，涵盖 11 大类剂型 217 个品种，其中，国家发明专利产品 25 个，全国独家生产品种 21 个，收载于《中国药典》品种 99 个，国家基本药物目录品种 43 个，在心脑血管、跌打、妇科、保健等多个领域拥有企业原研产品。掌握多项国内国际领先的现代制药专利技术，在中药提纯技术、冷冻干燥技术、中药注射剂生产、诊断用药以及三七中药材种植等领域具备权威优势。

集团公司旗下梧州双钱实业是全国最大、实力最强的龟苓膏生产企业，是实现龟苓膏生产工业化的先驱，原研首创的“双钱牌”龟苓膏获国家地理标志保护产品，近年又陆续成功研制出了双钱龟苓宝保健功能饮料和可吸型龟苓膏、果冻型龟苓膏等新产品，市场前景广阔。

近年来，中恒集团的企业规模不断发展壮大，发展触角不但已延伸到全国各地，还不断谋求国际化拓展，并充分依托中恒集团雄厚的实力和影响力，紧跟药品创新主流，全力向国际前沿制药研发技术探索进军，为人类大健康事业尽力尽责，造福民生。

Zhongheng Group, held by the private capital, is a diverse, modern, cross-industrial and group operating listed company (stock code:600252) who owns several industries including pharmaceuticals, health food and so on. Being honored as the National High-tech Enterprise, top 100 of Chinese pharmaceutical companies, top 100 of Taurus Listed Companies, top 20 of Chinese most competitive pharmaceutical listed enterprises, National Advanced Employer and in 3 consecutive years being awarded with “Chinese Quality Credit AAA Grade Enterprise” and “National advanced enterprise implementing excellent performance model”, Zhongheng Group has been praised and accepted by the public.

Guangxi Wuzhou Pharmaceutical (Group) Co., Ltd. is a subsidiary of Zhongheng Group with a developing history of more than eight decades, which is a modern and comprehensive high-tech pharmaceutical enterprise integrating manufacturing, marketing, R&D and planting. Possessing the largest TCM manufacturing base of modern science and technology in China and the advantage of various product resources, Wuzhou Pharmaceutical owns 310 Certificates of Drug Registration and 217 varieties in 11 categories of TCM dosage, among which 25 National Patent Products and 21 National Exclusive Products are existing, 99 varieties are collected into Chinese Pharmacopoeia and 43 varieties are collected into National Essential Drug List. Wuzhou Pharmaceutical has originally developed its own products for multiple areas such as cardio-cerebrovascular, traumatic injuries, gynecology and health care. Having a number of modern pharmaceutical patent technologies lead in China and abroad, Wuzhou pharmaceutical takes an authoritative advantage in the fields of TCM refinement and purification technology, lyophilized technology, TCM injection production, diagnostic medicine and the medicinal herbs planting of notoginseng.

As a subsidiary of Zhongheng Group, Wuzhou Double Coins Industrial Co.,Ltd. is the largest and most powerful manufacturer of Gui Linggao and the pioneer to industrialize Gui linggao production, which has originally initiated the brand “Double Coins” awarded as the protection product of “National Geographical Symbol”. In recent years, the new products like “Double Coins” Guiling Bao healthy beverage, sucking Gui Linggao and jelly Gui Linggao are subsequently and successfully developed, which win a wide market prospect.

In recent years, the enterprise scale of Zhongheng Group is growing stronger and its antenna of development is not only extended all around the country but also to the world for seeking international development. Fully relying on its solid strength and influence, keeping up with the pharmaceutical mainstream of innovation, exploring and marching toward the pharmaceutical research and development technology of international frontier, Zhongheng Group is trying its best to fulfill the responsibilities for human’s big health careers and benefit people’s livelihood.

南京圣和药业股份有限公司

Nanjing Sanhome Pharmaceutical Co., Ltd.

南京圣和药业股份有限公司始建于 1996 年，是一家集医药研究、药品生产和市场营销为一体的国家重点高新技术企业。

圣和人以让更多的人享受健康的快乐为自己的使命，努力提高新产品的科技含量，致力于新产品的科研开发，迄今已获新药证书百余本，拥有国家发明专利及国际专利数十项。通过自有技术、独立开发的中西药品种中有国家一类新药，有国家重点新产品，有国家中药保护品种，有全国独家产品。公司还承担了包括国家 863 计划、重大新药创制专项、国家创新基金、国家火炬计划在内的国家和省级重点科研项目 30 余项。新产品的开发不仅为企业的建设增添了经济实力，还为企业可持续发展蕴藏了生机。公司先后被省市科技部门认定为“南京市高新技术企业”和“江苏省高新技术企业”，2003 年被国家科技部认定为“重点高新技术企业”，2008 年，国家人力资源和社会保障部批准设立“博士后科研工作站”，圣和也设有省级工程技术研究中心、省级企业技术中心、国家级创新药物孵化基地等。

圣和药业目前拥有片剂、颗粒剂、胶囊剂、冻干粉针剂、粉针剂、软膏剂、大容量注射剂、小容量注射剂等十多种剂型生产线，多达 30 余种的药品行销国内市场，其中“圣诺安”、“圣诺灵”、“消癌平”等多个主导产品分别被国家、省、市认定为“高新技术产品”。公司以不断推出疗效好、市场前景广阔的新品上市，形成了本企业科技创新的特色。

公司建立十八年来，一步一个脚印走出自己发展的路子。2004 年，中华全国总工会授予公司“五一劳动奖状”荣誉称号，公司还先后被国家、省市有关部门评定为“国家重点高新技术企业”、“中国优秀民营科技企业”、“中国化学制药行业工业企业百强”、“2013 年度全国工商业联合会科学技术奖”、“江苏省优秀民营企业”、“江苏省质量信用等级 A 级企业”等荣誉称号。

Sanhome is a health care company founded in 1996 which is devoted to pharmaceutical studies, medicine production and marketing.

Guided by the mission of blessing more people with enjoyment of good health, Sanhome makes great efforts to raise the technology content of the new and high-tech products. Committed ourselves to the scientific research and development of new products, Sanhome has got 100 plus new drug certificates in so far and been awarded more than10 national patents and international patents. In the new drug research center established by the company, we have independently developed various kinds of Chinese Traditional Medicine and Western Medicine with the exclusive technology of our own, among which there are national 1st rank new drug, national key products, TMC under national protection, National Patent products. Sanhome have also borne the responsibility of conducting more than 30 scientific research projects including National 863 Projects, Projects of New Drug Discovery Initiative, National Innovation Fund and National Torch Program. The research and development of new products have been a substantial drive for the sustainable and vigorous development of the company. In 2001, the company was listed among the "Nanjing New and High-tech Enterprises" by Nanjing Science and Technology Bureau. In 2003 Sanhome was certified as "New and High-tech Enterprises of Jiangsu" by Science and Technology Government Agency of Jiangsu and was certified as national "Key New and High-tech Enterprises" by Ministry of Science and Technology. In 2008 postdoctoral research workstation was approved to establish by Ministry of Human Resources and Social Security. In addition, provincial engineering technology research and development center, provincial enterprise technology center and national innovation medicine incubation base are established in succession in Sanhome.

Presently, Sanhome possesses various production lines which can produce tablets, granules, capsules, freeze-dried powder injection, powder injection, ointments, large volume injections, and small volume injections. 30 plus varieties are marketed nationwide. Our leading products including “ShengNuoAn”, “ShengNuoLing”, “Xiao Yanping” have endowed with the honorable title of “New and High-tech Product” by Jiangsu province and Nanjing city. Sanhome has formed the characters of scientific and technological innovation by keeping on launching and producing new products with desirable therapeutic effects and broad market prospects.

In the eighteen years since it was founded, Sanhome formed its development path step by step. In 2004, it is awarded the honorable title of “May 1st work certificate” by All China Federation of Trade Unions. Sanhome has been awarded various honorable titles by the government, including “National Key New and High-tech Enterprise”, “Excellent science and technology private enterprise of China”, “National Double Love and Double Selection Advanced enterprise”, “National Excellent enterprise of staff concern”, “China AAA grade credit enterprise”, “the best practitioner of manufacturing industry informatization of China”, “Excellent private enterprise of Jiangsu”, “A grade quality credit rating enterprise of Jiangsu”.

贵州信邦制药股份有限公司

Guizhou Xinbang Pharmaceutical Co., Ltd.

贵州信邦制药股份有限公司成立于 1995 年元月，注册地为黔南州罗甸县，管理总部设在贵阳市。2010 年 4 月 16 日，公司股票在深圳证券交易所成功挂牌上市，股票代码：002390。2013 年，公司获评中国上市公司口碑榜“最具成长性上市公司”奖。

公司注册资本 5 亿元，总资产 45 亿元，净资产 23 亿元，员工 4300 余人，下属贵州科开医药有限公司、贵州省肿瘤医院有限公司等 15 家控股公司，形成了集医药工业、医药流通、医疗健康服务为一体的医疗医药产业链。

在医药工业方面，公司以传统中药材种植、中药饮片生产、制剂生产、新药研发和药品销售为基础，建立了中药材规范化种植基地、中药饮片生产基地、口服制剂生产基地和注射剂生产基地。现拥有国药准字号品种 71 个，其中国家基本医疗保险品种 38 个，列入《国家基本药物目录》（2012 年版）品种 17 个。公司“信邦”和“邦消安”商标被评为“贵州省著名商标”；银杏叶片、益心舒胶囊等 7 个主打产品被评为“贵州省名牌产品”。

在医药流通方面，公司拥有医药流通企业 6 家，配送网络以贵阳为中心，覆盖省内各地州市，拥有药品、器械、耗材等上千余品种。其中，科开大药房旗下拥有 7 家医药零售门店，已经初步形成了覆盖下属医院和主要合作医院的医药零售网络。

在医疗健康服务方面，公司拥有贵州省肿瘤医院、贵医附属白云医院、贵医附属乌当医院、贵医安顺医院等 4 家医疗机构。其中，三级甲等医院 1 家，三级综合医院 2 家，二级综合医院 1 家，床位 2500 余张，形成了集医疗、教学、科研、预防、保健、康复、宁养于一体的医疗健康产业。

秉承“精诚至信，众志兴邦；健康民众，发展民生”的企业理念，公司坚持科学发展观，致力于医药医疗健康产业的发展，为人类的健康而不懈努力。

Guizhou Xinbang Pharmaceutical Co., Ltd (hereinafter refer to as GZXB) was established in Jan 1995, registered in Luodian county of Guizhou province, and whose headquarter was set in Guiyang city. On April 16, 2010, GZXB was listed in Shenzhen Stock Exchange (SZSE) sucessfully and the stock code was 002390. In 2013, our company honored the reputation of "the most growth listed company" in Chinese listed companies.

GZXB has the registered capital of RMB 500 million yuan, the total assets of RMB 4.5 billion yuan, the net assets of RMB 2.3 billion yuan and employ more than 4300 employees. GZXB own 15 subsidiaries such as Guizhou Kekai pharmaceutical Co., Ltd and Guizhou Cancer Hospital Co., Ltd. And it has formed a medical and pharmaceutical industry chain constitute by the pharmaceutical industry, medicine distribution, medical and health services.

In the pharmaceutical industry aspect, base on the traditional Chinese herbal planting, Chinese Herbal pieces production, medicament production, new drug development and pharmaceutical marketing, the company establishes the corresponding production and processing base. Now GZXB has 71 drug products that have approved by CFDA (Chinese Food and Drug Administration), in which 38 products is listed in the Catalogue of Drugs for Basic National Medical Insurance, 17 is listed in the "National Essential Drugs List" (2012 edition). The trademark of "Xinbang"and "Bangxiao'an"in GZXB was honor the 'famous trademark of Guizhou province, 7 flagship product included Ginkgo biloba tablet and Yixinshu capsule were honored the "Brand-name products of Guizhou Province"

In pharmaceutical distribution aspect, GZXB has six pharmaceutical distribution companies, The center of distribution networks is in Guiyang city, and can cover all the city and county in Guizhou province, and own thousand products of drug products, instuments, consumables. Among them, the Kekai pharmacy which owns seven retail stores, has developed in a pharmaceutical retail network, covering the affiliated hospital and major cooperative hospitals of GZXB.

In the aspect of medical and health services, the GZXB owns 4 medical institutions, include the Guizhou Cancer Hospital, the Affiliated Baiyun Hospital of Guiyang Medical College, the Affiliated Wudang Hospital of Guiyang Medical College and the Affiliated Anshun Hospital of Guiyang Medical College; Among them 1 is third-grade class-A hospital, 2 are third-grade general hospital and 1 is second-grade general hospital; and totally have more than 2,500 hospital-beds. and integrally form the medical health industry comprising the medical, teaching, research and development, prevention, health care, rehabilitation and hospice.

Adhering to the corporate idea of "absolute sincerity cause the trust; working together to the country prosperous; healthy the people and the development of livelihood," GZXB insists the scientific outlook on development, commits to the industry development of the pharmaceutical, medical and health care; and will do tireless efforts for human health.

山东步长制药股份有限公司

Shandong Buchang Pharmaceutical Co., Ltd.

步长的事业起步于 1993 年，经过二十余年艰苦奋斗，已发展成一个以医药产业为主，同时涉足高科技产业、健康产业等众多领域，多元化经营的产业集群。其医药板块“步长制药”是一家专注于中药专利药研发、生产、销售的国内知名企业。在山东、陕西、河北、吉林设有生产基地，同时在北京、上海、广东设有分公司，分支机构遍布中国主要省份。经过多年发展，公司已建成一支高素质、专业化团队，拥有十个事业部、十家药厂，销售网络交叉覆盖全国 3 万个医院和 20 万零售药店。

赵涛董事长 1996 年被评为全国优秀青年企业家，中国侨商投资协会副会长，并被推选为中国企业家协会常务理事。2001 年中国“创业之星”，陕西“三五”人才，2003 年与杨利伟等人荣膺十大中华英才称号，2004 年荣获“中国十大风云人物”。2008 年 11 月荣获“最具社会责任企业家”，2008 年 12 月荣获“2008 品牌中国年度人物”，2010 年，赵步长、赵涛父子被誉为“中国特色慈善家”。2012 年在第九届中国最佳企业公民评选颁奖盛典中赵涛被评为“中国最具社会责任企业家”。2012 年荣获中国创业发明金奖。2013 年荣获“年度慈善家”。

自 2008 年起，公司创始人赵步长教授、赵超博士双双当选第十一届、第十二届全国人大代表，这是党和国家给予步长的最高荣耀和最大鼓励。2010 年 11 月，丹红注射液荣获“中国首个中药专利金奖”；“步长脑心通”荣获“中药产品品牌十强”等荣誉称号。2012 年，步长制药凭借在企业社会责任方面的突出表现再次荣膺“最佳企业公民”大奖。2013 年，步长蝉联中国制药工业百强中药企业第一，并荣膺“2013 中国五星级企业公民”荣誉称号。

公司勇于承担社会责任，在社会公众心目中树立了良好的企业形象。公司自 1997 年起，连续多年位居当地民企纳税前茅；社会公益事业方面的捐款 4 亿多元。共铸中国心活动自 2008 年发起至今，共组织近 5000 名医生志愿者，先后走过四川、宁夏、山东、内蒙古、西藏、青海等地区的 300 多个乡镇，为二十多万人次进行过诊疗救治，并免费救助先心病儿童，使 300 多名先心病儿童手术后重获健康。公司已连续多年荣获“中国医药卫生行业社会责任孺子牛奖”。

Buchang Pharma, established in 1993, has developed into a diversified industrial cluster after twenty-year arduous struggle, based on main pharmaceutical industry and meanwhile involved in high-tech, health, education and many industries. The pharmaceutical part, Buchang Pharma CO. LTD., is a famous enterprise in China, engaged in the research & development, production and sales of TCD (traditional Chinese Drugs) patent medicines. Buchang Pharma has production bases in Shandong, Shaanxi and Heibei province, at the same time, set up filiales in Beijing, Shanghai and Guangdong. Branched organizations are all over China. According to years of development, the company has have owns a highly qualified and professional team, 10 business departments, 10 pharmaceutical manufacturers, and the sales network has covered 30,000 hospitals and 200,000 drug stores.

In 1996, Mr. Zhao Tao, the Chairman of Buchang, was awarded as the National Outstanding Young Entrepreneurs, vice president of China Overseas Chinese Investment Association, and was elected as the standing director of China Entrepreneurs Association. China Enterprising Star in 2001, "the third five years plan" shaanxi talent; In 2003, honored Ten Prominent Chinese award, including Yang Liwei as the same title; In 2004, won the China Top Ten Person; In November 2008, won the "most social responsibility of entrepreneurs". In December 2008 was awarded "2008 China Brand Person of the year". In 2010, Zhao Buchang and Zhao Tao (both father and son) were known as "China Characteristics Philanthropist". In 2012 in the ninth China awards best corporate citizen evaluation, was named "China's most socially responsible entrepreneurs"; In 2012, won the Golden Award of Chinese Entrepreneurial Invention; In 2013, rewarded the "Annual Philanthropist".

Since 2008, the founder of Buchang Pharma, Prof.Zhao Buchang and the President Dr. Zhao Chao, were both elected the representatives of the 11th and the 12th National People's Congress, which was the greatest honor and the biggest encouragement of the government and the country. In November 2010, Buchang Danhong Injection obtained "The First Gold Prize of Traditional Chinese Medicine"; Buchang Naoxintong Capsule got the "Top 10 Product Brand of Traditional Chinese Medicine"etc. In 2012, with outstanding performance in social responsibility,Buchang Pharma got the "Best Corporate Citizens" award again. In 2013, Buchang Pharma had continuously won the first one of National Top 100 Pharmaceutical Industry Enterprises and got the 2013 China Five-star Enterprise Citizen honorary titles.

Buchang Pharma undertakes the social responsibility valorously and sets a good corporate image in the public minds. Since 1997, Buchang company has ranked first of tax pay private enterprise continuously for many years in the local place. Donate up to 400 million Yuan in social public welfare. since launched in 2008 to now, Build China Hearts activity has organized nearly 5000 doctors volunteers, successively passed Sichuan, Ningxia, Shandong, Inner Mongolia, Tibet, Qinghai and more than 300 villages and towns regions, which has been diagnosis and treatment for more than 200,000 patients. Meanwhile, it also gives free relief to the congenital heart disease children, which makes more than 300 congenital heart disease children regain his health after the operation. Buchang Pharma has won the China Medicine and Health Industry Social Responsibility - A Willing Ox Award consecutively for many years.

悦康药业集团有限公司

Youcare Pharmaceutical Group Co., Ltd.

悦康药业集团 1988 年创建，2001 年在北京经济技术开发区投资建厂，成立集团总部。集团业务涵盖新药研发、制剂生产、流通销售及国际贸易等，建立了以安徽原料药基地为支撑的北京、上海、广州、重庆四个特色制剂产业基地，形成从原料到制剂的全产业链体系。2013 年集团医药主营业务收入 49 亿元，位列中国制药工业百强第 38 名，中国制药工业研发十强；国家级重点高新技术企业；中关村“十百千”工程重点培育企业；北京生物医药产业跨越发展工程 G20 规模企业；北京开发区纳税 50 强企业 (26 名)；中国制药工业国际化先导企业等。

集团现有产品品规近 200 个，涵盖抗生素、心脑血管、消化系统、抗肿瘤、抗病毒、免疫类疾病等 12 大类。其中，头孢曲松、奥美拉唑肠溶胶囊、盐酸二甲双胍缓释片等多个产品销量居全国之首，注射用兰索拉唑获国家科技进步二等奖。

集团生产的银杏叶提取物注射液为国内独家产品，原料由法国进口，是中法植物提取物技术合作的成果。2014 年 3 月，集团董事长于伟仕随国家主席习近平访问法国，并在两国政府见证下，与法方合作公司签署植物提取物及天然药物合作开发协议。

集团现有 7 个一类新药，近百个三类强仿药物在研。其中：全球一类创新药枸橼酸爱地那非片获得 22 个国家的化合物发明专利，预计 2014 年获得生产批件，市场预期为 30 至 50 亿元 / 年。

继 2011 年集团固体制剂通过欧盟 GMP 认证后，集团加大国际化步伐，2013 年 3 月，集团在美国纽约设立公司，并已向美国 FDA 申报了 3 个药品的注册申请。目前，集团收购美国洛杉矶某药厂进展顺利，计划 2014 年年内正式签约。

悦康以生物医药产业为核心，不断向需求终端延伸产业链，集团确立围绕医疗大健康领域进行多元化发展。目前，集团在欧洲和美国已开展天然成分的保健品、化妆品业务，并计划在美国建立国际体检机构，开展国际高端医疗服务。

Youcare Pharmaceutical Group Co., Ltd. was founded in 1988. In 2001, Youcare headquartered and built the first plant in BDA, Beijing. It's a diversified pharmaceutical Group integrated with R&D, manufacturing, logistics, sales and international trade. Depending on the API industrial base in Anhui province and focusing on branding, four brand preparations industrial bases in Beijing, Shanghai, Guangzhou and Chongqing have been established. Youcare has created an integrated industrial chain. With pharmaceutical main business income of 4.9 billion CNY, Youcare ranked among the top 100 enterprises of Chinese pharmaceutical industry in 2013 (No. 38). Moreover, Youcare is one of the Top 10 R&D Enterprises in Chinese pharmaceutical industry, the State-class Key High-tech Enterprises, Key Fostering Enterprise of Zhongguancun “Ten-Hundred-Thousand Project”, “Across Beijing Biomedical Industry Development Project” (G20 project) Enterprises, the Top 50 Tax Payer Enterprises (No.26) in BDA and China Chemical Drug International Leading Eenterprises.

There are about 200 approvals in Youcare, covering 12 categories shuch as antibiotics, cardio-cerebral vascular drugs, gastrointestinal drugs, antineoplastic agents, antiviral agents and immunomodulation drugs. Especially, Ceftriaxone, Omeprazole enteric-coated capsules, Metformin hydrochloride sustained-release tablets and other products have ranked in the forefront of national product sales. Moreover, Lansoprazole for injection has won the second award of National Science and Technology Progress Award.

With the raw material from France, Extract of Ginkgo Biloba Leaves injection is the exclusive product in China produced by Youcare. This is an important achievement of Sino-French cooperation in plant extracts technology. The Chairman of Youcare, Mr Yu, accompanies with President Xi Jinping to France in Mar, 2014, and signed the plant extracts and natural medicine cooperative development agreement with France cooperation in the witness of the two governments.

New drug R&D: There are 7 new drugs of the first category and about one hundred strong imitation drugs of the third category under research. Aildenafil citrate tablet, a global innovative drug of the first category, has obtained 22 national compound patents. Production licenses will be obtained in 2014 with the expected-marketing value of 3-5 billion CNY per year.

Internationalization: After passing the EU GMP inspection of solid preparation in 2011, Youcare speed up the pace of internationalization. An overseas company in New York is established in Mar. 2013, and 3 ANDA has been submitted to FDA. At present, the acquisition of a pharmaceutical company in Los Angeles progresses well, and the contract is expected to be formally signed within the year 2014.

Diversification: Youcare focuses on biomedical industry, continues to extend the industrial chain to terminal demand, and makes diversified development around the medical health field. Currently, Youcare has established business cooperation with European and American partners in healthcare products and cosmetics with natural ingredients, and plans to establish international medical institution and provide high-end services in the United States.

江苏奥赛康药业股份有限公司

Jiangsu Aosaikang Pharmaceutical Co. Ltd.

江苏奥赛康药业股份有限公司 (奥赛康药业) 是集医药、研发、生产、市场推广和销售为一体的国家火炬计划重点高新技术企业。公司 2014 年再度入选 “全国医药工业百强企业”，位列第 71 位。

公司已建立现代化企业制度，拥有完善的经营管理体系、卓越的科技研发体系、顶尖的生产制造体系、稳定的质量保证体系、专业的学术推广体系、匹配的销售服务体系及药品的不良监测体系。

公司专注于质子泵抑制剂注射剂（PPI）和抗肿瘤注射剂的研发和市场推广，多个产品为国内首仿，目前是全国质子泵抑制剂（PPI）系列品种领军企业之一。公司拥有“博士后工作站”、江苏省抗消化道溃疡药物工程技术研究中心”、连续三年荣获 “中国医药企业创新力二十强” 荣誉称号，并连续五年获得“中国医药研发产品线最佳工业企业”殊荣，是国家级“守合同重信用企业”。奥赛康药业在全国医药行业中已树立了卓越的品牌影响力和领先的研发创造力。

Jiangsu Aosaikang Pharmaceutical Co. Ltd (ASK Pharm) is a key hi-tech enterprises of the National Torch Program that integrates and streamlines innovative research and development with manufacture, marketing promotion and sales of pharmaceuticals products. ASK Pharm has ranked 71 out of the “100 Top National Pharmaceutical Companies” in 2014.

ASK Pharm has establish a modern enterprise management system , with comprehensive management system, superior R&D facility, state-of-the-art manufacturing capacity, sustainable product quality assurance, professional sales network, and after-marketing drug use monitoring and surveillance.

ASK Pharm specializes in proton pump inhibitor (PPI) products and oncology medicines. ASK Pharm has launched many first generic drugs, and ASK is one of the primary national of proprietary PPI injections. It owns a post-doctoral research station and Jiangsu Provincial engineering research center for peptic ulcer disease. It has also received the honor of “Top Ten National R&D Innovators” for 3 consecutive years and “Best R&D Pipeline Pharmaceutical Manufactures” for 5 consecutive years. It has received the reputation of “ National Class award of Honor the Contract and Keep the Promise“ .It has become one of the most influential brands and a leading R&D innovator in China’s pharmaceutical industry.

重庆植恩药业有限公司

Zein Pharmaceutical Co., Ltd.

重庆植恩药业有限公司创办于 2001 年，是立足于重庆的一家集研发、生产和销售一体化的新兴医药企业，是一家集两江工程中心、手性工程中心和新药设计工程中心等三大研发中心、原料药生产基地、制剂生产基地和销售总部的集团公司。

植恩药业在研发方面具有丰富的经验。目前已经获得新药证书 33 项、临床批件 32 项、生产批件 51 项；申请国家发明专利数十项，其中已获国外专利授权 3 件，国内专利授权 12 件。公司已开展研发项目 32 项，承担包括国家重大新药创制项目（“11.5”和“12.5”）等 70 余项各类课题，并获得全国及省级奖项数十项。目前在研项目涉及神经系统药物、代谢系统药物、消化系统药物及其他类药物，其中神经系统药物已成为公司发展的主要方向，其中包括化药 1 类新药 2 项、中药 5 类新药 1 项。

植恩药业产业化能力较强，产能正逐步扩大。现有原料药生产基地年生产能力超过 40 吨，新建 82000 平方原料药生产基地将使产能提高到每年 60 吨 -80 吨，核心 API 品种奥利司他质量及产能达到国际先进水平，产品已热销巴西、澳大利亚、德国、波兰、新加坡和韩国，且已经在美国和印度递交上市申请，未来国际市场将进一步拓宽。现有制剂生产线可生产胶囊剂、颗粒剂、片剂、栓剂等剂型，在建制剂生产线将新增冻干剂型、小 / 大容量注射液等剂型，在建制剂产业化基地建筑面积 33330 ㎡。

公司产品丰富，后续产品充足。目前主打产品有奥利司他、盐酸多奈哌齐、盐酸罗匹尼罗、甲磺司特等，即将上市的重点产品包括盐酸他利克索和盐酸兰地洛尔等。

植恩药业具有强大的一级市场到达终端市场的分销商网络。目前拥有零售终端及医院终端销售人员 500 余人。产品覆盖 30 个城市 2000 多家医院，40000 家药店。外贸方面，原料药出口到全球 20 多个国家。

公司以“木直因心，植药为仁”为座右铭，以“创建中国医药与健康服务的领先企业”为发展目标。在强大的医药研发团队、高效的医学注册能力、广泛坚固的医药渠道网络、专业化的市场销售能力、权威的政府事务及专业机构合作能力支持下，将公司打造成行业内知名的高新技术医药企业。

Founded in 2001, Zein is a pharmaceutical enterprise in Chongqing, which focused on research, production, sales and market. As a group company, Zein owns three R&D centers which are Liangjiang Medicine Co., Ltd., Chiral Engineering Center and New Drug Design Engineering Center, an API manufacturing base, a preparation manufacturing base and a sales company.

Zein is experienced in R&D. At present, it has obtained 33 new drug certificates, 32 clinical approvals and 51 production licenses and has already applied dozens of National Invention Patents, in which 3 foreign patents and 11 domestic patents have been authorized. Zein has initiated 32 R&D projects, assumed more than 70 projects, including “Major National New Drug Development Project” (“11.5” and “12.5”) and acquired dozens of national/province awards. Zein’s understudied projects involve drugs of neural system, metabolic system and digestive system etc, in which neural drugs are the main products, including 2 State Category I New Drugs and 1 Chinese Herb Category V New Drug.

Zein is equipped with a strong capability of industrialization which is growing continually. The production capability of the API manufacturing base is more than 40 tons, and the new 82,000 m2 API manufacturing base that is under construction will increase the capability to 60-80 tons. The quality and capability of core API, Orlistat, reaches the international advanced level and Orlistat is popular in Brazil, Australia, Germany, Poland, Singapore and Korea. The listing applications have been submitted to United States and India to explore the potential international market. The existing preparation production line meets the manufacturing requirements of capsule, granule, tablet and suppository etc. The new line under construction that covers a building area of 33330 m2, will add the production of lyophilized powder and large/small volume injection.

Zein owns a rich product catalog and plenty of follow-up products. Currently, the fist products are Orlistat, Donepezil Hydrochloride, Ropinirole hydrochloride and suplatast tosilate. The key products, including Talipexole Hydrochloride and Landiolol Hydrochloride will be marketed soon.

Zein also owns a strong distributor network from primary market to terminal one. There are more than 5000 salesmen distributed from the retail terminal to the hospital terminal. Zein’s products cover 30 cities, including 2,000 hospitals and 40,000 drugstores. Zein’s APIs are exported to more than 20 countries worldwide.

Zein develops medicines with a beneficent heart and pursues to be one of the leading companies in Chinese medicine and health service. With the supporting of strong pharmaceutical research and development team, efficient medical registration ability, wide selling network, professional market-selling ability, and cooperation with government and professional institutes, Zein is growing to be a well-known and high-tech pharmaceutical enterprise.

正大青春宝药业有限公司

Chiatai Qingchunbao Pharmaceutical Co., Ltd.

正大青春宝药业有限公司位于杭州西湖风景区桃源岭下，其前身杭州第二中药厂原来是百年老店胡庆余堂的制胶车间，1972 年独立建厂，经过长期的艰苦奋斗和改革创新，逐步发展成为我国中药行业规模最大、经济效益最好的现代化企业之一，现为上海医药集团股份有限公司之核心企业。

公司拥有完善的科研、信息系统、技术中心、产品检测中心和完整的全国销售网络。能生产注射剂、片剂、颗粒剂、胶囊剂 等 8 个剂型近百种产品，参麦注射液、丹参注射液、青春宝抗衰老片等主要产品生产规模大、工艺先进、技术含量高。公司“中药质量计算分析技术及其在参麦注射液工业生产中的应用”项目获国家科技进步一等奖。

Chiatai Qingchunbao Pharmaceutical Co., Ltd. is located in Taoyuan ling of Hangzhou West Lake Scenic Area. Its predecessor, Hangzhou Second Traditional Pharmaceutical Works was established in 1972, which came from a former workshop of Hu Qing Yu Tang – “King of Chinese Medicine in the South of Yangtze River”. Through long-term hard work and innovation, it has become one of the largest scale and Shanghai Pharmaceutical Group Co., Ltd..It has comprehensive R&D and information systems, technology and inspection center, and sales network throughout the country. The company can produce about 100 kinds of products in 8 dosage forms, including injections, tablets, granules, capsules and so on. Among them, Shenma injection, Danshen injection, Qingchunbao Anti-aging tablets are the major products with large output, high quality lever and advanced technology. The research project “Technology of TCM quality evaluation aided by computation, and its application in the manufacture of Shenmai injection” has won the National Science and Technology Progress Award (second prize).

深圳奥萨制药有限公司
Shenzhen AUSA Pharmaceuticals Ltd.

深圳奥萨制药有限公司位于广东省深圳市南山区科技园国家高新技术产业带，为国家级高新技术企业。公司拥有固体制剂、体外诊断试剂、医疗器械等符合国家 GMP 规范的生产车间；药理研究中心、药学研究中心、分子生物学中心等研发基地；并承担国家发改委“深圳国家生物产业基地复方创新药物实验中心”、国家十二五“企业孵化基地”和建有国家人社部“博士后工作站等；

奥萨开创了一条独具奥萨特色的，经济、快捷、高效、更能解决中国人群临床重大疾病问题的创新药物研发思路，即：以药物基因组学为先导，流行病学为基础的创新药物研发思路，这更适合中国国情。公司的研发策略是主要针对严重影响健康的慢性复杂性疾病，以药物基因组学研究为先导，对疾病发生、发展和治疗的分子生物学机理进行深入研究，设计并开发出更为安全有效的治疗方案和相关的诊断产品，以获得更大市场潜力和社会效益。

经过七年发展，目前公司已经上市产品包括一类新药以及医疗器械，在研创新产品 20 余项。其中 I 类新药“依叶”是首个基于中国人群特点研发的、更适合中国人使用的 H 型高血压治疗药物；“依叶”的研发成果分别在 2008 年和 2010 年被欧洲和美国脑卒中防治指南列入为重要证据；“依叶”还与我公司自主开发的 MTHFR 基因诊断试剂盒组成了世界上首个应用于常见心脑血管疾病的个体化诊疗产品对，提供了脑卒中从诊断、预测、预防、治疗的一条龙服务，能更有效，更经济地预防脑卒中。

Shenzhen AUSA Pharmaceuticals Ltd.is a research-based pharmaceutical company and committed to improve quality of health care for patients with cardiovascular diseases and diabetes through the research, development and commercialization of genomic-based diagnositic tools, clinical laboratory services and innovated new drugs. To that end, the company conducts sophisticated genomic research to develop clinically-validated molecular diagnostics which provide individualized information on response to certain types of therapy, as well as the likelihood of disease occurrence. These diagnostic technologies generate information that healthcare providers and patients can use in making treatment decisions. AUSA R&D has two distinct research departments. The PharmaTherapeutics Group focuses on discovery of new drugs and related modalities; and The Diagnostics Group focuses on development of genomic-based diagnosis tool and service.

AUSA´s management team has extensive experience in a variety of cutting-edge technical fields including the molecular diagnostics, information technology, biotechnology, pharmaceutical and genomic research and industries. Team members have demonstrated continued success in starting businesses, researching and developing novel drugs, launching products, building successful organizations and delivering value to patients.

沈阳三生制药有限责任公司
Shenyang Sunshine Pharmaceutical Co., Ltd.

沈阳三生制药有限责任公司成立于 1993 年，是集研发、生产和销售一体的生物制药企业。

根据 Frost and Sullivan 的资料， 按 2013 年的哺乳动物细胞表达系统的生物药品销售额计，我们在中国排名第一；而按所有生物药品销售额计，我们在中国排名第二。

公司的两款核心产品为特比澳和益比奥。我们的专利产品特比澳，是全球独家的的重组人血小板生成素。益比奥是中国重组人促红素第一品牌，占 43.6% 市场份额。此外，我们还有干扰素、白介素等 9 个优质产品。

公司拥有 20 种在研产品，其中 14 种产品作为国家一类新药开发。肾科方面，有 3 种下一代红细胞生成刺激剂。肿瘤方面，包括三种单克隆抗体。

我们预期于不久将来在美国开始特比澳的一期临床试验。于 2014 年，我们开始于俄罗斯及泰国进行益比奥的多中心生物仿制药临床试验。

我们的产品在国际市场已销售至 20 多个国家，并已在乌克兰、土耳其、巴西、哥伦比亚、埃及、印度尼西亚、伊朗、巴基斯坦等国家获得 GMP 认证。

3SBio is a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products in China.

Our two core products are TPIAO and EPIAO. TPIAO, our proprietary product, is the only rhTPO in the world. EPIAO is the NO.1 rhEPO of China, got a market share of 43.6% by sales in 2013. In addition, we have nine other products in nephrology, oncology and other therapeutic areas.

We have a robust pipeline of 20 product candidates, 14 of which are being developed as National Class I New Drugs in China. We have eight product candidates in nephrology, including three next-generation erythropoiesis-stimulating agents (ESAs).

We expect to start Phase I clinical trials in the United States for TPIAO in the near future. In 2014 we started multi-center biosimilar clinical trials for EPIAO in Russia.

Our international market spread more than 20 countries. GMP approval has been granted by Ukrine, Turkey, Brazil, Colombia, Egypt, Indonesia, Iran, Pakistan, etc.

亚宝药业集团股份有限公司

Yabao Pharmaceutical Group Co., Ltd.

亚宝药业是一家有着 37 年历史的集团公司。集药品和大健康产品的研发、生产、物流、销售和中药材种植于一体，下设 21 个分子公司，有员工近 6000 人，是山西省医药行业首家上市公司和首批认定的高新技术企业。

公司建有 7 大生产基地、3 大研究基地、2 大中药材种植基地。7 大生产基地全部通过国家新版 GMP 认证，其中，北京生物制药通过了美国 FDA cGMP 认证，三分公司通过了欧盟 GMP 认证。

主要产品有中西药制剂、原料药和药用包装材料等共计 300 多个品种，主要为老年慢性病用药和妇女儿童用药，拳头产品丁桂儿脐贴是国家标志性名牌产品。

现有各类营销人员 3000 多人，建立了专业的商务、代理、临床、电子商务、国际贸易营销队伍，销售网点覆盖全国 32 个省市的终端市场。同时，公司还建立了药品配送中心，开展药品配送业务。

公司拥有一支国际化的专业研发队伍，各类研发人员总计 200 余人，其中博士 22 人，硕士 150 人。

在全国 4700 家医药企业中，亚宝药业综合实力排名第 90 名，是工信部认定的“中国医药工业百强企业”。其中，创新力居第 15 名，是“中国医药企业创新力 20 强”。“亚宝”商标为中国驰名商标。

Yabao Pharmaceutical Group Co., Ltd. has a history of 37 years, integrating R&D, production, marketing, logistics and plantation of Chinese herbal medicine with 21 subsidiary companies and about 6000 employees. Yabao is the first listed company among Shanxi Pharmaceutical enterprises and the first batch of new high-tech enterprise.

Yabao owns 7 production bases, 3 R&D bases and 2 Chinese herbal plantation bases. All the 7 production bases has passed the new GMP certification, thereinto, the production line of Beijing Yabao Bio-pharmaceutical Company has passed the FDA certification and No.3 Branch has passed EU GMP certification.

Yabao has more than 300 products in term of Chinese and western medicine, API, and pharmaceutical packaging materials, which are dominated by the medicines for the old age chronic illness and for women and children. Thereinto, “Diarrago”, is a kind of landmark product in China.

Yabao has more than 3000 marketing personnel and has established the marketing teams for professional commerce business, agents, clinic, e-commerce and international trade, with 32 provinces and cities covered by sales network. At the same time, Yabao has established drug distribution center for drug delivery.

Yabao has a internationalized research team with more than 200 research employees; thereinto, there are 22 doctors and 150masters.

Among the 4700 pharmaceutical enterprises, Yabao took the 90th place in term of comprehensive strength, being an accredited “China Hunderd Pharmaceutical Enterprises”. Its innovation strength takes the 15th place and is one of the 20 innovative pharmaceutical enterprises in China. The trade mark of “Yabao” is a famous trademark in China.

常州方圆制药有限公司

Changzhou Fangyuan Pharmaceutical Co., Ltd.

常州方圆制药有限公司其前身是江阴方圆制药有限公司，始创建于 1994 年 4 月，仅为研发代号“8907”（后定名硫酸依替米星）的科技型孵化企业。为形成产业化生产，江阴方圆制药有限公司于 2000 年 4 月迁址常州国家高新技术产业开发区“三药”科技产业基地，更名常州方圆制药有限公司。目前，常州方圆制药有限公司已成为常州市生物医药行业骨干企业，国家重点高新技术企业，江苏省高新技术企业。企业注册资本 5233 万元，资产总额 8.6 亿元。2012 年起，公司年销售收入、上交国家税收和实现利润，均以 30% 以上的比例递增。

常州方圆制药有限公司主导产品是商标名为“创成”的硫酸依替米星。该产品是我国唯一拥有自主知识产权的抗生素类一类新药，为半合成抗生素领域的新一代半合成氨基糖苷类抗生素，具有高效、低毒、抗耐药菌等优点。该产品同时获得中国、英国、美国、俄罗斯、哈萨克斯坦、日本等国家专利，2002 年分别被评为国家科技进步二等奖，江苏省科技进步一等奖。目前，硫酸依替米星产品已拓展到包括原料药、小容量注射剂、冻干粉针剂等，且均被列为国家重点新产品、江苏省高新技术产品、江苏省名牌产品和江苏省优秀新产品。由于产品学术水平和生产工艺达到国际先进水平，2011 年入选“国家十二五重大专项（大品种改造）”。公司已有覆盖全国的医药营销网络。

常州方圆制药有限公司坚持“以人为本”理念，制定政策，鼓励、选拔和引进各类人才；建立“我以服务方圆为责任，我以方圆发展为荣誉”的企业文化，以创新为核心驱动力，通过技术创新、产品创新、商业模式创新和管理创新，融和全体员工，努力将公司发展成为生物医药行业的新锐企业。

Changzhou Fangyuan Pharmaceutical Co., Ltd whose predecessor is Jiangyin Fangyuan Pharmaceutical Co., Ltd was established in April 1994. It was a technical incubate enterprise with its research code “8907” (late named after the Etimicin Sulfate). For industrialization product, Jiangyin Fangyuan Pharmaceutical Co., Ltd moved to Changzhou National Hi-tech Technology Industrial Develop Distinct --“Pesticide, Veterinary medicine and Drug” Technology Industrial base, and changed its name into Changzhou Fangyuan Pharmaceutical Co., Ltd. Now Changzhou Fangyuan Pharmaceutical Co., Ltd is a professional pharmaceutical enterprise in Changzhou, and it’s also the National key high-tech enterprise and Jiangsu Province Hi-tech enterprise. The company’s registered capital is 52.33 million RMB and the total assets is 860 million RMB. Since 2012, our annual sales income, national tax revenue and profits are all increased as 30% proportion.

Changzhou Fangyuan Pharmaceutical Co., Ltd’s leading product—“ChuangCheng” Etimicin Sulfate is the only National-level Class I New Drug of antibiotic with independent intellectual property rights, which is the latest generation of Semi-synthetic aminoglycoside antibiotics. It owns advantages such as high efficiency, low toxicity and anti resistant bacteria. This product has been granted patent in several countries which includes China, US, British, Russia, Kazakhstan and Japan. Etinmicin Sulfate has been awarded the Second Grade Prize of National Advancement in Science and Technology and First Grade Prize of Advancement in Science and Technology of Jiangsu Province in 2002. Now the product model has been expanded to API, small capacity injection and freeze-dries powder injection. All these forms have been listed as the National-level Major New Products, High-tech Products of Jiangsu Province and Excellent New Product of Jiangsu Province. Its academic level as well as the production process has reached the international advanced level, so it was selected by the “ National twelfth five-year major projects” (major variety transformation) in 2011. The company has the medicine marketing network covering the whole country.

Changzhou Fangyuan Pharmaceutical Co., Ltd insists “People First” as the principle, sets up policy to encourage, selects and introduces all kinds of talents; establishes “ To serve Fangyuan as our responsibility, takes Fangyuan”s development as our proud” as culture of the company, takes innovation as the core driving force, with all staff’s efforts, through technical innovation, product innovation, business model innovation and management innovation, making Fangyuan to be the new prominent enterprise of biopharmaceutical industry.

上海东富龙科技股份有限公司

Shanghai Tofflon Science and Technology Co., Ltd.

上海东富龙科技股份有限公司（简称东富龙，Tofflon）是一家为全球制药企业提供冻干制剂、小容量水针注射剂、无菌冻干原料药等自动化制药装备系统的设备与服务供应商。东富龙成立于 1993 年，经过 20 载艰苦奋斗，锐意进取，东富龙已有超过 5000 多台无菌注射剂的关键制药设备（其中超过 3000 台冻干机）、500 多套无菌药品制造系统，服务于全球 30 多个国家和地区的近千家知名制药企业，并已成功进入到西欧、北美等高法规市场，广泛应用于生物制品、疫苗、血制品、抗生素、化学药品、诊断制剂、保健品、兽药、中药西制等领域。2011 年 2 月 1 日，东富龙正式在深圳证券交易所创业板上市（股票名称：东富龙；股票代码：300171）。

今天东富龙聚焦于无菌注射剂核心区域的自动化、隔离化、系统化发展趋势的研究和开发，致力于提供具有全球竞争力的无菌注射剂核心区域的整体解决方案。汇聚全球技术，东富龙在上海总部建立了综合研究所，在美国、欧洲、印度建立全球设计所和技术中心，与美国、欧洲、日本合作伙伴成立合资企业和开展技术合作，拥有具有全球竞争力的五大现代化的制药装备生产基地，拥有中外员工近 2000 名，先后通过了德国 TUV ISO9001、ISO14001、OHSAS 18001、CE、UL、PED、ASME 等国际认证，对接各国制药标准（USFDA / MHRA / WHO / TGA / MCC 等），提供无菌冻干系统解决方案、无菌水针系统解决方案、无菌冻干原料药系统解决方案等，致力于成长为全球无菌注射剂核心区域整体解决方案的主流供应商。

未来东富龙秉承“专业技术服务于制药工业”的使命，聚焦制药工业关注的挑战和压力，从药物创新、制药工艺、核心设备、系统工程方面提供系统整体解决方案，服务于全球制药工业。东富龙致力于从“中国的东富龙成长为世界的东富龙”，从“单一设备供应商成长为系统方案解决者”，发展成为全球制药系统整体解决方案的主流供应商，为实现社会、客户、股东、员工及其家庭幸福的最大化而不懈努力！

Shanghai Tofflon Science and Technology Co., Ltd. (Short for “Tofflon”) is a pharmaceutical equipment and service provider for lyophilized injectables, sterile liquid injectables and sterile lyophilized API of the pharma and biotech industry in the world. Since its foundation in 1993, Tofflon has supplied more than 5000 equipments(including more than 3000 freeze dryers) and 500 systems for nearly 1000 pharmaceutical companies across over 30 countries and regions in the world which have been widely applied in the fields of bio products, vaccine, blood serum, antibiotics, chemicals, diagnostic reagents, healthcare foods, veterinary vaccine and herbs. Among them Tofflon products have been successfully stepping into highly regulated markets like Western Europe and North America. On February 1, 2011, Tofflon grows up to a public company in Shenzhen Stock Exchange (Stock Name: Tofflon; Stock Code: 300171).

Today Tofflon focuses on studying the growing tendency of “Automation, Isolation and Systems Integration” and developing globally competitive and integrated solutions for the critical aseptic process of sterile injectables for the pharma and biotech industry. Taking “Synergy Global Advanced Technologies” strategy, Tofflon builds comprehensive development institute in Shanghai headquarters, is building design houses and technical centers in USA, Europe and India, establishes joint ventures and technology collaboration with the technology partners from USA, Europe and Japan. Furthermore Tofflon has built five modern pharmaceutical equipments manufacturing bases with global competitiveness. It has approved with all the international regulatory certifications like German TUV ISO9001, ISO14001, OHSAS 18001, CE, UL, PED, ASME, etc. Thanks to nearly 2000 Chinese and foreign employees professional works, it can provide freeze drying system solution, sterile liquid injectables integrated solution, sterile API integrated solution to meet all the leading regulatory requirements like USFDA / MHRA / WHO / TGA / MCC, etc. Tofflon aims to grow up to the leading integrated solution provider for the critical aseptic process of sterile injectables for the pharma and biotech industry.

In the future to commit to its mission “Expertise in Pharmaceutical Industry”, Tofflon will continuously work with pharmaceutical industry to face and meet the challenges and pressures in the industry through offering more competitive solutions with its expertise from drug innovation, pharmaceutical technology, core equipments and pharmaceutical engineering. In the following years, Tofflon will dedicate itself to grow from “China Tofflon to Global Tofflon”, from “Equipment Supplier to Solution Provider” so as to grow up to a total solution provider of pharmaceutical manufacturing systems and engineering for the global pharma and biotech industry to contribute to the maximum benefits and welfare of its served society, customers, stockholders, employees and their families.

齐鲁制药有限公司

Qilu Pharmaceutical Co., Ltd.

公司总部位于山东省济南市，是中国大型综合性现代化制药企业，专业从事治疗肿瘤、心脑血管、抗感染、精神系统、神经系统、眼科疾病的制剂及其原料药的研制、生产与销售。现有员工 8000 余人，其中大专学历以上人员占 72.8%。

公司始终坚持创新发展战略，以市场需求为核心，以产品创新为先导，广泛拓展国内外科研开发合作，注重人才的引进与培养，建有一支高素质的科研队伍，具备专业而高效的研发能力，已先后研制成功了近百个国家级新药，为公司未来的发展建立了合理的在研产品线，多项研究被评为国家、省级科技进步奖，并创造了良好的社会效益。

公司建有占地 190 万平方米的制剂、化学合成、生物技术、抗生素发酵等七大生产基地以及现代化的生产车间，全自动生产线和其他主要生产设备及检测仪器均购自于世界主要专业制药设备制造商，抗生素类原料药、头孢类原料药、抗肿瘤类原料药等数个产品已具有国内乃至世界领先的生产能力和生产水平。

做最优质、最安全的产品是齐鲁人坚定的承诺和行动。公司建设了严格规范的质量控制机构和完善的质量保证体系，是首批国家食品药品监督管理局 GMP 认证企业。其中非无菌原料药（发酵、化学合成）、无菌原料药及多种制剂通过了美国、欧盟、澳大利亚、英国、南非以及其它国家和地区药品监管机构的认证。

公司的产品结构科学完整，已上市产品达 160 余种，具有治疗领域广、产品系列化特点。凭借过硬的产品质量、全心全意为客户的服务宗旨，在医药领域树立了齐鲁品牌，拥有遍布全国各大省市，远销欧洲、北美、俄罗斯、南美、东南亚、中东等地的世界级销售网络，以卓越的服务向中国和世界呈现着完全可以信赖的真诚。

Located in Jinan, Qilu Pharmaceutical is one of the leading pharmaceutical companies in China. It focuses on developing, manufacturing and marketing of generic drugs and active pharmaceutical ingredients in the therapeutic areas of Oncology, Cerebrovascular & Cardiovascular, Infections, Psychological and Neurological System, Respiratory System, Ophthalmological Diseases, etc. Qilu has 8000 employees.72.8% of them have junior college or above educational backgroun.

Oriented by market demands, Qilu Pharmaceutical adopts a strategy of innovation & development. The company widely cooperates with domestic and international partners on R&D projects. Qilu enrolled many qualified personnel and have a highly qualified research team. Many projects are awarded State or Provincial Scientific and Technological Progress Award and benefit greatly to the society.

Qilu Pharmaceutical has seven manufacturing sites covering an area over 1,900,000m^2including finished dosage forms, chemical synthesis, genetic-engineering, fermentation, etc. The automatic production lines, key equipment and analytical instruments are imported from major professional vendors. Now Qilu Pharmaceutical is one of the leading global suppliers of Antibiotic APIs and Oncology APIs with huge capacity and good quality.

Thanks to the integrated and stringent system of quality control and quality assurance, the company is a leader of cGMP implementation in China. Its non-sterile APIs (fermentation and chemical synthesis), sterile APIs and comprehensive finished dosages have been respectively approved by USFDA, European Directorate for the Quality of Medicines (EDQM), Therapeutic Goods Administration (TGA) of Australia, Medicines and Healthcare products Regulatory Agency (MHRA) of UK, Medicines Control Council (MCC) of South Africa, and some other national competent authorities.

Qilu Pharmaceutical has an integrated product structure and value chain with over 160 launched products. The company has established a comprehensive domestic and overseas sales network. The global presence has covered North America, Europe, CIS countries, South America, Asia, South Africa and Middle East. The valuable brand of the company has been well built with the quality products and good services.

北京科信必成医药科技发展有限公司

CoSci Med-Tech Co., Ltd.

北京科信必成医药科技发展有限公司总部位于北京中关村国家自主示范区海淀核心区，成立于 2003 年，是一家拥有多项国内外自主知识产权的国家高新技术企业，是“中关村国家自主创新示范区创新型企业”，全国企事业知识产权试点单位，国家技术转移示范机构，北京市专利示范单位，中关村 20 周年突出贡献企业，2010 年 ~2012 年连续三年获得德勤高科技、高成长中国 50 强及亚太 500 强。

科信必成先后承担了国家“十一五”、“十二五”重大新药创制项目，多项国际化合作项目列入中关村科技园区海淀园专项发展资金。研发中心建立可达到 FDA、EMA 药物制剂标准的化学药物速释、缓释、控释口服固体制剂技术平台。开发品种涵盖心脑血管、呼吸系统、神经系统、退行性疾病、解热镇痛等多个领域，在每个领域均有系列产品满足不同治疗时期的需求。科信必成拥有 13 项具有独立自主知识产权可产业化的围绕控缓释共性关键技术平台，主要包括渗透泵控释片给药系统技术、群控释放渗透泵控释片技术、固体分散物工业化制备技术、醋酸纤维素水分散体微囊包合技术、水为润湿剂制备凝胶骨架片技术、蜡质骨架材料双层缓释片制备技术等，截至目前申请药物制剂国家发明专利 140 项，获得 71 项授权；申请国际 PCT 专利 6 项，1 项已获得美国和欧洲 13 国授权。

科信必成是专注于口服固体制剂产业化的药品研发机构，已为国内 50 多家制药企业提供服务，其中包括 38 家上市公司以及 2012 工信部医药工业企业百强榜前 100 强中的 20 家。近年公司加大与国际制药企业的合作力度，将最先进的创新理念和制剂技术引进，并消化吸收再创新，推进国内制药技术研发与工业化水平的进步，从而真正的打造具有国际先进水平的药物制剂技术平台，实现口服药物速、缓、控释等制剂技术和产品达到国际水平，助推中国医药产业实现国际化。

CoSci Med-Tech Co.,Ltd. is an technology driven innovative pharmaceutical service enterprise located in Beijing Zhongguancun Science and Technology Park. Its focus is the R&D and industrialization of oral solid modified-release formulations, with its own patented innovative Drug Delivery Technologies.

During the last 12 successful business years, CoSci has filed 140 patent applications and granted 71 by the Chinese Office of Intellectual Properties.

We've also filed 6 international PCT applications and 1 was approved by EU Office and US office.

CoSci's 13 technology platforms:

Milti-Porous Osmotic Pump Controlled-Release Tablet

Complete Dissolution of Drug Content From Osmotic Pump Formulations

Enteric-Coated Pellet

Tablet Matrix Using Water as Wetting-Agent

Double-Layer Wex-based Matrix

Sustained-Release Pellet

Industrial Production of Solid Dispersions

Microencapsulation of Cellulose Acetate Dispersables

Extended-Release Drug Delivery System

Oral Dipersable Pellets

Mirco-Teblet

Colon-Release Formulations

Multi-Unit Sustained-&Controlled-Release Formulations (Mirco-Pellet Compression)

were positively assessed by domestic and global partners. Well accepted is also the philosophy of CoSci: we realize products rather than technology, which lead to marketing value of our partners. Currently we have 118 valuable products in our pipeline.

上海中信国健药业股份有限公司

Shanghai CP Guojian Pharmaceutical Co., Ltd.

上海中信国健药业股份有限公司（以下简称“中信国健”）是由中国中信集团有限公司旗下中国中信股份有限公司（原“中信泰富有限公司”）投资控股的生物医药高新技术企业。公司自 2002 年创建以来，专注于抗体药物的研发、中试和产业化，现已发展成为国内抗体制药领域的领军企业，提供覆盖治疗肿瘤、自身免疫性疾病、抗器官移植排斥反应等重大疾病领域的靶向药物。

作为一家以研发为基础的生物制药公司，中信国健已成功构建了抗体药物开发和产业化平台并掌握核心技术，具备持续开发新药的创新能力。公司生产规模位居行业前列，产品在国内抗风湿生物制剂市场占有率稳居首位。

Shanghai CP Guojian Pharmaceutical Co., Ltd. (CPGJ) is a biopharmaceutical company invested and controlled by China International Trust and Investment Corporation(CITIC Limited). Since established in 2002, CPGJ has committed to the R&D, pilot scale development, industrialization and commercialization of antibody drugs. It has grown into a leading company in China's antibody sector that provides targeted drugs for cancer, autoimmune diseases and organ transplantation immunosuppression treatment.

As an R&D-based biopharmaceutical company, CPGJ has successfully developed its core technologies to continuously develop and commercialize new biologics therapies. CPGJ's antibody manufacturing capacity is among the largest in the industry.

深圳微芯生物科技有限责任公司

Shenzhen Chipscreen Biosciences, Ltd.

微芯生物是由资深留美归国团队创立于 2001 年的生物医药领域的领军企业，专长于原创小分子药物研发，具备完整的从药物作用靶点研究到临床候选药物开发及产业化的能力，拥有一支专长于原创新药研发的技术、管理和知识产权队伍。微芯生物以自主创建的“基于化学基因组学的集成式药物发现及早期评价平台”为其核心竞争力，以“原创、安全、优效”为其目标，致力于为患者提供可承受的创新机制治疗药物。在开发针对重大疾病、有全球专利保护及临床效果独特的创新小分子药物等方面均取得了多项突破性进展。微芯生物也是国家重大科技专项的首批“创新药孵化基地”，独立承担了多项国家“863”和重大新药创制科技专项项目， 2013 年荣获国家科学技术进步奖一等奖。

Chipscreen is a leading integrated biotech company specialized in discovery and development of novel small molecule pharmaceuticals. The company has utilized its proprietary chemical genomics-based discovery platform to successfully develop a portfolio of commercial, clinical and preclinical stage programs in a number of therapeutic areas including oncology, metabolic disease and autoimmune/inflammatory diseases. Our core competence is the science-driven approach in discovery, strong pipeline building capability, experience with IP, and regulatory expertise.

Chipscreen's business strategy is to generate differentiated drug candidates across multiple therapeutic areas. Drug candidates are either developed by Chipscreen or co-developed and commercialized in a partnership at the research, preclinical and clinical stages.

Chipscreen was established as Sino-foreign joint venture in 2001 by several highly regarded Chinese returnees from the United States with academic, scientific, and industrial experience. Our founders established our company out of a common vision to create the leading drug discovery and development firms, and to provide affordable innovative pharmaceuticals in China.

青岛黄海制药有限责任公司

Qingdao Huanghai Pharmaceutical Co., Ltd.

青岛黄海制药有限责任公司是中国研发、生产、销售缓控释制剂的高新技术企业。历经医药改革大潮的洗礼，现拥有全资子公司两家，参股公司四家，形成了以医药制剂生产为主业，向上覆盖药用原辅料生产，向下涵盖药品物流配送的综合性医药产业格局。

公司以打造中国缓控释制剂领军企业为战略目标，以抗肿瘤药物、心脑血管用药、内分泌用药、神经类疾病用药为产业重心，产品涵盖片剂、胶囊剂、口服液体制剂、颗粒剂、小容量注射剂等 100 多个品种规格。主要产品有伲福达、伲利安、畅欣达、麦特美、元顺、复方甘草口服溶液等。其中，伲福达连续多年在全国同类品种中的产销量排名中名列第一，被多次认定为“山东名牌产品”，“伲福达”商标属中国驰名商标，是国内硝苯地平类降压药中唯一获此殊荣的产品，具有极高的社会美誉度。

公司建立了完善的生产质量管理体系，2012 年一次性通过口服制剂新版 GMP 认证，产品质量名列前茅。公司以缓控释技术为核心，是国内缓控释制剂的生产基地。公司积极与国内外一流的医学院校、研发机构合作，装备有国际先进水平的研发设备和检验仪器，研发实力雄厚。公司营销以学术服务为主要特色，营销网络遍布全国各地。

公司先后荣获“国家 AAA 级信誉企业”、“中国医药制造业纳税百强企业”、“中国化学制药行业工业企业综合实力百强企业”、“山东省医药行业最具实力企业”等荣誉称号。公司秉承“真诚、务实、专业、责任”的企业文化，不断完善，不断进取，在“呵护生命每一天”的品牌理念指引下，为人民大众的生命健康而不懈努力。

Qingdao Huanghai Pharmaceutical Co., Ltd is a R&D based high-tech enterprise; focus on the discovery, development, manufacture and marketing of sustained and controlled release drugs. After the reform, it has two wholly-owned subsidiaries, four shareholding companies, covering not only pharmaceutical preparations, but also the upstream and downstream, including API and excipient supply, drug logistic and distribution. The company has set up a comprehensive whole industry chain management pattern.

Leading in China sustained and controlled-release preparation technology is the company strategic goal. The enterprise architecture rests on four pillars, which are four therapeutic areas, cardio-cerebral vascular, endocrine, neurology and oncology. The products cover a wide range, more than 100 varieties including granules, small volume injections, tablets, capsules, oral solutions etc., and main branded products include Nifedipine (Nifedipine Sustained-release Tablets II), Nilian (Candesartan Cilexetil Capsules),Changxinda (Isosorbide Dinitrate Sustained-release Tablets), Metformi(Metformin Hydrochloride Sustained-release Tablet) , Yuanshun (Paracetamol,Caffeine, Pseudoephedrine Hydrochloride and Chlorphenamine Maleate Capsules), and Compound Glycyrrhiza Oral Solution, etc.. Among these products, Nifuda production and sales are ranked No. 1 in the country for many years. It has been repeatedly identified as "Shandong Famous Brand". "Nifedipine" is the only one in nifedipine category awarded Chinese well-known trademark with high social reputation.

The company established an advanced production quality management system, which passed oral preparation new GMP certification in 2012. The products are of high quality and reliable. The sustained and controled-release preparation technology is company's core competitiveness, QingDaoHuangHai is the production base of sustained and controled-release preparation technology. The company has been collaborating with domestic first-class medical institutions, research institutions. The advanced R&D equipment and testing equipment help to strengthen the R&D capability. The sales and marketing of company products is based on academic services, building a sales network throughout the country.

The company has been honored as "national AAA credit enterprise", "Chinese medicine manufacturing tax hundred enterprises", "Chinese industrial enterprises in the chemical and pharmaceutical industry, the overall strength of hundred enterprises", "Shandong Province pharmaceutical industry's most powerful enterprise". Sincere, Pragmatic, Professional and Responsible are the key of company culture. Qingdao Huanghai will continuously improve its products and services through continuous innovation to contribute to life and healthcare. "Caring For Life every day " is not only brand philosophy, but also the actions.

江苏豪森医药集团有限公司

Jiangsu Hansoh Pharmaceutical Group

江苏豪森医药集团有限公司，成立于 1995 年，经过 19 年的持续稳健的发展，已成为集化学、生物药物研究，医药中间体、原料药合成，制剂生产和产品销售于一体的现代化创新型医药集团。豪森连续多年位居“全国医药工业百强”前 30 强，“中国创新力十强医药企业”前 3 强。豪森被国家工信部、财政部认定为“国家技术创新示范企业”。

从美国新泽西、上海到连云港，豪森建立了完整的药物研发体系。3 万平米的研发中心、近千人的专业技术人员、上千台国际先进的研发设备和检测仪器、每年数亿元的研发投入，豪森已成为行业内技术集聚、人才集聚、资金集聚的研发高地！

在抗肿瘤、精神、糖尿病、心血管等 6 大疾病领域，豪森已有近 50 个品种正在服务于患者。盐酸吉西他滨荣获国家科技进步二等奖；近 20 个研发项目列入国家“重大新药创制”科技重大专项。历经十多年的研发，两个自主创新药物吗啉硝唑和甲磺酸氟马替尼将率先投放市场，还有 10 多个 1.1 类创新药物正在进行临床研究。

药品质量事关患者的生命安全。豪森坚持“全员、全过程、持续改进”的质量方针，以“质量源于设计”等先进理念为引导，建立了从研发、生产至销售全过程的质量管控体系。

豪森的所有产品已全部通过新版 GMP 认证，抗肿瘤注射剂率先通过美国 FDA 认证，这是世界对豪森品质的肯定。

面向未来，豪森将以创新为发展的主旋律，在产业高端构建研发优势、品质优势、人才和管理优势，做响豪森品牌，做优民族医药，做强中国创造！

Jiangsu Hansoh Pharmaceutical Group, established in 1995, through 19 years of sustained and steady development, has grown into a modern innovative pharmaceutical group covering chemical & biological drug research, pharmaceutical intermediates & active pharmaceutical ingredients synthesis, finished dosage formulation manufacturing and sales. Hansoh ranked among Top 30 in 100 of National Pharmaceutical Industry and Top 3 in 10 Innovative Pharmaceutical Enterprises in China for many years. Additionally, Hansoh is awarded National Technology Innovation Model Company by National Ministry of Industry and Information Technology and National Ministry of Finance.

Hansoh has a complete R&D system for drugs, with the R&D centers located in New Jersey of U.S.A., Shanghai and Lianyungang. With 30,000 square meters of R&D center, nearly 1000 professional technical personnel, thousands of international advanced R&D equipments and testing instruments, and hundreds of millions of R&D investment every year, Hansoh has become an R&D highland attracting technology, talents and capital in the pharmaceutical industry.

Nearly 50 kinds of products, covering six major disease fields, such as Oncology, Psychotropic, Diabetic and Cardiovascular, Hansoh's products are serving patients in need. Among them, one product named Gemcitabine HCl, was granted the second prize of National Scientific and Technological Progress, and nearly twenty R&D projects are listed in Major New Drug Discovery and Manufacture of National Major Scientific Special Project. Through more than ten years research and development, two innovative drugs, which are developed and researched by Hansoh independently, named Morinidazole and Flumatinib Mesylate will take the first lead and be launched on the market. Besides, over 10 Class 1.1 drugs are under clinical research.

Quality of a drug is connected to the safety of patients' lives. Sticking to the quality policy of “All staff, The whole process, Continuous Improvement”, and lead by the advanced concept of “Quality by Design”, Hansoh has established the quality control system covering the whole area from R&D, manufacture to sale.

All the products of Hansoh have been granted with new GMP certificates, and the anticancer injectables have been approved by US FDA ahead of the peers, which to some certain extent, is the global affirmation to Hansoh's product quality.

Confronted with the future, Hansoh will still prioritize innovation, trying to build superiority in R&D, quality, talents and management. Standing at the high-point of the pharmaceutical industry, we firmly believe Hansoh people will further promote their brand and strengthening China creation.

深圳信立泰药业股份有限公司

Shenzhen Salubris Pharmaceuticals Co., Ltd.

深圳信立泰药业股份有限公司是集高端处方药、介入医疗器械等生物医药产品研发、生产、销售于一体的综合性医药上市集团，精耕于心血管、介入医疗器械等高端领域。公司成立于 1998 年 11 月，于 2009 年 9 月在深圳证券交易所上市。十余年来，公司锐意进取，诚信经营，在技术创新、品牌建设、经营业绩、社会效益、行业口碑等方面得到全面提升。

Salubris, the leader in China's CV sector , is an integrated pharmaceutical company engaging in R&D , manufacturing and distribution of innovative , branded generics and advanced medical devices .

Shenzhen Salubris Pharmaceuticals Co., Ltd. was founded in November 1998. In September 2009, the company was successfully listed in Shenzhen Stock Exchange.

Over the last 10 years, the company forges ahead, honest operates. In the aspects of technology innovation, brand construction, business achievement, social efficiency and industrial reputation are entirely progress forwarded.

信达生物制药（苏州）有限公司

Innovent Biologics (Suzhou) Co., Ltd.

信达生物制药 (苏州) 有限公司成立于 2011 年 8 月 , 由中组部“千人计划”国家特聘专家俞德超博士等在苏州工业园区创立，致力于开发用于治疗危及人类健康和生命的各种疑难疾病的抗体新药以满足国内外医药市场的巨大需求，并建造国内规模最大、符合国际标准的产业化基地，为国内广大生物制药公司提供高质量、高标准的服务。至 2015 年，公司引入了国内外知名创投基金（包括美国富达集团、美国礼来基金、新加坡淡马锡、联想控股和苏州创业投资集团创投），成功完成了 2.75 亿美元的投资，公司注册资本 3204.8644 万美元。

信达的目标是做中国最好、国际一流的高端生物制药公司，研究开发、生产中国老百姓用得起的高端生物药。公司现已建成一条包括 10 个新药品种的产品链，适应症覆盖肿瘤、眼底病、糖尿病、自身免疫疾病等领域。产品链中具有全球自主知识产权的创新药物共 7 个。已成功递交 7 项临床试验申请，获得 1 项临床研究批件。产业化基地总投资 27 亿元，建筑面积 9.3 万平方米，包括 2 条 1,000L、6 条 15,000L 产业化生产线，符合 CFDA、FDA 和 EMA 的 GMP 标准，设计年产蛋白药 1600 公斤，年产值 230 亿元。目前基地基建工程已经完成，1000L 生产线已经完成设备安装，正在进入试生产。

2015 年 3 月，信达生物成功与全球 500 强公司——美国礼来制药达成国际战略合作，此次合作共涉及 3 个单克隆抗体新药，获得首付及里程碑付款等 140 亿元。这是迄今为止中国生物医药领域金额最大的国际合作，是第一个中国企业将自主创新生物药的国际市场成功授权给全球 500 强企业，也是第一个中国企业与全球 500 强企业达成的在高端生物药开发方面从研发、注册、生产到销售的全面合作。这项合作表明信达生物制药现有的技术、平台以及创新能力和创新成果得到了国际认可。这项合作的达成，有望使国产高端生物药走出国门，走进发达国家市场，并开创中国生物医药企业发展新的模式，将促进江苏省生物医药产业的发展。基于信达生物对创新发展及创新合作方面作出的贡献，2015 年 6 月，信达生物制药作为唯一一家中国优秀创新型企业，应邀参加了在美国国务院召开的“第六次中美创新对话”，董事长俞德超在大会上发表了演讲。

信达生物制药已与国内外多家知名高校、科研院所和生物公司建立合作，共同进行抗体药物技术开发，支撑技术服务平台的建设。其中，信达与四川大学合作共建“信达 - 川大生物技术药物研发中心”，并与湖北大学、中山大学、美国佛罗里达大学、韩国汉阳大学等建立产学研合作。此外，信达生物制药与美国 Adimab 公司和 Aragen 公司建立了战略合作关系。

信达生物制药组建了一支具有国际先进水平的高端生物药开发、产业化人才团队，团队成员已达 250 多人，核心成员包括俞德超、孙左宇、刘晓林、关灼铭、林巧、余彩玲、Scott Wheelwright 等 22 位国内外技术专家。其中公司创始人俞德超博士是世界上第一个上市的溶瘤免疫治疗药物“安柯瑞”(Oncorine) 和中国第一个拥有全球知识产权的单克隆抗体新药“康柏西普”(Conbercept) 的发明者和主要开发者，是目前国内唯一一位发明并开发上市两个国家 1 类新药的科学家，拥有 61 项发明专利 (38 项为美国专利)。信达核心管理团队的技术和水平得到了各级政府的认可和支持，获得了中组部“千人计划”、“江苏省创新团队 (现代服务业)”、“江苏省高层次创新创业人才”、“姑苏创新创业领军人才”和“苏州工业园区科技领军人才”等多项荣誉。俞德超当选 2013 年“国家生物医学领域最具影响力的海归人才”、2014 年“创新中国十大年度人物”。

Innovent Biologics is a leading biopharmaceutical company in China. Innovent was founded on the principle that patients in China deserve the highest quality of products developed worldwide, but at affordable local prices.

From the beginning, Innovent has worked to bring highly complex drugs to the Chinese populace. These drugs require demanding technical skill to manufacture, and are mostly under-represented in China compared to the worldwide market place.

These drugs also require sophisticated manufacturing facilities to prepare them safely. Innovent has always maintained a single quality standard, which is to meet the highest worldwide standard, the same standard embraced by all large multinational corporations that have products in the US and Europe. Our patients in China will receive this same level of quality as those in the US and Europe.

Innovent is very cost conscious, which is how we will bring these products to market in China at a price our patients can afford. We are building our manufacturing plant in China with Chinese workers according to a design by architects and engineers with international experience. We are also building to a scale that enables us to enter economies that others can not achieve. We can do this because we work with external partners to manufacture their products. Thus, our products will be manufactured at the international quality standard but at a lower cost than that could be achieved in Western countries.

华领医药技术（上海）有限公司

Hua Medicine (Shanghai) Ltd.

华领医药技术（上海）有限公司是中国新药研发创新的领军企业，目前专注于 2 型糖尿病和神经退变性疾病的个性化治疗创新药物研究。这家由国际顶尖的医药研发专家和投资团队创办的公司目前拥有两个创新药物的国际开发权。其中，全球首创口服 2 型糖尿病药物即将正式启动 II 期临床研究。同时公司正在针对一个已知多适应症中枢神经靶点进行先导化合物研究，该适应症包括抑郁症和帕金森疾病相关的异动症。华领医药以先进的 " 中西合璧、联合创新 " 的运营模式，充分利用中国的人才优势和高质量的药物研发能力，在中国开发适合患者需求的创新药品。通过这些努力，华领医药必将促进中国的医药研发创新进入新的阶段，从而成为全球的创新中心。

Hua Medicine (Shanghai) Ltd. is a leading, innovative drug development company in China focused on novel therapies for the treatment of diabetes and CNS disorders. Founded by an experienced group of entrepreneurs and international investment firms, Hua currently has world-wide rights to two novel assets. The most advanced program is a first-in-class, oral drug for the treatment of Type 2 Diabetes that will shortly initiate Phase 2 trials in China. The company has also internally developed earlier-stage compounds focused on a highly validated CNS target for multiple indications including Parkinson's Disease associated dyskinesia and Depressive Disorder. Hua's strategy is to leverage the cost-efficient and high-quality drug discovery capabilities available in China, while partnering or licensing the most promising drug assets from the US and abroad. Through these efforts, Hua intends to be the driving force behind China's evolution into a global innovation center for drug development.

歌礼生物科技（杭州）有限公司

Ascletis Bioscience Co., Ltd.

歌礼是一家由海归团队创立的创新型医药企业。歌礼立足中国，面向世界，致力于癌症和传染性疾病领域创新药物的研发、生产和销售，为中国患者提供最佳的、有自主知识产权的创新药物，满足他们的医疗需求。歌礼生产基地位于浙江绍兴滨海新城，占地 23 亩，建筑面积 1.8 万平方米，规划建设固体制剂车间、原料药车间、检验中心及相应配套设施等，用于公司创新药物的生产。

歌礼通过自主开发和战略合作，开发、引进最优秀、最适合中国市场的一流产品和技术，充分利用中国现有的研发能力和资源，进行临床中晚期开发，以中国患者可以承受的价格将领先的创新药物推向市场。截至目前，歌礼共拥有四个临床阶段的 1.1 类候选药物：丙型肝炎病毒（HCV）NS3/4A 抑制剂 ASC08；HCV NS5A 抑制剂 ASC16；RNAi 靶向治疗肝癌药物 ASC06；HIV 蛋白酶抑制剂 ASC09。

慢性病毒性丙型肝炎（丙肝）是歌礼当前的重点研究领域。以 ASC08 和 ASC16 等直接抗病毒药物（DAA）为核心，歌礼为中国患者提供了三联疗法和全口服免干扰素疗法等两个完全与国际临床前沿接轨的丙肝治疗方案，并形成不同产品梯次，为中国 4000 万丙肝患者提供更多、更佳的治疗选择。

歌礼核心产品 ASC08 已在欧美和台湾地区完成了 34 个临床试验，受试者高达 2400 人。2015 年年初在台湾完成的二期临床试验表明，以 ASC08 为核心组成的三联疗法对占中国丙肝患者总数 57% 的基因 1b 型患者治愈率达到 100%。该临床研究报告已在第 24 届亚太肝病学会学术年会上正式发布并获大会主席特邀主题报告荣誉。

在推进现有各项产品的开发和上市的同时，给病人带来突破性新药的承诺也推动歌礼不断探索外部的合作机会。在相继与罗氏、杨森等国际药业巨头建立广泛的战略合作关系之后，歌礼将继续在全球范围内寻找处在不同开发阶段的创新产品，以灵活、开放的合作心态和形式，与国内外同行建立合作，加快研发出新型和有效的产品交付到中国以及全球市场。

Ascletis is an emerging biotechnology company, dedicated to discovering, developing and commercializing important new treatments for infectious diseases and cancer. Ascletis' GMP commercial manufacturing facility is located in BinHai New City, ShaoXing, Zhejiang. The 18,000 m2 state-of-art facility houses various modules such as formulation, active pharmaceutical ingredient (API), QA/QC etc.

To date Ascletis has four clinical stage drug candidates in its product pipeline: ASC08, a phase IIb HCV protease inhibitor partnered with Roche; ASC16, a phase IIa HCV NS5A inhibitor licensed from Presidio Pharmaceuticals; ASC06, a clinical stage, first-in-class, systemically delivered RNAi therapeutic for the treatment of liver cancers licensed from Alnylam Pharmaceuticals; and ASC09, a next-generation HIV protease inhibitor licensed from Janssen, a pharmaceutical company of Johnson & Johnson.

Chronic hepatitis C (CHC) is currently the primary disease focus of Ascletis. With its two direct-acting antiviral agents (DAA), ASC08 and ASC16, Ascletis provides two regimens for 40 million CHC patients in China, an interferon (IFN)-containing triple therapy and an all-oral IFN-free therapy. Both of the regimens offer comparable efficacy and safety profiles to the current leading regimens for HCV treatments in USA.

Ascletis' lead product, ASC08, also known as Danoprevir, is a second-generation HCV NS3/4A protease inhibitor. It has been evaluated in 27 phase I and 7 phase II clinical trials with a total of approximately 2400 healthy volunteers and patients tested. DAPSANG (Phase II Study) results show that after 12-week treatment of ASC08 in combination with PEG-IFN and ribavirin, the cure (SVR12) rate observed in genotype 1 non-cirrhotic patients in Taiwan was 94% and in genotype 1b non-cirrhotic patients in Taiwan the SVR12 rate was 100%. DAPSANG results were presented at the 2015 annual meeting of the Asian Pacific Association for the Study of Liver and received one of the event's top honors, known as the Choices of President Awards.

While conducting drug development for existing drug candidates, Ascletis is engaged in a continued globally search for innovative medicines at various stages of development, with a clear goal to accelerate the delivery of novel and effective products to the China marketplace as well as markets worldwide.

江苏亚盛医药开发有限公司

Ascentage Pharma Group Corp Limited

亚盛医药专注于原创药物研发，有多年原创小分子靶向抗肿瘤药物研发经验和成功记录。公司主要瞄准国际新型小分子靶向抗肿瘤药物研发热点及发展趋势，设计、筛选、评价、优化与研发具有自主知识产权的系列原创小分子靶向抗肿瘤药物，填补国内该类技术研究及市场产品空白，并进军国际高端医药市场。亚盛医药在基于靶向蛋白结构的药物设计与优化领域形成了多项核心技术，拥有四十多项国际发明专利，已成功开发近 10 项原创小分子靶向抗肿瘤药物进入临床前或不同阶段国际临床研究，所有在研项目均为新化合物结构的原创 1.1 类新药。

亚盛医药专注于已为临床验证的癌症靶点，其研发产品管线主要细胞凋亡路径关键蛋白的抑制剂，通过抑制 BCL-2/ Bcl-xL，IAP 和 MDM2-p53 等，重启肿瘤细胞的凋亡程序；第二代和第三代的针对癌症治疗中出现的激酶突变体的抑制剂；与肿瘤治疗的有密切相关性的表观遗传学靶点的抑制剂等。

公司现有研究人员 60 多人，其中中组部“千人计划”国家特聘专家入选者 3 人，具有多年海外原创药物研发经验高层次人才 7 人，硕士及博士人数占公司总人数一半以上，拥有高级职称人员 10 多人。

Ascentage Pharma is a China-based, global-oriented, clinical-stage biopharmaceutical company, dedicated to discovery and development of the “first-in-class” and the “best-in-class” targeted small-molecule cancer therapeutics. A rich portfolio of innovative small-molecule agents has been discovered and developed through the company's unique, robust, and world-class innovative drug development pipeline. Currently, Ascentage Pharma has three molecules in phase I-II trials in US, Australia and China, and another four molecules at IND reviewing or IND-enabling stages.

Ascentage Pharma focuses on clinically validated cancer targets. Its established R&D platforms include: inhibitors to a number of key proteins, including Bcl-2/Bcl-xL, IAP and MDM2-p53, that restore a tumor cell's apoptotic program; 2nd and 3rd generation of kinases inhibitors that overcome mutants resistance issues in cancer patients; inhibitors to epigenetic targets with enormous potential in oncology therapy.

Each of Ascentage Pharma's co-founders, Dr. Dajun Yang, Dr. Ming Guo and Dr. Shaomeng Wang, has over 20-year new drug R&D experience in the US and in China. The company has established a successful R&D model in targeted therapeutic area, with more than 50 PCT patents and patent applications. Ascentage Pharma's team is well trained to international standard, with proven track record in lead optimization, clinical candidate selection as well as IND filing and clinical development with both FDA and CFDA. Ascentage Pharma has built a talented and experienced team covering the entire drug discovery and development process, including Medicinal Chemistry, Analytical and Formulation, Pharmaceutical Sciences, Process Development, Biological Sciences, Regulatory and Compliance, Preclinical Studies and Clinical Development Departments.

再鼎医药（上海）有限公司
ZAI Lab (Shanghai) Co., Ltd.

再鼎医药（上海）有限公司是一家立足中国，专注于研发新型药物的生物科技公司。公司目前正在为延长患者的生命建立一套完整的治疗产品梯队。再鼎主要是着眼于中国本地市场，并期望该产品梯队能使全球市场都受益。再鼎医药有一支在制药和生物科技管理方面都经验丰富的一流团队。该团队不仅成绩显著，在中国他们曾成功地将五种新型药物推进了临床试验阶段，他们不仅开拓了新的监管渠道，在最短时间内数次通过监管部门的审批，在美国多次主持临床试验，并且首次成功地将由中国研发的药物推进到了三期临床试验阶段。再鼎医药致力于成为国际化的医药研发领军人物，秉承一流的团队合作精神，专注于培养自己的创新力和创造力。

ZAI Lab is a leading biotech company based in China focused on discovering and developing innovative medicines for unmet medical needs globally. The company is building a strong portfolio of therapeutic programs aimed at transforming patients' lives. Zai Lab has a world class leadership team with deep experience at global pharmaceutical and biotech organizations. The team has a strong track record of success – successfully taken five novel drug candidates into clinical trials in China, pioneered new regulatory channels, secured regulatory approvals in record times, conducted multiple IND trials in the US, and brought the first China discovered drug into Global Phase III trials. Zai Lab is committed to build a globally leading drug research and development powerhouse with a culture of excellence and teamwork and a strong focus on fostering innovation and creativity.

方恩（天津）医药发展有限公司
Fountain Medical Development Ltd.

方恩（天津）医药发展有限公司是一家能够提供全方位与国际标准接轨的临床开发服务的 CRO（合同研究组织）公司。方恩以天津为中心分别在美国宾州、北京、上海、南京、广州、成都、香港、台湾及韩国建立了分支机构。方恩现有员工 400 多位，中国大陆的临床运营团队分布在全国 25 个城市，目前还在不断的发展壮大中，致力于为国内外生物制药或医疗器械客户提供高质量低成本的全方位的临床研究服务。

方恩自成立以来，参与并承担了“十一、五”及“十二、五”重大新药创制项目，通过了国内外大中型制药企业的数十次稽查，为许多国内外领先的医药企业及全球一些非盈利机构和一些新兴的生物医药公司提供临床研究服务。至今为止，方恩已支持提交国内外 14 个新药证书并有 8 个已经批准；承接了 200 多项临床试验项目包括多个治疗领域下的入组 10000 例的上市后研究；与亚洲 300 多家临床试验机构保持着良好的合作关系；目前已经为分布于中国大陆、香港、台湾和韩国的各阶段临床试验入组了近 60000 例受试者。

相信丰富的临床经验、对合作需求的敏锐触觉、顺应合作伙伴需求及对细节的专注性将成为方恩成功发展的基石。

Fountain Medical Development Ltd. (FMD) is a Contract Research Organization (CRO) offering a full range of ICH GCP compliant clinical research services,these services target multinational pharmaceutical and medical device companies looking to establish their medical product(s) in the US, Europe, and parts of East Asia (including China, Hong Kong, Taiwan, and South Korea).Our extensive global experience in multiple therapeutic areas, is comprehensive and transcends other local and global CRO's.

Our competitive costs and rich clinical experience allow us to pass significant savings onto our clients. Our extensive clinical experience and high sensitivity for cooperation not only satisfies the detail oriented requirements of our partners, but also establishes a solid foundation for FMD to thrive. In the course of our steady growth and expansion, we have successfully completed more than 200 clinical trial projects and enrolled more than 60,000 patients in clinical trials; in addition, we have maintained stable partnerships with more than 300 sites in Asia. As a global CRO, FMD has completed many pivotal international studies, the results of which can be used in FDA and EMA applications, ensuring that FMD is your trustworthy CRO of choice.

药明康德新药开发有限公司

WuXi AppTec Co., Ltd.

药明康德新药开发有限公司于 2000 年 12 月成立，总部位于上海外高桥保税区，是全球领先的制药、生物技术以及医疗器械研发服务平台公司，在中美两国均有运营实体，面向全球制药公司、生物技术公司以及医疗器械公司提供一系列全方位的实验室研发和研究生产服务，服务范围贯穿从药物发现到推向市场的全过程。药明康德的服务旨在通过高性价比、高效率的服务帮助全球客户缩短药物及医疗器械研发周期、降低研发成本。

自成立以来，药明康德始终保持高速增长势头。2007 年 8 月，成功在美国纽交所上市（NYSE: WX），成为中国首家海外上市的研发服务企业；随后收购美国 AppTec 实验室公司，进入大分子和医疗器械领域。目前，药明康德已发展成为中国规模最大，全球排名第五的 CRO 企业，在全球共拥有超过 10000 名员工，研发团队 7000 余人；在全球 21 座城市拥有大规模的研发生产基地和办事处，已有及在建研发设施总面积达 46 万平方米；客户 3000 余家，囊括全球排名前 20 位的大型制药公司和排名前 10 的生物技术公司；2014 年度集团服务收入超过 6.7 亿美元，继续在业内居于绝对领跑地位。

十多年来，药明康德成功打造了一个开放式、全方位、一体化的研发服务技术平台，凭借公司在发现化学合成领域的雄厚实力实现了全面发展。近几年来，药明康德又新增了一系列服务，包括分析服务、生物分析服务、工艺研究、工艺研发服务、API 生产服务、药物代谢及其动力学服务、研发生物学、药理学、制剂、毒理学、基因组服务、生物制剂生产服务、抗体及生物诊断试剂的生产和销售服务以及临床研发和产品注册服务等。

几经寒暑，“药明康德”已成为全球新药研发服务领域的知名品牌，在技术水平、服务质量、知识产权保护等方面均得到了客户的广泛认可，与全球 3000 多家客户建立了长期的研发合作伙伴关系，并获得来自默克、礼来、巴斯夫等诸多客户的肯定与嘉奖。

药明康德的高速增长获得了国内外的高度关注，公司连续六年荣膺“Deloitte 亚太地区高科技高成长 500 强”，连续五年入选“Deloitte 中国地区高科技高成长 50 强”，并且被《快速公司》杂志评选为“世界最具创新力企业年度 50 强”。

药明康德的创新产业模式和研发服务能力也得到了政府的高度认可。2007 年，公司获得科技部批准建设“药物先导化合物研究国家重点实验室”，进入首批企业国家重点实验室的建设行列；2011 年被国家科技部认定为“国家级创新型企业”；2007-2014 年连续八年入选国家商务部评选的“中国十大服务外包领军企业”。

药明康德以及“药明康德模式”的崛起，正逐渐影响着中国的新药研发服务产业，北京、上海、苏州等大中城市，新药研发服务企业像雨后春笋般涌现；新药研发服务行业的崛起，改变了国际上中国新药研发“只有仿制、不会创新”的片面认识，积累了中国药企的自主创新能力，树立了中国新药研发的国际品牌。

从最初的 4 位创始人，到现在的 10000 多名员工；从单一合成服务，到全方位一体化的医药研发服务；从外高桥研发基地起步，到现在横跨中美两国，药明康德前进的脚步从未停歇。本着“变革新药研发，造福人类健康”的理想，药明康德将继续致力打造并完善其开放式、全方位、一体化研发服务技术平台，帮助任何人、任何公司更快、更好地研发新药，探索无限可能！

作为医药研发服务行业的领头羊，药明康德为中国新药研发的自主创新注入了活力，正在引领中国新药研发服务行业全面蓬勃发展。

Established in December 2000, WuXi AppTec (NYSE: WX) is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform with operations in China and the United States. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services throughout the drug R&D process. Our services are designed to help our worldwide customers shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions.

WuXi AppTec has successfully established a fully integrated services and technology platform during the past decade. The company built its initial capabilities around discovery chemistry and has further enhanced the integrated services with analytical services, bio-analytical services, process research, process development services, API manufacturing services, DMPK/ADME, discovery biology, pharmacology, formulation, toxicology, genomic services, biologics manufacturing services, antibody and biological research reagent manufacturing and sales, and most recently clinical research and regulatory services.

WuXi AppTec has developed from four founders and a single laboratory in December 2000 to 10,000 employees and 5 million square feet of laboratory and manufacturing space, including facilities under construction. The company is actively improving its capabilities and capacity through new expansions in its global business. Capitalizing on the great advantage of conducting R&D services both in China and in the U.S., WuXi AppTec is building an alternative R&D engine to serve the global life-science industry.

正大天晴药业集团股份有限公司

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

正大天晴药业集团是集科研、生产和销售为一体的创新型医药集团企业，是国内最大的肝健康药物研发和生产基地，为国家重点高新技术企业、国家火炬计划连云港新医药产业基地重点骨干企业，2014 年位列中国医药工业百强企业榜第 20 位，在江苏省医药行业中位列第二。2014 年，肝病用药在国内医院市场占有率近 20%，肝病用药市场占有率连续多年稳居行业第一。

正大天晴始终将科技创新作为企业发展的重要战略，是国内创新药物研究投入最多的药企之一。正大天晴以药物研究院为创新载体，“江苏省新型肝病药物工程技术研究中心”、“国家级博士后科研工作站”、“国家级企业技术中心”等高层次研发平台相继在正大天晴建立，自主创新能力不断增强。随着企业的发展和研发能力的提升，研发费用投入也将向跨国公司看齐，逐步从销售收入的 8% 提高到 15%。目前，研究院在研项目 200 多个，其中一类新药 37 个，生物药 20 个。截止 2014 年底，公司有效专利及专利申请 331 项，其中发明专利 306 项；授权公告的专利 169 项，其中发明专利 147 项；国际授权专利 13 项。

未来发展中，正大天晴药业将继续强化核心竞争力的打造，建立健全科学高效的研发体系，使公司的研发水平始终与国际前沿接轨。一是由“肝病领域”拓展到“大消化领域”，保持市场占有率第一；二是进军肿瘤药领域，树立起该领域高端、专业的新形象；三是呼吸感染领域，力做该领域的领导者。在 2014 年实现百亿药业集团的基础上，十三五末将实现年销售额 200 亿元，为中国医药工业和地方经济发展再做新贡献。

CTTQ is an innovative pharmaceutical group that engages in drug R&D, manufacturing, and marketing. It has the largest R&D and manufacturing base for liver disease drugs in China, is honored as one of the National Key High and New Tech Enterprises, and ranked 20th in National Top 100 Medical and Pharmaceutical Powers in 2014.

CTTQ currently has 10 subsidiaries, 3 manufacturing plants, 2 R&D centers (in Nanjing and Lianyungang), 4 joint labs (in Shanghai and Chengdu), and 1 business development office in California, USA. CTTQ has passed multiple EU and US GMP inspections, and it is the first company that obtained the national new version of GMP certification in 2011. Its customer base spans over 30 countries. With more than 6000 employees, CTTQ has 2014 sales totaled RMB 10 billion.

Innovation and cooperation are CTTQ's core values. Its R&D investment on innovative drugs takes the leadership among domestic counterparts. In recent years, it has developed several high level R&D platforms, including Jiangsu Province Liver Disease Innovative Drugs Technology Research Center, National Postdoctoral Research Fellow Station, and State-level Enterprise Technology Center. More than 10 projects were designated as National Key New Drug Innovation Science and Technology Project. Its R&D Institute has a highly capable research team of over 700 employees, with about 60% holding post-graduate degrees or senior technical certificates.

CTTQ invests over 8% of its annual sales revenue as R&D budget (not including fixed assets) every year. At present, it manufactures 70 prescription medicines in China in 5 main therapeutic categories, including liver diseases, oncology, respiratory diseases, diabetes, and antibiotic. It has more than 270 projects in its product pipeline, in which State Category I innovative drug projects make up more than 35%.

CTTQ attaches great importance to intellectual property and patent protection. It has filed 331 patents, including 306 inventions by the end of 2014. Among them, 170 patents we have been granted, including 148 inventions and 14 patents granted in foreign countries. Tian Qing Gan Mei, one of our top-selling products, won China Golden Patent Award.

As a responsible corporate citizen, CTTQ is driven by a strong desire to improve Chinese medical treatment and promote public health, through both Tianqing Liver Disease Research Fund and CR-HepB Program. It donated RMB 10 million to establish the former in 2011, which was designed for healthcare professionals in under-developed areas to study liver diseases, and overall national improvement of liver disease prevention and medication. CR-HepB Program is a unified registry system in China, forming an important data resource for government and medical institutions to achieve standardized management of HBV patients. CR-HepB data have been published in EASL, AASLD, and APASL.

In the future, CTTQ aims to increase R&D investment from 8% to 15% of sales revenue to match international standards. This will significantly strengthen CTTQ's core competitiveness and optimize its R&D system. CTTQ's long-term development goal is expanding its presence in Oncology, Respiratory diseases, Cardiovascular, and Diabetes, and building up leading positions in these therapeutic areas in China.

北京泰德制药股份有限公司

Beijing Tide Pharmaceutical Co., Ltd

北京泰德制药股份有限公司成立于 1995 年，是一家研发、生产和销售化学药物及生物制剂的高新技术企业，是国内最大的靶向药物研制、生产基地。现有员工 2500 人。

泰德制药经过 20 年的发展，先后被国家科技部和北京市认定为国家重点高新技术企业、北京市高新技术企业，入选中关村国家自主创新示范区创新型试点企业和“十百千工程”等。先后获得北京市生物医药产业跨越式发展工程（G20 工程）杰出贡献企业、中国医药企业制剂国际化先导企业、中国医药工业最具投资价值企业、中关村最具影响力信用企业等荣誉称号。根据国家工业和信息化部统计数据，公司已连续三年位列中国医药行业工业企业主营业务收入全国百强。

泰德制药的产品质量真正达到国际水平。公司全部生产线通过国家 2010 版 GMP 认证。2008 年，公司通过日本厚生劳动省无菌注射剂 GMP 认证，成为中国第一家向日本出口注射剂的制药企业，截至目前，累计销售注射剂产品近千万支，在国内制药行业起到重要的示范作用，并被评为北京市药品质量管理示范企业。

政府和行业也对泰德制药的产品给予了高度评价并授予多项荣誉，公司主导产品前列地尔注射液（凯时 ®）和氟比洛芬酯注射液（凯纷 ®）均被评为国家重点新产品、国家火炬计划项目、北京市自主创新产品和北京市科学技术奖，还被北京市评为 G20 工程突出贡献大品种。2014 年，公司产品凯时 ® 被评为北京市著名商标。

目前，公司拥有注射剂、片剂、胶囊、颗粒剂、外用贴剂、冻干制剂、生物制剂等多个剂型产品。泰德制药秉承“关怀生命、精益创新”的宗旨，以开发具有独立知识产权的创新药为目标，以独立创新、自主研发和引进吸收再创新为发展方向，立足国内，放眼世界，为社会提供更优质的新药产品、为改善大众的健康水平而不懈努力！

Beijing Tide Pharmaceutical Co., Ltd, established in 1995, is a new high-tech enterprise integrating research, development, production and sale of chemicals and biologics and is the biggest domestic base for development and production of targeted drugs, with 2500 employees at present.

After 20 years of development, Tide Pharmaceutical Co., Ltd has been rated as the national high-tech enterprise, Beijing new high-tech enterprise, the selected innovative pilot enterprise in national independent innovation demonstration zone in Zhongguancun and Ten Hundred Thousand Project" by Ministry of Science and Technology and Beijing City successively, and obtained honorary titles such as outstanding contribution enterprise of great-leap-forward development project of Beijing bioengineering and pharmaceutical industry (G20 Project), the leading international enterprise for medicine preparation enterprise in China, the most valuable investment enterprise in China medical industry, the most influential credit enterprise in Zhongguancun. According to statistical data of Ministry of Industry and Information, the company has been listed in Nationwide Top Hundred for main business income of China pharmaceuticals industry for three years continuously.

The product quality of Tide Pharmaceutical has reached international level. All production lines of the company have passed GNP certification of national version 2010. In 2008, the company passed sterility injection GMP certification of MHLW, becoming the first Chinese pharmaceutical enterprise of exporting injection to Japan. Up to now, injection products have been sold accumulatively for nearly ten million injections, playing an important role in domestic pharmaceutical industry. The company is rated as the demonstration enterprise in Beijing City on pharmaceutical quality management.

The government and the industry also highly praise products of Tide Pharmaceutical Co., Ltd, and grant it many honors. Alprostadil Injection (Kaishi®) and Flurbiprofen Axetil Injection (Kaifen®), the leading products of the company, are rated as National Key New Products, national Torch Program project, Beijing Independent Innovation New Product and Beijing Science and Technology Award. They are also rated as Large Category with Outstanding Contributions in G20 Project by Beijing City. In 2014, the companys product Kaishi® was rated as a famous trademark of Beijing City.

At present, the Company possesses many dosage forms of products such as injection, tablet, capsule, granule, external-use patch, freezing- dry preparation, biologics and so on. The Company adheres to the tenet of caring for life, seeking for innovation, aiming at development of innovative drugs with independent intellectual property, focusing on independent innovation, independent research and development, introduction, absorption and re-innovation. The Company will make use of domestic and international markets to provide more superior new drugs for society and make unremitting endeavor to improvement of public health level.

中国药科大学

China Pharmaceutical University

中国药科大学是一所历史悠久、在药学界享有盛誉的教育部直属“211 工程”重点建设大学，坐落于历史文化名城古都南京。前身为始建于 1936 年的国立药学专科学校（四年制），是我国历史上第一所由国家创办的高等药学学府。

学校学科涵盖理学、医学、工学、经济学、管理学、文学、法学 7 个学科门类。药学一级学科为国家重点学科。药理与毒理学、化学、临床医学三个学科在 ESI 排名进入世界前 1%。学校拥有 24 个本科专业，5 个专科（高职）专业；药学、中药学 2 个一级学科博士点，24 个二级学科博士点，5 个一级学科硕士点，30 个二级学科硕士点，3 个专业学位授权点；药学、中药学 2 个博士后流动站，23 个学科专业可招收博士后研究人员。

学校是全国医药院校中唯一一所连续三次获得国家级教学成果一等奖殊荣的高校。学校就业率一直位列教育部直属高校及江苏省高校前茅。

学校推进科研创新，研发普惠良药。建有“天然药物活性组分与药效”国家重点实验室和省部级以上重点实验室、工程技术中心和创新平台共 18 个。与海外 40 多个国家和地区的院校及科研机构建有学术联系。“十一五”期间获国家“重大新药创制”科技重大专项项目 40 余项，资助经费达 2.15 亿元，获批项目数、经费数均居全国高校之首。

截至 2013 年底，学校全日制在校生 15000 余人，其中：研究生 3300 余人，本专科生近 12000 人。专任教师 859 人，其中中国工程院院士 2 人、德国科学院院士 1 人、“国家杰出青年科学基金”获得者 3 人、“长江学者”4 人、“万人计划”1 人、“国家级教学名师”2 人。学校拥有玄武门、江宁两个校区，占地 2200 余亩。

今天的中国药科大学，正朝着建设国际知名的高水平研究型大学的目标努力迈进。

China Pharmaceutical University (CPU), situated in the well-known historical and cultural ancient capital city of Nanjing, is one of the “211 Project” key universities affiliated to the Ministry of Education of China. It has been known for its long history and good reputation in China’s pharmaceutical field. The University was founded in 1936 as National College of Pharmacy, China’s first independent higher educational institution of pharmacy.

CPU provides such seven disciplines as science, medicine, engineering, economics, management, arts and law. The first-level discipline of pharmacy was enlisted as National Key Discipline. CPU has entered the world’s top 1% in ESI ranking in such three disciplinary areas as pharmacology and toxicology, chemistry, and clinical medicine. CPU offers 24 bachelor’s degree programs, 5 associate (polytechnic) programs, 30 research-oriented master’s degree programs under second-level disciplines, 5 master’s degree programs under first-level disciplines, 3 professional degree programs at the master’s level, 24 research-oriented doctoral degree programs under the two first-level disciplines of Pharmacy and Traditional Chinese Pharmacy and 23 post-doctoral research programs.

Among all medical and pharmaceutical universities in China, CPU has been the only one that has won First Prize of National Teaching Achievements for three times consecutively. The overall employment rate of graduates has always been on the top among all universities under the direct supervision of the Ministry of Education of China and all local colleges and universities under the supervision of Jiangsu Province.

The University promotes innovation in research and aims to develop novel medicines for public health. It has 18 research-oriented platforms, including the State Key Lab of Natural Medicines, provincial and ministerial key labs, engineering centers and innovative platforms. CPU has maintained academic collaboration with overseas universities and research institutions in over 40 countries and regions. In the nation’s “High-Tech Novel Drug Research" projects during China’s 11th Five-Year Plan period from 2006 to 2010, the university undertook a total of over 40 key projects with a total amount of research funds of 215 million RMB, ranking No.1 among all universities across the nation in terms of either the total number of projects or the total amount of funds.

By the end of 2013, CPU hosts more than 15000 full-time students with approximately 12,000 bachelor’s or associate degree candidates and more than 3,300 postgraduates and PhD candidates. Its faculty include 859 full-time teachers, including 2 academicians of the Chinese Academy of Engineering, 1 academician of German Academy of Sciences, 3 professors supported by the National Science Foundation for Distinguished Young Scholars, 4 “Changjiang Scholars”, 1 professor supported by the “Ten-Thousand Talents Program" of the Chinese Academy of Sciences, and 2 “National-level Outstanding Teachers”. The University is composed of two campuses, namely Xuanwumen Campus and Jiangning Campus, which cover a total area of about 2200 mu (146.6 hectares).

Today, CPU is striding forward towards its goal of becoming a world-famous high-level research-oriented university.

沈阳药科大学
Shenyang Pharmaceutical University

沈阳药科大学是一所具有光荣革命传统的学校，1931 年诞生于江西瑞金，是我国历史最悠久的综合性药科大学。学校占地面积 63.7 万平方米，建筑面积 36.8 万平方米，教职工 1141 名。

学校学术氛围浓厚，科研工作深入扎实。在药物新剂型设计与评价、创新药物的合成与筛选、中药与天然药物药效物质基础和质量标准、药物代谢和药物动力学、药理与毒理学、药物经济学等领域的研究均居国内领先水平。学校是国家中成药工程技术中心、沈阳国家新药安全性评价研究中心的重要组成单位，教育部创新药物研究与设计重点实验室 1 个，有 4 个国家中医药管理局批准的中药三级实验室、1 个中药二级实验室，27 个省市级工程技术研究中心或重点实验室。我校于 2008 年成功申报国家级综合性新药研究开发技术大平台项目，该综合平台是唯一由地方院校承建的国家综合平台。学校孕育了一大批新药创新成果，科学研究与应用实践密切结合，在医药行业和经济建设中发挥了重要作用，获得了巨大的经济效益和社会效益。“十一五”期间，我校科研经费达到 2.54 亿元，发表学术论文 6480 篇，其中 SCI 收载论文 1684 篇。学校主办的《沈阳药科大学学报》和《中国药物化学杂志》现已成为国家药学类核心期刊。《亚洲社会药学》等三种国际学术期刊于 2005 年创刊。

学校坚持“团结、勤奋、求实、创新”的校训精神，立足辽宁、面向全国，建设药学教育领域国内一流、国际知名的教学研究型大学。

Shenyang Pharmaceutical University (SPU) was founded in Ruijin,Jiangxi in 1931 which is the oldest comprehensive pharmaceutical university with a glorious revolutionary tradition.It covers a total area of 637,0000m^{2}with a construction area of 368,000m^2 and has 1141 faculty members.So far SPU has developed into an institution of higher pharmaceutical learning with multi-disciplinary, multi-tiered and multiform education. It consists of 8 schools (School of Pharmacy, School of Pharmaceutical Engineering, School of Traditional Chinese Medicine, School of Life Science and Biopharming, School of Business Administration, School of Medical Devices, School of Social Sciences, Languages and PE, School of Continuing Education) as well as Testing Center, Computer Center, Modern Education Center and Traditional Chinese Medicine Resource Center, etc.

SPU has been striving to creat a strong academic atmosphere and strengthen its research effort.As a result, its research achievements are among the best in China in fields including the design and evaluation of new drug formulation, the composition and selection of innovative drug,the pharmacodynamic material basis and quality standard for traditional Chinese medicine and natural drugs, drug metabolism and pharmacodynamics, pharmacology and toxicology,pharmacoeconomics, etc.SPU is Chinese Patent Medicine Engineering Technology Center and an important part of Shenyang National Research Center for New Drug Safety Evaluation.SPU is in possession of a key lab for new drug research and design under the Ministry of Education, 4 three-level labs approved by State Administration of Traditional Chinese Medicine, 1 second-level traditional Chinese medicine lab, 27 Engineering and Technology Research Center or key labs at municipal and provincial level.In 2008, SPU successfully applied for the project of National Comprehensive New Drug Research and Development Technology Platform, which was the only one of its kind to be built by a local university.It has harvested numerous new drug innovations, closely integrated scientific research and application practice, which help contribute to its important role in the medical industry and economic construction as well as its huge economic and social benefits.During the 11th Five-Year Plan, SPU received a total of 254 million scientific research funds, published 6480 academic papers, of which 1684 were included and recorded by SCI.Its Journal of Shenyang Pharmaceutical University and Chinese Journal of Medical Chemistry have become national core journals in the pharmaceutical field. Besides, its Asian Journal of Social Pharmacy and two other international academic journals started publication in 2005.

The school motto of SPU is “Unity, Diligence, Truth, Innovation”. Based in Liaoning and facing the whole nation, it has and will strive to build a first-rate teaching-research university in the domestic pharmaceutical field which is also internationally renowned.

北京大学药学院
Peking University School of Pharmaceutical Sciences

北京大学药学院始建于 1941 年，是国家重点药学院之一，在学科建设、师资培养、教学、科研等方面做出了重要贡献，为我国培养了大量药学高级人才。

药学院由六系（化学生物学系，药物化学系，天然药物学系，药剂学系，分子与细胞药理学系，药事管理与临床药学系）、一室（天然药物及仿生药物国家重点实验室）、一所（应用药物研究所）、一中心（药学实验教学中心）组成。北京大学药学学科于 2007 年被认定为国家一级重点学科，在教育部 2012 年学科评估中排名第一。

学院的科学研究主要集中于心脑血管疾病、肿瘤、老年病等重大疾病，以天然药物及仿生药物国家重点实验室为核心，药物化学、生药学、药理学等重点学科为依托，在核酸药物、糖类药物、中药及天然药物等领域积累了较雄厚的基础，取得了国内领先、国际上有影响的成绩，有些研究成果已达到国际先进水平。学院承担国家自然科学基金、“973”、“863”、国家科技支撑计划、国家科技重大专项等国家级及省部级重要科研项目，参与北京大学“211”及“985”工程建设。学院获得国家自然科学二等奖 3 项，省部级奖励 35 项；近五年获得发明专利 85 项，发表研究论文 1422 篇（其中 SCI 收录 950 篇）。2009 年以来，药学院积极面向国家重大需求，承担了国家“重大新药创制”科技重大专项课题“北京大学综合性创新药物研究开发技术大平台的建设”，构建了完整的创新药物发现与研发体系，新药研发自主创新能力明显加强，目前有 1 个抗肿瘤一类新药被 SFDA 批准进入 II 期临床研究，另外 2 个一类新药进入临床研究。

药学院与国内外知名大学、科研机构、制药企业有着广泛的合作与交流，促进了国际学术影响力与科研水平的稳步提升。

北京大学药学院今后几年的奋斗目标是：逐步发展为一所学科齐全、具有国际一流水平的药学院。

Peking University School of Pharmaceutical Sciences (SPS), established in 1941, is a national key pharmaceutical school. In the past decades, SPS has made great achievements in discipline construction, faculty training, teaching, and scientific research, and has nurtured a large number of high-level pharmaceutical scientists and professionals.

SPS is composed of six academic departments (Chemical Biology, Medicinal Chemistry, Natural Medicine, Pharmaceutics, Molecular and Cellular Pharmacology, Pharmacy Administration and Clinical Pharmacy), one key laboratory (State Key Laboratory of Natural and Biomimetic Drugs), one institute (Institute of Applied Pharmaceutical Research), and one center (Pharmaceutical Teaching Laboratory Center). The pharmaceutical science discipline of Peking University became an accredited national key discipline in 2007, and was ranked the first in discipline evaluation by Chinese Ministry of Education in 2012.

The scientific research of SPS is mainly focused on major diseases including cardiovascular and cerebrovascular diseases, tumor, and senile diseases. With the State Key Laboratory of Natural and Biomimetic Drugs as the core, and with the support from key disciplines (Medicinal Chemistry, Pharmacognosy, and Pharmacology), SPS has built up a solid foundation in the scientific research of nucleic acid drugs, saccharide drugs, and natural medicines (including traditional Chinese medicines). Some research achievements have reached international top level. SPS undertakes national key research programs, including projects from National Natural Science Foundation of China (NSFC), “973” and “863” projects, and National Key Technologies R&D Programs, as well as provincial and ministerial research projects. SPS also participates in the “211” and “985” project of Peking University. SPS has won 3 National Natural Science Award (class two), and 35 awards at provincial and ministerial levels. In the past five years, SPS has obtained 85 issued patents, and has published 1422 research papers (950 cited by SCI). To meet the primary demands of the nation, SPS has been establishing the Peking University Comprehensive Center for Drug Discovery and Development (CCDDD) since 2009, which is supported by the Primary Drug Innovation Program of National Science and Technology Mega Projects. Thus far, SPS has built up an integrated research and technology system for the discovery and development of innovative drugs. One class I anti-tumor innovative drug (IND) has entered phase II clinical trial, and two other class I INDs have been approved for clinical trial by SFDA.

SPS has extensive cooperations and communications with top universities, research institutes, and pharmaceutical enterprises at home and abroad. The international impact and academic strength of the School has been increasing in the past years.

In the coming years, Peking University School of Pharmaceutical Sciences aims to develop into a comprehensive and international top-level pharmaceutical school.

复旦大学药学院
School of Pharmacy Fudan University

复旦大学药学院创建于 1936 年，是我国最具影响力的五所高等药学院校之一。

药学院下设药物化学、药剂学、药理学和临床药学四大学科群，按药学一级学科专业招收本科生，分为药学和临床药学方向。已培养本科生 5500 余名、硕士生 600 余名、博士生 120 余名，受到了社会和用人单位普遍欢迎，其中 6 人已成为“两院”院士。目前在读研究生 300 余名、本科生（含留学生）260 余名。获得国家精品课程 1 项（药理学）、全国百篇优秀博士学位论文 2 篇（药剂学）。

现有教职员工 130 人，其中：正高职称 33 人，副高职称 38 人；博士生导师 39 名，硕士生导师 32 名。拥有国家“千人计划”特聘教授 3 名、入选上海市“千人计划”特聘教授 2 名、973 项目首席科学家 3 名、国家“杰出青年基金获得者”2 名和“优秀青年基金获得者”1 名、教育部“长江学者”特聘教授 1 名、教育部新世纪优秀人才 5 名、上海市领军人才 1 名、上海市优秀学科带头人 4 名等。

学院以药学基础及应用基础研究为主，兼顾新药开发，侧重于抗感染药物、抗肿瘤药物、心脑血管药物的新理论、新技术、新方法、新产品等研究。拥有智能化递药教育部和全军重点实验室，国家中医药管理局三级实验室（中药制剂、中药生药分析）。设有仪器分析测试、计算机辅助药物设计、动物实验、药物筛选与药效评价、放射药学与分子影像、药物制剂中试等多个技术支撑平台。

2007 年以来，承担国家重大科学研究计划（973）、国家重大创制新药技术专项、863 计划项目、国家自然科学基金等国家及省部级项目多项，到位科研经费约达 2 亿元；授权专利 128 项；年均发表 SCI 论文 100 篇以上 获得教育部自然科学一等奖 2 项等。

Founded in 1936, School of Pharmacy Fudan University (SPFDU) has a long history and now is one of five most influential pharmacy schools in China.

SPFDU is organized into four main academic departments: Pharmaceutical Chemistry, Pharmaceutical Science, Pharmacology and Clinical Pharmacy.

SPFDU has undergraduates majored in pharmacy and clinical pharmacy. So far, about 5500 undergraduate students, 600 masters and 120 PhD have graduated from SPFDU and 6 of them have been awarded as national Academicians. Currently students of SPFDU consist of almost 300 graduate students and over 260 undergraduates including foreign students. Besides, Pharmacology was awarded as national excellent course and 2 theses about pharmaceutical science were selected as the national excellent Ph.D. Thesis.

The SPFDU has 130 faculties, with 33 professors and 38 associate professors, which include 39 doctoral supervisors and 32 master supervisors. There are 3“Thousand Person Plan” distinguished professors from the national project and 2 elected “Thousand Person Plan” distinguished professors from Shanghai project, 3 chief scientists of national key scientific research project (973), 1 Yangtze Distinguished Professor recognized by the Ministry of Education, 2 National Outstanding Youth Foundation Winners and other 5 cross-century talents recognized by the Ministry of Education, 1 leading figure in Shanghai, and 4 outstanding academic leaders in Shanghai.

Based on pharmaceutical basic research and applied basic research, and taking account into the development of new medicine, SPFDU focuses on research about the new theories, new technologies, new methods and new products of anti-infective drugs, antineoplastic drugs and cardiovascular drugs. The School has Smart Drug Delivery laboratory, Key Laboratory of Ministry and Three-level laboratories of Traditional Chinese Medicine (TCM) and the TCM crude drug analysis of the State Traditional Chinese Medicine Administration. It also includes several supporting technical platforms: Specialized Integrated Platform of National New Drugs Development, Screening and Efficacy Evaluation Platform for Antivirals, Technology Platform for the development of New Formulation and New Drug Delivery System, GLP Laboratory Animal Center, Instrument Test Center.

Since 2007, SPFDU has accomplished national key scientific researches (973), major projects of national development of new drugs,863 and national and provincial projects of the national natural science foundation. Also, SPFDU achieved funding about 2 billion, 128 patents, over 100 publications on SCI annually and 2 first prize of natural science from the Ministry of Education.

军事医学科学院毒物药物研究所
Institute of Pharmacology and Toxicology Academy of Military Medical Sciences

毒物药物研究所是 1958 年 5 月由军事医学科学院药物、化学、药物三系合并而成。成立以来，研究所牢记使命，始终围绕国家和军队重大需求，走过了辉煌的历程。

历经几代科学家 50 多年的奋斗，针对外军装备的 6 类 14 种制式化学战剂，我所建立了完备的防化医学体系，带领我国防化医学实现了从无到有、从弱到强的历史性转变。目前全军装备的 14 种防化药品全部由我所研制，特别是抗神经性毒剂特效药是我国药物发展史上结构全新药物研发的典范。以抗神经性毒剂防治药物研究作为重要组成部分的“战时特种武器伤害医学防护”获得了医药卫生领域迄今为止唯一的国际科技进步特等奖。

21 世纪以来，我国生物安全形势面临严峻考验。2005 年，我国各地禽流感频发，有演变为当年 SARS 危机可能。时任国务院总理温家宝亲临我所召开应急防控会议，要求尽快研制抗流感特效药。我所临危受命，在短时间内突破国外技术的壁垒，创新建立了磷酸奥司他韦生产工艺，按时完成国家战储任务。2011 年，全球最大磷酸奥司他韦原料药生产线通过国家验收，标志我国禽流感防控药物生产和储备不再依赖国外。

我所建立以来，共获得国家和军队新药证书 73 个，其中国家一类新药证书 7 个，形成了以抗毒、抗神经精神疾病、抗病毒及超级菌研究为优势特色的创新药物研发体系。研究所目前拥有国家重点实验室、国家工程技术研究中心、国家战略药品研发基地、国家药品安全评价和食品安全风险评估等五个国家级创新药物研发平台，是我国创新药物研究的一支重要力量。

Institute of Pharmacology and Toxicology, Academic Military Medical Sciences established in 1958, is a comprehensive institute composed of a good variety of disciplines, including pharmaceutical chemistry, pharmaceutical analysis, pharmaceutics, drug metabolism, pharmacology, hygienic toxicology, experimental pathology and biochemistry.

Orienting to the studies of novel medications, BIPT has advanced instruments and facilities as well as the advanced means and techniques in all the fields of research and development (R & D) of new drugs,and it has been able to complete independently the whole process of preclinical researches concerning the development of a new drug. It usually involves the drug design, synthesis, pharmacological evaluation, safety evaluation and supply of preparations for clinical trials. Several new drugs involved in antihypertensive, analgesics, diabetes mellitus, antiviral, has been developed successfully.

天津药物研究院

Tianjin Institute of Pharmaceutical Research

天津药物研究院始建于 1959 年，原是国家食品药品监督管理局直属的全国综合性医药科研单位之一。目前是以新药研究为主业的国有独资高新技术企业，汇聚了中国工程院院士、享受国务院特殊津贴专家等专业人才，设立了药学硕士点和博士点，建立了博士后科研工作站。

院学科整体优势强，可进行药物创新研究、化学制药研究、现代中药研究、新药评价（G L P）、新型制剂技术及工程化研究、药品质量及分析测试研究、医药信息研究，涵盖了整个药学研究领域，建立了以释药技术与药代动力学国家重点实验室为代表的多个国家及省部级重点实验室，是国家 “创新型企业”和全国企事业知识产权示范单位”。

近年来，承担了 100 多项国家重大新药创制专项等国家课题，共获得 200 多件新药证书和生产批文，申报专利超过 800 项，还负责编辑出版四本科技核心学术期刊。

Tianjin Institute of Pharmaceutical Research (TIPR) was originally founded in 1959, and was one of affiliated research institutes of State Food and Drug Administration of China (SFDA). As a national key hi-tech industry focused on the development of new drugs, TIPR has a research team, including academician of Chinese Academy of Engineering, specialists receiving state allowance and senior research fellows. In addition, TIPR provides Master programs in Chinese Medicine, pharmaceutical science and PhD program in pharmacology, as well as post-doctoral training center.

TIPR leads the research in pharmaceutical areas and has seven major research divisions, including center for drug innovation, department of medicinal chemistry, department traditional Chinese medicine, center for drug evaluation (GLP), center for pharmaceutical formulation technology and engineering research, department of analytical testing of pharmaceutical quality, and center for medical intelligence, covering the entire field of pharmaceutical research. In the meanwhile, TIPR has established State key laboratory of drug delivery and pharmacokinetics which was granted by Ministry of Science and Technology of China. Also, TIPR is “the innovative enterprises” and “the national demonstration units of intellectual property”.

In the past years, TIPR has engaged in over 100 special projects of national key novel drug innovation; the number of new drug certificates and licenses for production granted by central authority is over 200, and patent application is over 800. TIPR also hosts publication of four core periodicals in pharmaceutical research field.

中国医学科学院北京协和医学院医药生物技术研究所

Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College

中国医学科学院北京协和医学院医药生物技术研究所（原名抗生素研究所）成立于 1958 年，是我国抗感染药物的主要研发单位，也是我国第一支青霉素的诞生地，为我国抗生素的研发、人才培养及工业化生产起到了奠基的作用，在我国重大疾病、尤其是传染病的防控中作出了突出贡献。随着生物学理论与技术进步和社会的发展，药物研究的范围扩展至肿瘤、心血管、免疫调节等领域，1986 年研究所更名为医药生物技术研究所。

研究所现有在职人员近 500 人，包括中国工程院院士，国家（部）级 “突出贡献中青年专家, 长江学者特聘教授, 国家杰出青年基金获得者, 硕、博士生导师，客座教授及在读研究生等。

进入 21 世纪后，研究所被国家确立为公益性研究机构，加强了药学基础研究平台的建设和国际合作，研究所的 “微生物与生化药学” 成为国家重点学科，是我国药物研究、硕博士研究生教学和科学技术产业化的核心基地之一。

Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, initially named as Institute of Antibiotics founded in 1958, was a national key institute for discovery and development of anti-infective agents in China. As the place of giving birth to the first ampule of penicillin in China, the Institute laid a solid foundation for discovery and development of antibiotics, nurturing professional talents and industrial production of antibiotics and made great contribution to prevention to the area of cancer, cardio-vascular system and immunoregulation, etc. In 1986, the institute was changed name as Institute of Medicinal Biotechnology. Today, there are more than 500 employees in the institute including Academician of Chinese Academy of Engineering, National Outstanding Scientists, Cheung-Kong Scholars, National Distinguished Young Scholars founded by NSFC, Supervisors for Doctoral Degree, Visiting Professors and Postgraduate Students, etc. In the new century and millennium, as the social commonwealth research institute, the institute strengthened platform building for basic research of pharmacology and international cooperation. Meanwhile, microbial and biochemical pharmacy in the institute was evaluated and authorized as national key subject by Ministry of Education, P. R. China. Now IMB becomes as one of the central primary base for drug research, postgraduate education and industrialization of scientific and technology in China.

首都医科大学附属北京天坛医院
Beijing Tiantan Hospital, Capital Medical University

首都医科大学附属北京天坛医院始建于 1956 年，是一所以神经外科为先导，神经科学为特色，集医、教、研、防为一体的大型现代化三级甲等综合教学性医院。经过半个多世纪的艰苦创业和奋发努力，医院实现了跨越式发展，医疗技术水平以及医院的知名度跻身于国内一流医院的行列。

目前医院现有床位 1150 张，设有 30 余个临床科室和 11 个医技科室，年门诊量达百万以上、年住院病人近 3 万人次，拥有各类先进的医疗设备。

Founded in 1956, Beijing Tiantan Hospital affiliated to the capital medical university, a quaternity consisting of medical treatment, scientific research, medical education and disease especially associated with neurosurgery serving as a precursor. Through hard work and strenuous efforts for more than half a century, the hospital has already achieved leap-and-bound development and ascended into the top-level hospitals in China in terms of medical technology and hospital fame.There are 1150 beds over 30 clinical departments and 11 adjunct departments at present in hospital equipped with various advanced medical equipments, and furthermore, patient visits steadily increased tallying up to over 1,000,000 outpatient visits per year and 30,000 inpatient admissions per year.

中国药促会大事记
（2014 年 11 月 - 2015 年 9 月）

2014 年

11 月 6 日

中国药促会“我国现有药品招标采购制度研究”课题研讨会在京召开。

11 月 10 日 -12 日

中国药促会代表团赴台参加“2014 两岸生技新药产业合作论坛”和“两岸创新医药项目交流会”并参观了台湾国家生技医疗产业策进会以及位于台湾宜兰县的杏辉医药集团。台湾生策会会长陈维昭与中国药促会执行会长宋瑞霖签署了双方《合作备忘录》，旨在促进两岸医药产业合作，共同推动医药产业创新发展。

11 月 19 日

中国药促会“中国制药企业政策环境评估蓝皮书”课题研讨会在京召开。

11 月 20 日

中国药促会“中国仿制药产业发展政策研究”课题开题会在京召开。

11 月 26 日

中国药促会在卫计委药政司召开了“基本药物可及性与合理性比较研究”课题结题会。

12 月 2 日 - 5 日

中国药促会执行会长宋瑞霖与国家卫生和计划生育委员会科教司司长秦怀金、国际司司长任明辉、疾控局副局长王斌参加金砖国家第四次卫生部长会议系列活动，并一同出席了在巴西首都巴西利亚举办的金砖国家卫生高官会议、金砖国家药物研发和可获得药物技术会议。会议形成了向金砖国家第四次卫生部长会议的最终报告和联合公报。

12 月 16 日

中国药促会“医保谈判药品目录研究”课题中期汇报会在京召开。

12 月 18 日

中国药促会“从制药大国走向制药强国”课题汇报会在京召开。

12 月 23 日

中国药促会“大医改背景下药师的地位与作用研究”课题结题会在京召开。

2015 年

1 月 9 日

中国药促会在江苏省连云港市召开了 2015 年会长会议扩大会议。会议通过了中国药促会 2015 年度重点工作计划和安排，还就如何促进我国药物的创新发展进行了热烈讨论，与会代表还对中国药促会的工作提出了意见及建议。会议研究了工作，凝聚了思想，达成了共识，取得圆满成功，为中国药促会 2015 年的工作奠定了坚实的基础。

1 月 16 日

中国药促会受国资委推荐，成为民政部下属中国社会组织促进会行业协

会商会分会执行理事单位。

1 月 27 日

中国药促会“我国现有药品招标采购制度研究”结题会在北京召开。

1 月 29 日

中国药促会针对湖南省药品招标工作提出相关意见，并印发了《中国医药创新促进会对 2015 年湖南省药品集中招标采购工作的意见》。旨在优化湖南省的医药政策环境和招商引资环境，建议湖南有关方面本着尊重市场主体合法权益和合理诉求以及市场规律的原则，对药品招标工作相关制度和操作规程尽快作出调整，最终为人民群众的健康保障提供坚实物质基础。

2 月 5 日

中国药促会研究部撰写了新华社内参《外资药享受超国民待遇，国产创新药在哭泣》，旨在呼吁应当重视国产创新药物，促进我国药物创新发展。

2 月 9 日

中国药促会执行会长宋瑞霖在京会见了来访的美国 BioCentury 公司主席 Karen Bernstein 一行。双方围绕“中国医疗健康战略家全球情报”出版物、“2015 国际医药创新论坛”等活动的合作进行了深入友好的交流，并达成诸多共识。

3 月 24 日

中国药促会秘书长陈昌雄在京会见了加拿大不列颠哥伦比亚大学尚德商学院高级管理培训部副院长 Bruce Wiesner 一行。双方借此次机会，彼此增进了了解，并就未来双边合作事宜进行了深入友好的交流。

3 月 28 日

中国药促会与贝达药业股份有限公司共同主办了国家“十一五”、“十二五”重大新药创制专项项目暨凯美纳 1 线适应症发布会。

4 月 9 日 -10 日

中国药促会秘书长陈昌雄在日本东京出席了由日本制药工业协会（JPMA）主办的亚洲医药创新联盟（APAC）会议，会议旨在推动亚洲药物创新发展。

4 月 21 日

中国药促会在江苏省徐州市召开药物研发专业委员会和药物临床研究专业委员会成立大会暨中国创新药物研发研讨会。会议通过了《中国医药创新促进会专业委员会管理办法》及《中国医药创新促进会专业委员会财务管理制度》，并确定了工作重点。国家食品药品监督管理总局药品化妆品注册管理司副巡视员李金菊出席了本次会议。

5 月 4 日

中国药促会对安徽蚌埠药品采购方案与中央鼓励创新、市场配置资源精神不一致，以及涉嫌违反《反垄断法》等法律的行为，撰写了《关于吁请立即纠正安徽省蚌埠市公立医疗卫生机构药品采购中违法行为的报告》，并报送国家卫生计生委、国务院医改办、国家发展改革委、国家工商总局、安徽省卫生计生委。

5 月 13 日

由中国药促会（PhIRDA）、生物技术工业组织（BIO）、中国外商投资企业协会药品研制和开发行业委员会（RDPAC）共同主办的“中美生物医药创新研讨会”在美国洛杉矶召开。国家重大新药创制科技重大专项行政负责人、国家卫生计生委副主任刘谦率领国家卫生计生委代表团一行、中国药促会会长孙飘扬、执行会长宋瑞霖、秘书长陈昌雄共同出席了会议。

5 月 15 日

中国药促会执行会长宋瑞霖率团访问了 LEK 洛杉矶公司，双方围绕 GPO 在药品供应链中所扮演的角色、发展历程、运行模式、案例经验以及未来发展趋势等内容进行了深入交流。

5 月 19 日

中国药促会撰写了针对蚌埠药品采购涉嫌违法行为的举报信，并收集相关举证材料，向国家发展改革委价格检查与反垄断局，国家工商总局反垄断与反不正当竞争执法局报送。

5 月 21 日

深圳信立泰药业股份有限公司正式加入中国药促会。

5 月 21 日

中国药促会执行会长宋瑞霖在京会见了美国安进公司董事长兼首席执行官罗伯特 • 布拉德韦、全球商业运营执行副总裁安东尼 • 霍珀。双方围绕中国医药产业政策环境和安进公司未来在中国的发展战略等主题进行了深入交流。

5 月 24 日

由中国药促会主办，江苏恒瑞医药支持的“艾坦患者援助项目”启动仪式在山东省青岛市顺利召开。“艾坦患者援助项目”将为更多胃癌患者提供免费治疗机会，并同时开展多种患者关爱项目，延长患者生命，提升患者生存质量。

5 月 25 日

中国药促会执行会长宋瑞霖走访了会员单位青岛黄海制药有限责任公司，与企业相关负责人员进行了座谈并参观了黄海制药的综合车间。

5 月 29 日 -30 日

由中国药促会与清华大学法学院药事法研究所和中国医药企业管理协会共同主办的中国药品管理制度创新高端论坛于北京顺利召开。中国药促会执行会长宋瑞霖出席了会议并作关于药品管理法律制度沿革命的主题报告。

6 月 16 日

中国药促会执行会长宋瑞霖受邀出席了全国性行业协会与重庆市巴南区人民政府战略合作共促经济发展交流会。双方签署了合作备忘录，共同促进我国医药产业创新发展。

6 月 19 日

中国药促会“医保谈判药品目录研究”课题结题会在北京召开。

6 月 25 日

中国药促会执行会长宋瑞霖在京会见了来访的加拿大阿尔伯塔大学（University of Alberta）医学院院长、皇家科学院院士 Richard Fedorak 一行。双方就生物医药创新研发、科技成果转化和医师培训等领域的合作进行了深入友好的交流。

7 月 3 日

中国药促会医药政策专业委员会成立大会暨药品招标采购政策研讨会在京召开。宗旨是为了优化我国医药创新的政策环境，提高中国创新药物发展水平，推动我国医药产业创新、健康发展。来自产业界、高等院校和科研院所的医药政策的专家 60 多人出席会议。会议通过了《中国医药创新促进会专业委员会管理办法》及《中国医药创新促进会专业委员会财务管理制度》，并确定了工作重点。

7 月 8 日

中国药促会“基本药物可及性与合理性研究”课题结题会在北京召开。

7 月 10 日

华领医药（技术）上海限公司、歌礼生物科技（杭州）有限公司以及信达生物制药（苏州）有限公司正式加入中国药促会。

7 月 13 日 -16 日

中国药促会执行会长宋瑞霖率领调研组赴德国、比利时展开调研。考察期间，调研组分别走访了德国制药工业协会（VFA）、拜耳医药总部、公立医疗保险机构 KKH 公司、拜耳欧洲大区办公室、欧洲制药工业协会联合会（EFPIA）以及亚洲事务欧洲研究所，对德国和欧盟相关药物政策和医疗保险制度进行了深入交流。

7 月 24 日

由中国药促会主办的，以“政府简政放权后，药师如何在医药卫生体系中发挥作用”为主题的“第六届中国医院药学政策论坛”在四川省成都市召开。来自国家卫计委药政司、中国药师协会等单位的相关同志和各

医疗机构的药剂科主任及临床专家，以及全国各地药学领域的代表共计500余人参加了会议。论坛的讨论话题，引起了有关政府部门领导、医院管理者、医院药学工作者、医药产业界和学者的深入思考。对于医改的讨论，对于如何提升药师能力建设的话题，将会是论坛组织者和参与者永恒不变的主题。

7月27日-29日

中国药促会执行会长宋瑞霖率团赴日本东京开展政策调研活动。活动期间，调研组先后访问了日本制药商协会（JPMA）、日本厚生劳动省和PMDA，并实地参观了日本最大的批发物流公司ALFRESA公司总部以及武田制药湘南研究所、卫材制药总部。代表团就中日医保体系、医药分业、药品审评政策、药品定价、药品专利制度等方面的异同进行了深入交流。

8月12日

中国药促会执行会长宋瑞霖在京会见了来访的日本制药团体联合会国际委员会委员长赤田幸雄一行，双方就中日医药产业政策及合作进行了深入交流。

8月19-20日

亚太经济合作组织（APEC）医药产业伦理大会于菲律宾马尼拉举行。中国药促会代表受邀出席活动并参与嘉宾讨论。

9月16日

中国药促会执行会长宋瑞霖在京会见了来访的法国益普生公司（Ipsen Pharma）副首席执行官Christel Bories一行。

9月24日

中国药促会第十届会员大会第二次会议在北京顺利召开。中国药促会64家会员单位代表以及药物研发、药物临床研究、医药政策专委会专家，共计100余人应邀出席了会议。大会听取并审议了宋会长所作的年度工作报告、《中国药促会2014-2015年度会费收支情况报告》、8家企业的入会申请、会费标准修订案和章程修订案以及《关于设立中国药促会医药创新投资专业委员会的议案》，并且以无记名投票的方式选出了中国药促会2015-2016年度轮值会长、2016-2017年度候任轮值会长和第十届秘书长；专题报告阶段，孙咸泽副局长专门就我国最新药品安全监管与改革相关政策作专题报告，并和与会代表进行交流讨论。

9月24日

经中国药促会第十届会员大会第二次会议审议通过，江苏亚盛医药开发有限公司、再鼎医药（上海）有限公司、方恩（天津）医药发展有限公司和药明康德新药开发有限公司正式加入中国药促会。

Remarkable Events of PhIRDA
(November 2014 – September 2015)

Year 2014

November 6

PhIRDA held seminar on “Current Drug Bidding and Procurement Regulatory in China” in Beijing.

November 10-12

PhIRDA delegation visited Taiwan to participate in the “2014 Cross Strait Biotech Industry Development Forum” and “Cross Strait Medical Innovation Program Communication Meeting”, and meanwhile visited Institute for Biotechnology and Medicine Industry and Sinphar Group in Ilan, Taiwan. Chairman Chen Weizhao from IBMI and Executive President Song Ruilin from PhIRDA signed the Memorandum of Cooperation, aiming to promote cross-strait cooperation as well as innovation and development in pharmaceutical industry.

November 19

PhIRDA held seminar on “Blue Book of Policy Environment Assessment of China Pharma Industry” in Beijing.

November 20

PhIRDA held kickoff meeting on “Policy Study of Generics Industry Development in China” in Beijing.

November 26

PhIRDA held closing meeting on “Comparative essential drug Study of its accessibility and rationality” at National Health and Family Planning Commission.

December 2-5

PhIRDA Executive President Ruilin Song, Director-General of the Department of Science and Technology Huaijin Qin, Director-General of the Department of International Cooperation Minghui Ren and Deputy Director-General of Disease Control Bin Wang from National Health and Family Planning Commission, attended the Fourth BRICS Health Ministers Meeting. Final report and joint communique had been reached among the BRICS Health Ministers.

December 16

PhIRDA held middle-term meeting on “Negotiation Medicare Drug List” in Beijing.

December 18

PhIRDA held meeting on “From big pharmaceutical giant to strong pharmaceutical country” in Beijing.

December 23

PhIRDA held closing meeting on “Pharmacists’ Role under the Background of Health Care Reform” in Beijing.

Year 2015

January 9

PhIRDA held extended meeting of 2015 President Board Meeting in Lianyungang, Jiangsu Province. The meeting adopted the 2015 work plan and arrangement. The delegates had a heated discussion on how to promote drug innovative development in China and also make suggestions and give advice to PhIRDA. During the meeting, researches were done, thoughts were condensed and consensus was reached. It was a complete success and laid a solid foundation for 2015.

January 16

Recommended by the State-Owned Assets Supervision and

Administration Commission of the State Council, PhIRDA became a syndic unit of the Chamber of Commerce of the China Council for the Promotion of Social Organization subordinates to the Ministry of Civil Affairs.

January 27

PhIRDA held closing meeting on “Current Drug Bidding and Procurement Regulations in China” in Beijing.

January 29

PhIRDA gave guidelines on drug bidding work in Hunan province and the 2015 PhIRDA Guidelines on Drug Bidding Work in Hunan Province was published. Aiming to optimize the medical policy environment and the investment environment, PhIRDA suggested Hunan authorities to make adjustments on drug bidding regulatory and operating procedures as soon as possible according to the market discipline and shouldn't go against the legitimate rights and interests of market players and their reasonable needs, which eventually, to provide a solid material foundation for people's health.

February 5

PhIRDA Research Department wrote for Xinhua News Agency Internal Publication “Foreign Drug Enjoys Super National Treatment, Domestic Innovative Drug Is Crying", calling for attention on domestic innovative drugs and promoting the development of China's drug innovation.

February 9

PhIRDA Executive President Song Ruilin met in Beijing with BioCentury Chairman Karen Bernstein. They carried on thorough and friendly communication on “China's Health Care Strategist Global Intelligence”, 2015 International Pharmaceutical Innovation Forum, etc. and reached broad consensus.

March 24

PhIRDA Secretary-General Chen Changxiong met with Bruce Wiesner, Associate Dean, Sauder School of Business at UBC and his companies. The two parties took this opportunity to enhance mutual understanding, and carried on thorough and friendly communications on bilateral cooperation in the future.

March 28

PhIRDA and Beta Pharm co-hosted press-conference “Eleventh-Twelfth Five Year National Major New Drug Innovation Project – Conmana First Line Indication”.

April 9-10

Chen Changxiong, Secretary-General of PhIRDA, attended the 4th Asia Partnership Conference of Pharmaceutical Associations (APAC), which was hosted by the Japan Pharmaceutical Manufacturers Association (JPMA). The aim of this conference was to expedite the launch of innovative medicines for the peoples in Asia.

April 21

PhIRDA hosted the establishment ceremony of Drug R&D Specialty Committee and Clinical Research Specialty Committee. The meeting approved PhIRDA Specialty Committee Management Methods and Finance Regulations, and pointed out work focus. Deputy DG Li Jinju from CFDA attended the meeting.

May 4

PhIRDA stated that Bengbu goes against the central government guidance which encourages innovation, streamlining administration and letting the market determine the distribution of resources, meanwhile it is an allegation of lawbreaking, including Antitrust Law, etc. PhIRDA sent report to relevant Ministries, including State Council Health Reform Office, Anhui Health and Family Planning Commission, National Development and Reform Commission, State Administration of Industry and Commerce, etc., for alleged violations of the Antitrust Law.

May 13

PhIRDA together with BIO and RDPAC co-hosted “Sino-US Biopharmaceutical Innovation Cooperation Forum” in Los Angeles. Vice Minister Liu Qian from NHFPC, Chairman Sun Piaoyang and Executive President Song Ruilin attended the forum.

May 15

The Executive President of PhIRDA Song Ruilin led research team to visit LEK Consulting LA Office. The two sides shared views about the GPO role, history, model, cases and future trend, etc.

May 19

PhIRDA wrote the complaint letters about alleged violations of Bengbu drug procurement, collected evidence materials and reported to the Price Control and Antitrust Bureau of National Development and Reform Commission, State Administration for Industry Antitrust and Anti-Unfair Competition Law Enforcement Bureau.

May 21

Shenzhen SALUBRIS Pharmaceutical Co., Ltd. formally joined PhIRDA.

May 21

The Executive President of PhIRDA Song Ruilin met Robert Bradway, the Chairman and CEO and Anthony Hopper, Executive Vice President of Commercial Operations of of Amgen in Beijing. The two sides had deep exchanges on topics around the Chinese pharmaceutical industry policy environment and Amgen future development strategy in China.

May 24

Sponsored by PhIRDA, supported by Jiangsu Hengrui Medicine the launching ceremony of "Eitan patient assistance program" was held in Qingdao, Shandong Province. "Eitan patient assistance programs" will provide more opportunities for free treatment of gastric cancer, and also to carry out a variety of patient care items, prolong patients' life, and improve the quality of patients' life.

May 25

The Executive President of PhIRDA Song Ruilin visited member Qingdao Huanghai Pharmaceutical Co., Ltd., had meetings with responsible personnel of enterprise and visited Huanghai pharmaceutical workshops.

May 29-30

Chinese DAL System Innovation Forum was held successfully by PhIRDA and Pharmaceutical Affairs of Tsinghua Law School, together with China Pharmaceutical Enterprise Management Association in Beijing. The Executive President of PhIRDA Song Ruilin attended the meeting and made keynote report on the legal regime of drug administration along revolution.

June 16

The Executive President of PhIRDA Song Ruilin was invited to attend the exchange meeting of promoting economic development with strategic cooperation between national industry associations and Banan District of Chongqing City. The two sides signed a memorandum of cooperation, so as to jointly promote the innovation and development of China's pharmaceutical industry.

June 19

PhIRDA "Medicare Negotiating Drug List" project completion meeting was held in Beijing.

June 25

The Executive President of PhIRDA Song Ruilin met Richard Fedora, the Dean of Medical School at University of Alberta, member of Royal Academy of Sciences in Beijing. The two sides conducted in-depth and friendly exchanges on cooperationon biopharmaceutical R&D, scientific and technological transformation and physician training, etc.

July 3

PhIRDA Drug Policy Specialty Committee Establishment Ceremony and Drug Bidding & Procurement Policy Seminar were held in Beijing. The aim is to optimize pharmaceutical innovation policy environment, improve the level of innovative drug development in China, and promote China's pharmaceutical industry innovation and healthy development. More than 60 experts from industry, universities and pharmaceutical policy research institutes attended the meeting. The meeting approved PhIRDA Specialty Committee Management Methods and Financial Regulation, and identified working priorities.

July 8

PhIRDA “Research on Accessibility and Rationality of Essential Medicines" project completion meeting was held in Beijing.

July 10

Hua Medicine (technical) Shanghai Limited, Ascletis Innovation Biotechnology (Hangzhou) Co., Ltd. and Innovent biopharmaceutical (Suzhou) Co., Ltd. officially joined PhIRDA.

July 13-16

The Executive President of PhIRDA Song Ruilin led research group to Germany and Belgium. The research group visited German Pharmaceutical Industry Association (VFA), Bayer headquarters, public medical insurance KKH, Bayer European Regional Office, European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Institute for Asian Affairs, and conducted in-depth exchanges on Germany and EU drug policies and medical insurance system.

July 24

Sponsored by PhIRDA, 6th Chinese Hospital Pharmacy Policy Forum was held in Chengdu, Sichuan Province under the theme of "Pharmacists' role in the medical and health system after the government decentralization". Related comrades from the Pharmaceutical Affairs Division of the National Health and Family Planning Commission and China Pharmacists Association, pharmacy directors and clinical experts in various clinical institutions, as well as representatives from realted areas across the country totaling more than 500 people attended the meeting. Topics discussed in the Forum caused deep thinking to the government department heads, hospital administrators, hospital pharmacy workers, pharmaceutical industry and academics. Topics on health reform and capacity building of pharmacists would be eternal themes for organizers and participants of the forum.

July 27-29

The Executive President of PhIRDA Song Ruilin led a delegation to Tokyo, Japan to carry out policy research. During the event, the research group visited Japan Pharmaceutical Manufacturers Association (JPMA), MHLW and PMDA, and toured Japan's largest wholesale and logistics company ALFRESA headquarter, Takeda Shonan Institute, Eisai Pharmaceuticals headquarter. The group conducted in-depth exchanges of similarities and differences between Chinese and Japanese health care system, pharmaceutical sub-sector, drug review policy, pricing and patent system and etc.

August 12

The Executive President of PhIRDA Song Ruilin met Akada Yukio, Chairman of the International Committee of Japan Federation of Pharmaceutical Group in Beijing. The two sides conducted in-depth exchanges on the Sino-Japan pharmaceutical industry policy and cooperation.

August 19-20

Asia-Pacific Economic Cooperation (APEC) Conference on pharmaceutical ethics was held in Manila, Philippines. PhIRDA representative was invited to attend and participate in the panel discussion.

September 16

The Executive President of PhIRDA Song Ruilin met Christel Bories, Deputy Chief Executive Officer of French company Ipsen (Ipsen Pharma) in Beijing.

September 24

The Second Meeting of PhIRDA 10th General Assembly was successfully held in Beijing. More than one hundred people from 64 PhIRDA members and Drug R&D, Clinical Research, Pharmaceutical Policy Specialty Committees, attended the meeting. The General Assembly approved the annual report by Executive President Song Ruilin, as well as 2014-2015 Finanical Report, applications by eight companies to join PhIRDA, amendments to fee standard and Constitution, and the proposal to establish the Innovation Investment Specialty Committee. The meeting also elected PhIRDA' 2015-2016 Annual Chairman, 2017-2017 Annual Chairman and Secretary-General; during the report session, Deputy Commissioner of CFDA Sun Zexian gave a report on China's latest drug safety supervision and reform, and discussed with participants.

September 24

Approved by The Second Meeting of PhIRDA 10th General Assembly, Jiangsu Ascentage Pharma Co., Ltd., and Zai Lab Pharmaceutical (Shanghai) Co., Ltd. FMD (Tianjin) Pharmaceutical Development Co., Ltd. and Wuxi Apptech Co., Ltd. officially joined PhIRDA.

地址(Add)：北京市朝阳区朝外大街26号朝外们写字中心A座2005　邮政编码(Zip)：100020
Room 2005,Suite A,Chaowai MEN Business Center,26 Chaowai Street,Chaoyang District,Beijing,P.R.China,100020
电话(Tel)：(8610) 85654830　　传真(Fax)：(8610) 85654833
邮箱(E-mail)：phirda@phrda.com　　网址(Web):www.phirda.com